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Thesis Summary 
 
Individuals within the aged population show an increased susceptibility to infection, implying 
a decline in immune function, a phenomenon known as immunosenescence. Paradoxically, 
an increase in autoimmune disease, such as rheumatoid arthritis, is also associated with 
ageing, therefore some aspects of the immune system appear to be inappropriately active in 
the elderly. The above evidence suggests inappropriate control of the immune system as we 
age. 
Macrophages, and their precursors monocytes, play a key role in control of the immune 
system. They play an important role in host defence in the form of phagocytosis, and also 
link the innate and adaptive immune system via antigen presentation. Macrophages also 
have a reparative role, as professional phagocytes of dead and dying cells.  Clearance of 
apoptotic cells by macrophages has also been shown to directly influence immune 
responses in an anti-inflammatory manner. Inappropriate control of macrophage function with 
regards to dead cell clearance may contribute to pathology as we age. 
The aims of this study were to assess the impact of lipid treatment, as a model of the aged 
environment, on the ability of macrophages to interact with, and respond to, apoptotic cells. 
Using a series of in vitro cell models, responses of macrophages (normal and lipid-loaded) to 
apoptotic macrophages (normal and lipid-loaded) were investigated. Monocyte recruitment to 
apoptotic cells, a key process in resolving inflammation, was assessed in addition to cytokine 
responses. Data here shows, for the first time, that apoptotic macrophages (normal and lipid-
loaded) induce inflammation in human monocyte-derived macrophages, a response that 
could drive inflammation in age-associated pathology e.g. atherosclerosis. Monoclonal 
antibody inhibition studies suggest the classical chemokine CX3CL1 may be involved in 
monocyte recruitment to apoptotic macrophages, but not apoptotic foam cells, therefore 
differential clearance strategies may be employed following lipid-loading. CD14, an important 
apoptotic cell tethering receptor, was not found to have a prominent role in this process, 
whilst the role for ICAM-3 remains unclear.  
Additionally, a small pilot study using macrophages from young (<25) and mid-life (>40) 
donors was undertaken. Preliminary data was gathered to assess the ability of primary 
human monocyte-derived macrophages, from young and mid-life donors, to interact with, and 
respond to, apoptotic cells. MØ from mid-life individuals showed no significant differences in 
their ability to respond to immune modulation by apoptotic cells compared to MØ from young 
donors. Larger cohorts would be required to investigate whether immune modulation of MØ 
by apoptotic cells contribute to inflammatory pathology throughout ageing.   
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Introduction 
 
1.1 What is ageing? 
Although the concept of ageing is familiar, it is a complex term to define. In a 1952 lecture on 
ageing entitled „An Unresolved Problem of Biology‟, ageing was described as a collection of 
changes that render human beings progressively more likely to die1. This unresolved 
problem of biology refers to the inextricable link of ill health with ageing, however current 
research aims to dissociate the two and ensure that healthy ageing and a greater quality of 
life come hand in hand with increased lifespan. It could be argued that science is much 
closer to solving the problem2, or at least gaining a better understanding of the underlying 
mechanisms that result in decline of health with advancing age, and therefore can look at 
ways to counteract the origins of ill health in the elderly. 
Improving the quality of life of the elderly is an area of increasing focus as both the relative 
and absolute number of elderly individuals in the population has not only increased over the 
last century but is set to increase further, due to improved social and economic conditions3. 
This leads to a huge economic burden, with a reduced working population, and increasing 
social and economic burden with regards to age-related disease3.    
Theories on the mechanisms behind ageing vary widely, from psychological and sociological 
theories based on reduced social engagement and inactivity, down to the cellular and 
molecular level such as shortening of telomeres, the protective sequences of DNA at the end 
of genes which protect DNA from damage during replication4. 
Biological theories cover evolutionary, molecular, cellular and systemic concepts4. Popular 
biological theories of ageing include wear and tear, accumulative waste, somatic mutation, 
error accumulation, telomere shortening, oxidative stress, mitochondrial damage, free-
radical, cross-linkage, autoimmune, reproductive cell cycle, DNA damage, and mTOR 
theories4. In reality many of these are backed by scientific evidence and also have 
considerable crossover with each other. No single theory can explain all phenomena 
associated with ageing, with the likely conclusion that ageing is a complex process with 
contributing factors from across the range of ageing theories5.  
1.2. Immunosenescence and inflammaging 
Immunosenescence, the ageing of the immune system, results in an increased susceptibility 
to infection in the aged population, implying a decline in immune function6-8. Paradoxically, an 
increase in autoimmune disease is also associated with ageing, a result of inappropriately 
active components of the immune system9,10. Ageing is an established risk factor in 
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autoimmune diseases such as rheumatoid arthritis, and is also associated with increased 
autoantibody titre11,12. The above evidence suggests not just a decline in overall immune 
function, but inappropriate control of the immune system with advanced age, with the net 
effect of chronic low-grade inflammation. This chronic low-grade inflammation has been 
associated with cardiovascular disease, diabetes, frailty and cognitive decline/dementia13.  
Inflammaging is a recently coined term to describe the low-grade chronic inflammatory status 
associated with many elderly individuals14,15. Franceschi et al. argue that many phenotypes 
of ageing can be explained by an imbalance of pro- and anti-inflammatory networks, which 
drive frailty and other common age-related pathologies15.  
Ageing of the immune system is associated with phenotypes that include thymic involution5, 
reduced population of naïve T lymphocytes, increased population of memory T and B cells 
with reduced antigen recognition16. Higher circulating levels of inflammatory mediators are 
also a feature of inflammaging, with consistently higher levels of Tumor Necrosis Factor-
alpha (TNF-α), interleukin-6 (IL-6) and C-reactive Protein (CRP) across studies13. Evidence 
also suggests reduced levels of circulating anti-inflammatory mediator IL-10 in the elderly, 
which could exacerbate the inflammatory environment17. The increase in inflammatory 
mediators such as IL-6 and TNF-α has been attributed to accumulated oxidative damage, 
increased adiposity and declining levels of sex hormones as we age13. 
Ageing of the innate immune system is multifaceted and still poorly understood. Research 
into age-related changes in innate immunity is less advanced than that of adaptive immunity, 
and methodology varies widely, often resulting in conflicting results7. In order to establish the 
cause of immunosenescence and inflammaging, studies must be undertaken at the cellular 
level to understand which components of the immune system are under or over active as we 
age. 
1.2.1. Senescence of monocytes and macrophages 
The innate immune system is not only the first line of defence following a breach of physical 
barriers, but is also vital in maintaining homeostasis in the body, clearing dead and dying 
cells or cells flagged as harmful or unwanted. Cells within the innate immune system are also 
link the innate and adaptive immune system, priming this second line of defence and working 
synergistically. When dysregulation of the innate immune system occurs consequences can 
be wide-reaching. 
1.2.1.1. Monocyte and macrophage function 
Macrophages, and their precursors monocytes, play an important role in host defence in the 
form of phagocytosis, and also link the innate and adaptive immune system via antigen 
presentation18. Classically-activated „M1‟ macrophages are pro-inflammatory, which can be 
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induced by encountering pathogenic material or pro-inflammatory mediators. Classically 
activated macrophages have been attributed to play a pathological role in inflammatory 
diseases including rheumatoid arthritis, inflammatory bowel disease asthma and 
atherosclerosis19. Alternatively activated „M2‟ macrophages have a largely reparative role, 
including clearance of apoptotic bodies and debris from tissues 20. 
1.2.1.2. Monocyte and macrophage senescence 
It is important to understand the root causes of monocyte and macrophage senescence in 
order to improve innate immunity in ageing. This could include whether changes in innate 
immune function are a result of changes in the overall populations of innate immune cells 
such as monocytes or macrophages, as seen in the adaptive immune system with naïve T 
cells and thymic involution16, or the reduced ability of an aged cell to function. The effects of 
an aged environment may also be driving the effects of immunosenescence, rather than the 
cells.  
A decrease in CD68-positive macrophage-lineage cells has been observed in human bone 
marrow in aged subjects21 which may account for the impact ageing has on innate immunity 
as monocytes/macrophages are one of the first cell types to respond to invading 
microorganisms. However this was not replicated in a murine model, important to note due to 
the frequent use of mice in ageing research22.  
In murine studies to address immune cell function in ageing, peritoneal macrophage function 
was impaired in aged mice with regard to adherence, opsonization, phagocytosis, superoxide 
production and antibody-dependent cell cytotoxicity23-25. Also, a decrease in phagocytic 
ability of kupffer cells, specialised tissue macrophages of the liver, was found in aged mice 
by Videla et al. 25. This would ultimately reduce the ability of macrophages to interact with 
and destroy pathogens and unwanted self, e.g. tumour cells, seemingly impaired functions in 
the elderly population with regard to increased risk of infection and cancer24. 
Another mechanism for infection control elicited by macrophages is pro-inflammatory 
cytokine production via toll-like receptor (TLR) stimulation to elicit an immune response. 
Interestingly, some impairment in TLR function has been observed with ageing26, which 
could be predicted with increased incidence of infection16, however this does not explain the 
systemic increase in inflammatory cytokines in the elderly population14.  
Renshaw et al. observed impaired TLR expression, including reduction in TLR4 expression, 
and impaired TLR function in peritoneal and splenic macrophages from aged female 
C57BL/6 mice26. In their study, function of TLRs was measured as secretion of cytokines IL-6 
and TNF-α following stimulation of TLRs with known ligands, further possible explanations for 
the increased incidence of infection in the elderly 26. Conversely, Boehmer et al. found no 
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change in TLR4 expression in peritoneal macrophages between young and aged female 
BALB/c mice, but results supported a decrease in TNF-α and IL-6 secretion following LPS 
stimulation 27. This was attributed to a decrease in basal levels of p38 and c-jun NH2-
terminal kinase (JNK) MAPK and resulting reduction in MAPK activation, also found by Ding 
et al. 24,27. Despite an apparent inability of aged macrophages to release this cytokine, TNF-α 
has been found in elevated levels in the circulation of elderly subjects, a characteristic of 
inflammaging28,29.  
CD14 expression, another key pattern recognition receptor (PRR) important in LPS 
response, was reduced in aged C57BL/6 (B6) mice30, however expression in monocytes and 
macrophages with ageing has not been extensively studied. CD14 expression and function 
would also be of interest with regards to AC clearance6,31. 
Research on human primary cells is one way of comparing young and aged individuals and 
has been carried out using peripheral blood mononuclear cells (PBMC), PBMC-derived 
macrophages (HMDM) and bone marrow-derived macrophages (BMDM). As found in the 
murine models, monocytes isolated from aged individuals display a decrease in IL-6 and 
TNF production following LPS activation, which was attributed to deficient PKC and MAPK 
activation32. Whether PBMC derived macrophages are comparable to tissue macrophages is 
a question which is yet to be answered, a simpler conundrum in murine models, where tissue 
macrophages can be harvested.  
1.2.1.3. Apoptotic cell clearance in ageing 
Very few studies have addressed the role of apoptotic cell clearance in ageing, and the 
association of systemic inflammatory markers in ageing. Whether there are defects in AC 
clearance through ageing, or subsequent immune-modulation following interaction with AC, 
could be a result of an aged cell failing to function, the effect on an aged environment on cell 
function, or likely a combination of both. The levels of redundancy shown in AC clearance 
may imply that even if cells become less efficient as we age, there may be other factors 
present that subsidise these effects e.g. presence of AC:phagocyte bridging molecules. 
A study in mice found reduced apoptotic keratinocyte clearance in vivo in aged animals, and 
a reduction in AC interaction with thioglycollate-elicited peritoneal MØ from old mice in vitro33. 
Aged mice also displayed an increased anti-nuclear antibody titre, as associated with ageing 
in humans, and seen in autoimmune disease12,33,34. AC interaction was also reduced in MØ 
from young mice in the presence of donor serum from aged mice in the same study, showing 
interesting effects of both cell ageing and an aged environment on MØ ability to clear AC33. 
This is an accessible method of assessing the influence of an aged environment on MØ 
function, which to date has not been replicated in human studies. 
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1.3. The macrophage – the professional scavenger of AC 
1.3.1. Apoptotic cell clearance 
Apoptosis, or programmed cell death, allows removal of aged, damaged, infected or 
unwanted cells in a controlled manner, an essential process for maintenance of homeostasis 
in multicellular organisms. Apoptosis is an immunologically silent method of cell death, and 
would be functionally ineffective without subsequent clearance of apoptotic cells (AC), or 
efferocytosis (fig. 1). Failed AC clearance can result in secondary necrotic bodies and 
potential inflammation35, and has been implicated in a number of pathologies.  Defects in 
genes associated with AC clearance are well established mechanisms behind autoimmune 
disease, such as deficient C1q expression, which has been show to drive systemic lupus 
erythmatomous (SLE)36. Other examples include age-associated pathologies, including the 
dubbed „inflammaging‟37, and a number of age-related conditions, including arthritis, 
neuropathy  and atherosclerosis (reviewed in35).  
 
 
Figure 1. Macrophage phagocytosis of apoptotic cells Differentiated THP-1 macrophage 
interacting with apoptotic Jurkat cell.  
In contrast, in vivo murine studies have found persistent apoptotic cells, without the 
associated inflammatory effects38,39. Necrotic cell clearance has also been found to be non-
inflammatory in some models40, highlighting gaps in the current understanding of clearance 
mechanisms and subsequent immune modulation. 
ACs are rarely observed in vivo due to clearance efficiency, which is the result of a complex, 
multi-stage process41. Neighbouring cells, termed „amateur phagocytes‟ are thought to assist 
in the removal of apoptotic cells before classical morphological features associated with 
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apoptosis are displayed42,43, resulting in the need for in vitro AC clearance models to gain a 
full understanding of the process. The recruitment of „professional phagocytes‟, such as 
macrophages (MØ) occurs at sites, often pathological, with high apoptosis levels, e.g. the 
atherosclerotic plaque35,44-46. 
1.3.2. Macrophages; janitors of cell death 
Macrophages are inherently plastic; they have the ability to respond to varying 
microenvironments and alter their phenotype accordingly, in a reversible manner47. The 
activation state, or phenotype, of macrophages depends greatly on the balance of 
extracellular stimuli encountered48. There are several classification systems of macrophage 
phenotypes, e.g. M1 v. M2, or classical v. alternative, however the polar classifications used 
to define macrophage phenotype is likely to be a simplistic view, and therefore MØ 
phenotypes are difficult to truly classify. Researchers have tried breaking down MØ 
phenotypes into further subgroups and allocate reliable markers for identification, however a 
spectrum of varying characteristics depending on local stimuli is likely to be a more 
physiologically relevant model49. 
Monocytes and MØ both have designated subpopulations, though the link between 
monocyte subpopulations, and subsequent MØ subpopulations remain ill-defined. Murine 
monocyte subpopulations are well characterised according to surface receptor expression, 
and are designated as CD62L+CCR2+CX3CR1loLy6hi (inflammatory monocytes), or CD62L-
CCR2-CX3CR1hiLy6lo (resident monocytes)50,51 . Murine monocyte subpopulations do not 
appear to directly correlate functionally with human monocyte subpopulations52, which is 
important to consider in investigations into monocyte recruitment from the blood, e.g. in 
atherosclerosis, where murine models are prominent. Human monocyte subpopulations 
consist of a majority of classical CD14hiCD16- monocytes, and a second CD14loCD16+ 
(CX3CR1hiCCR2-) non-classical subpopulation50,53.   
Classification of MØ activation was initially based on a linear M1-M2 scale, with classically-
activated MØ at one end of the spectrum (M1), and alternatively-activated MØ at the other 
extreme (M2), with different degrees of activation in between (fig. 2; left). This was largely 
based on whether cells were exposed to Th1 or Th2 cytokines. Mosser and Edwards (2008) 
have since proposed a more physiologically relevant  model, based on a colour wheel49 (fig. 
2; right), whereby prominent groups may preside (colour blocks), but MØ could have any 
combination of characteristics according to the surrounding milieu, therefore activation status 
is less easily categorised49. This would explain why, unlike monocyte subgroups, specific 
„M1‟ and „M2‟ markers have been difficult to define. 
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Figure 2. Schematic depicting models of macrophage activation based on Mosser and 
Edwards (2008)49. A MØ activation spectrum based on a colour wheel (right) has been 
proposed to replace the linear M1-M2 scale of activation (left). Rather than distinct M1 and 
M2 phenotypes on either end of a linear scale of MØ activation (left), prominent groups may 
preside (right), but MØ could still have any combination of characteristics according to the 
surrounding milieu. 
 
Some phenotypes of MØ activation are well defined, such as the response to the classical 
pro-inflammatory Gram-negative bacterial wall component lipopolysaccharide (LPS). This 
classical subpopulation is associated with a cell-mediated immune response to invading 
pathogenic material, and is inflammation is maintained by Th1 cells49. Classical/M1-like 
activation is induced by tumour necrosis factor (TNF), or toll-like receptor (TLR) ligands such 
as lipopolysaccharide (LPS), and interferon-γ (IFN-γ)49. This results in a pro-inflammatory 
phenotype. Markers include TNF-α, interleukin-1 (IL-1), IL-6 and IL-10 release, and 
increased microbicidal activity via superoxide and free radical production49. 
Alternatively-activated macrophages have reparative roles, and encompass a broader 
spectrum of MØ activation, such as wound-healing and regulatory MØ49. Wound healing 
phenotypes occur at sites of tissue damage, following granulocyte release of IL-4, stimulating 
arginase activity in mice49. Arginase converts arginine to ornithine, a precursor required for 
extracellular matrix production. In vitro, MØ treated with Th2-associated cytokines IL-4 and/or 
IL-13 are less efficient at dealing with pathogens, as determined by significantly reduced pro-
inflammatory cytokine release and reduced intracellular microbicidal activity49. Paracrine 
mediators released by these MØ also seem to control inflammation in the surrounding 
microenvironment. Regulatory macrophages, which are often grouped in with alternatively-
activated MØ, are less well defined. They can be observed in response to AC clearance, and 
have also been shown to dampen an inflammatory response, e.g. by increased IL-10 
release49. Other inducers of regulatory MØ phenotype include glucocorticoids, prostaglandins 
and IL-1049. 
In the case of interaction with ACs, it is thought a reparative role predominates in the 
surrounding MØs, promoting clearing up of debris and dampening/resolving inflammation via 
M1 M2 
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anti-inflammatory cytokine secretion and subsequent suppression of pro-inflammatory 
mediator release54-56. The alternative/M2 phenotype is associated with more efficient AC 
interaction than their M1 counterparts57. This phenotype may be less well defined in the 
plaque environment, where a large quantity of ACs are located, due to the large variety of 
pro-inflammatory and anti-inflammatory stimuli in the immediate microenvironment of the 
MØ46,58.  
1.3.3. Phagocyte recruitment – a balance of ‘find-me’ versus ‘keep-out’ signals 
In the case of professional phagocyte recruitment, e.g. MØ, ACs release „find-me‟ signals, 
which attract phagocytes from the surrounding areas. Phagocytes detect these „find-me‟ 
mediators, which could be soluble or microparticle-associated59,60, and move along a 
concentration gradient towards the cell requiring clearance. This area of research has been 
largely neglected by current in vitro methods of assessing AC removal, therefore there is 
large potential for discovery of further „find-me‟ mediators. 
A wide variety of mediator classes have been identified as „find-me‟ signals, including 
chemokines, lipids and nucleotides61-63. CX3CL1, also known as CX3CL1 or neurotactin, was 
the first and, until recently, the only chemokine to be discovered with a role in phagocyte 
recruitment to apoptotic cells61. CX3CL1 release has been shown in Burkitt‟s lymphoma (BL) 
cells in association with microparticles (MPs), which are released following zeiosis, or 
blebbing, of the AC membrane61. CX3CL1 ligates to the phagocyte surface receptor 
CX3CR1, stimulating phagocyte migration61,64. The release of CX3CL1 from apoptotic cells 
within the plaque may also play a direct role in monocyte recruitment, or be conferred to 
endothelial cells via MPs. CX3CL1 can also be cleaved from the surface of cells as a soluble 
mediator, which has previously been implicated in pathologies associated with failed AC 
clearance and inflammation65-67. A subset of CX3CR1+ monocytes have been identified50, 
and CX3CL1 has previously been shown to have a role in recruitment of monocytes to the 
atherosclerotic plaque via interaction of monocytic CX3CR1 ligation to membrane bound 
CX3CL1 on the endothelial cell surface64,68. CX3CL1 also increases the expression of 
phagocyte:AC bridging molecule MFG-E8 (milk fat globule-endothelial growth factor 8), thus 
contributing to successful clearance69. A recent study has implicated a wider range of 
chemokines as „find-me‟ signals released by cells induced to apoptosis via Fas/CD95 
ligation59. Monocyte chemotactic protein-1 (MCP-1/CCL2) and IL-8 (CXCL8) were shown to 
attract THP-1 monocytes and primary human neutrophils respectively59, which could have 
inflammatory consequences70. 
Intercellular adhesion molecule-3 (ICAM-3/CD50) has recently been identified as a mediator 
of phagocyte recruitment to apoptotic B cells, in association with MPs71. Whether ICAM-3, or 
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CX3CL1, is released in association with MPs by apoptotic MØ, which occur in atheroma, is 
currently unknown, and may have implications in atherosclerosis progression, a pathology 
with a high proportion of localised ACs, including apoptotic MØ46. 
Nucleotide chemoattractants adenosine triphosphate (ATP) and uridine-5‟-triphosphate 
(UTP) were shown to be released in early apoptosis, and interact with purinoreceptor-2 
(P2Y2) on the phagocyte surface63, and have been suggested to act as short-range effectors 
in phagocyte recruitment. This highlights potential differences in roles between „find-me‟ 
signals that have yet to be fully investigated. 
Lysophosphatidylcholine (LPC) and sphingosine-1-phosphate (S1P) are lipid mediators 
shown to have a role in phagocyte attraction to dead cells 62,72,73, which also have additional 
autocrine functions. LPC interacts with G-protein-coupled receptor (GPCR) G2A72, and has 
been shown to induce expression of monocyte, neutrophil and lymphocyte chemoattractants, 
MCP-1, IL-8 and RANTES (Regulated on Activation, Normal T cell Expressed and 
Secreted/CCL5) respectively74. S1P also has autocrine functions, inducing phagocytic IL-8 
and IL-10 secretion, and inhibiting TNF-α and IL-12p70 release75-77. 
In order to maintain immunologically silent removal of ACs, recruitment of phagocytes must 
be controlled in terms of phagocyte lineage. „Find-me‟ mediators have to compete with „keep-
out‟ signals such as lactoferrin, which has been shown to selectively inhibit migration of 
granulocytes, but not mononuclear phagocytes78,79. This is important given the evidence of 
AC-induced IL-8 release, a neutrophil chemoattractant59, and the possible detrimental effects 
of such recruitment with regards to inflammation70. As this is a relatively new area of 
research, more „keep-out‟ signals are likely to be discovered. 
1.3.4. Recognition and tethering – a balance of ‘eat-me’ versus ‘don’t eat-me’ signals 
Following phagocyte recruitment, ACs must be identified as phagocytic targets. This occurs 
via upregulation of „eat-me‟ flags, balanced with the downregulation of „don‟t eat-me‟ 
markers, usually associated with viable cells80. Identified „eat-me‟ markers are gained from a 
variety of mechanisms, including exposure of intracellular molecules (e.g. 
phosphatidylserine81,82 and annexin I83), modification, redistribution and removal of cellular 
proteins, lipids and glycoproteins (e.g. modification of ICAM-384, phosphatidylserine (PS) 
oxidation85, removal of sialic acid86) and binding of opsonins (e.g. mannan-binding lectin 
(MBL), complement component C1q87,88).   
Loss of PS asymmetry, resulting in extracellular exposure, is a well-established „eat-me‟ 
signal expressed during apoptosis81,82,89. PS is normally restricted to the inner leaflet of the 
cell membrane89, and redistribution is thought to be required for AC clearance81,82. PS 
exposure alone, however, is not enough for successful execution of AC clearance, 
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demonstrated by a lack of clearance of viable cells induced to express PS constitutively90. It 
may be that further „eat-me‟ markers are required, and also downregulation of „don‟t eat-me‟ 
markers is likely to be essential for engulfment80. Identified „don‟t-eat-me‟ flags CD300a91, 
CD3192 and CD4793 inhibit phagocytosis of viable cells, and have been manipulated by 
cancer cells to evade the immune system94. Mechanisms of action vary; CD300a 
competitively binds AC surface phospholipids, including PS91,95; CD31 on viable cells binds 
homophilically to phagocytic CD31, preventing ingestion, but becomes functionally altered 
following induction of apoptosis, enabling phagocyte tethering92; CD47 inhibits engulfment 
via phagocytic receptor SIRPα (SIgnal Regulatory Protein α), with successful engulfment 
only achieved following CD47 disruption93. 
The phagocytic receptor for PS proved elusive for a significant period of time, however 
several receptors have recently been identified, T cell immunoglobulin mucins 1 and 4 (TIM-
1, TIM-4)96, brain-specific angiogenesis inhibitor-1 (BAI1)97, stabilin-298 and the Receptor for 
Advanced Glycation Endproducts (RAGE)99. Numerous bridging molecules have also been 
identified as facilitators of phagocyte binding via AC expressed PS, including growth arrest-
specific 6 (Gas6), protein S and MFG-E8. Gas6 and protein S bridge to Mer on the 
phagocyte membrane, whereas MFG-E8 bridges to αv integrins
100. The phagocyte receptor 
LRP1 (low-density lipoprotein [LDL] receptor-related protein 1 or CD91) has been shown to 
bind PS when colocalized with redistributed calreticulin, which is upregulated during 
apoptosis93. Calreticulin can also associate with bridging molecules C1q and MBL for 
recognition by LRP188. Oxidative modification of PS results in recognition by phagocytic 
scavenger receptors such as CD36101. Scavenger receptors (SRs) CD68, SRA-1, SRB-1 and 
lectin-like oxidised LDL receptor-1 (LOX-1) also have roles in apoptotic cell recognition102-105. 
The importance of the role of PS in AC removal becomes clear with genetic alteration of PS 
recognition mechanisms, resulting in pathology, including atherosclerosis and Alzheimer‟s 
disease106-110. 
ICAM-3 is a cell surface receptor that is expressed on human, but not murine, leukocytes, 
resulting in it being overlooked in a lot of cell clearance models80. Functional modification of 
ICAM-3 during apoptosis allows phagocyte recognition71,84  
Alongside Gas6, protein S and MFG-E8, collectins (MBL, surfactant protein-A (SP-A), SP-D), 
complement components (C1q, C3b), thrombospondins (TSP-1) and pentraxins (C-reactive 
protein (CRP), serum amyloid P (SAP), pentraxin 3 (PTX3)) have all been shown to facilitate 
phagocyte:AC bridging111-119. Immunoglobulin M (IgM) and IgG antibodies also have a role in 
opsonising ACs120-122. Soluble CD14 has also been observed to bind PS and AC, but a role in 
AC clearance has not yet been established38. 
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Phagocyte interaction with AC clearance is largely associated with a dominant non- or anti-
inflammatory response55,56. Interestingly, many receptors implicated in clearance of AC are 
also involved in an inflammatory innate immune response. This has resulted in the 
hypothesis that certain „eat-me‟ flags on the AC surface are the equivalent to pathogen-
associated molecular patterns (PAMPs) on invading pathogens, and have been termed 
ACAMPs (apoptotic cell-associated molecular patterns)123. In support of this, Tennant et al. 
observed that monoclonal antibodies targeting LPS also bind apoptotic cells, indicating 
structural similarities between PAMPs and ACAMPs124. 
1.3.5. Tickling/Signalling and engulfment 
Phagocytic downstream signalling pathways, activated following AC interaction, vary 
according to the ligand:receptor combinations activated within the phagocytic synapse. This 
is likely to vary between different phagocyte and AC cell types/lineages, however these cell-
specific interactions are yet to be characterised. 
Two downstream signalling pathways have been characterised, with further pathways so far 
restricted to research in Caenorhabditis elegans125. One pathway ensues following 
interaction of TAM family receptor Mer126, BAI197, or αv integrins
127, with PS or PS bridging 
molecules. This activates the CrkII-Dock180-ELMO complex, initiating Rac activation via 
GDP-GTP exchange128. This initiates Scar/WAVE mediated cytoskeletal rearrangement, and 
subsequent AC engulfment129,130. 
A second pathway is initiated via phagocytic LRP-1 or stabilin-2 ligation via adaptor protein 
GULP (enGULfment adaPter protein), activating ABCA1 (ATP-binding cassette transporter 1) 
and/or ABCA7131-133. The full signalling pathway is yet to be established, however evidence 
indicates that the two pathways converge at the equivalent of Rac activation134. Following 
cytoskeletal rearrangement and AC phagocytosis, phagosomes acidify, fuse with 
lysosomes135, and ACs are digested. This process can regulate future events, including 
further engulfment potential136, cytokine release55,56 and self-antigen presentation. This is 
important in relation to atherosclerosis research, where ingestion of lipid-laden apoptotic cells 
may impact engulfment potential and cytokine release, given persistent ACs and 
inflammation within the atherosclerotic plaque46,58.   
1.3.6. What next for the phagocyte? Immune modulation following apoptotic cell 
clearance 
Cytokines are secreted proteins vital for intercellular communication, with an important role in 
regulating numerous physiological processes, including growth, adiposity and 
haematopoiesis137. The term encompasses interleukins (IL), tumour necrosis factors (TNF), 
interferons (IFN), colony stimulating factors (CSF), transforming growth factors (TGF) and 
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chemokines137. Cytokines play a key role in regulation of innate and adaptive immune 
responses137,138.  
AC ingestion has been shown to induce TGF-β1, IL-10, prostaglandin E2 (PGE2), platelet-
activating factor (PAF), and suppress mediators associated with inflammation, including 
TNF-α, IL-1, IL-12 and IL-855,56. Results also showed apoptotic cells were able to dampen a 
pro-inflammatory response to LPS56. TGF-β production could have particular significance, as 
it has been shown to regulate eicosanoid and nitric oxide synthesis in the favour of an anti-
inflammatory phenotype in murine MØ139. 
Resolution of inflammation is an active process in which regulatory MØ release of anti-
inflammatory mediators, and autocrine and paracrine suppression of pro-inflammatory 
mediator release, plays an important part. Following resolution of inflammation, aided by 
lipoxins, resolvins and protectins140,141, immune cells migrate into the lymphatic system, and 
accumulate in local lymph nodes142.  
 
Figure 3. Summary of key stages and mediators of apoptotic cell clearance Apoptotic 
cell clearance is initiated by ‘find-me’ mediator release (if professional phagocytes are 
recruited), followed by recognition and tethering given the correct balance of ‘eat-me’ and 
‘don’t eat-me’ flags on the apoptotic cell surface. ‘Tickling’ or signalling results in engulfment 
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of the apoptotic cell, and subsequent immune-modulation. Figure taken from Hawkins & 
Devitt80. 
 
1.4. Atherosclerosis as an example of defective AC clearance in ageing 
Cardiovascular disease (CVD) has been described as the largest single contributor to global 
mortality, and is predicted to continue to dominate in the future143. Risk factors include high 
blood pressure, high circulating levels of LDL, low circulating levels of HDL, physical 
inactivity, smoking and a genetic predisposition to hypercholesterolemia144. Low 
socioeconomic status, psychological factors e.g. stress and depression and inflammation, 
amongst other factors, are also thought to predispose individuals to CVD144.  
Age, obesity and diabetes are also risk factors, and with an ageing population, and 
increasing incidence of obesity and obesity-induced diabetes, the incidence of CVD is set to 
rise145. CVD is more prevalent in men, with death rates higher in areas of greatest 
deprivation146. With such high death rates, and a cost of £19 billion to the UK economy146, 
greater understanding of the drivers of this disease is required. 
CVD is one of the leading causes of death in the UK, with the common underlying cause of 
atherosclerosis. In 2010, 180,000 people died of CVD in the UK, including 46,000 premature 
deaths146. Atherosclerosis is caused by the gradual build-up of lipid deposits, live and 
apoptotic immune cells and fibrous material in the sub-endothelial space of arteries147,148. 
This occurs in major arteries at branching points, where the endothelial barrier is under 
stress and becomes breached or activated. The result of plaque formation is narrowing of the 
artery lumen, and should the plaque progress, necrotic core formation149. The necrotic core 
forms as cells trapped within the plaque die by apoptosis, however the usual mechanisms 
that result in the clearance of dead cells fail, resulting in the accumulation of secondary 
necrotic cells150. This is despite the continual infiltration of macrophages, professional 
scavengers of apoptotic cells150. Formation of a necrotic core occurs in advanced plaques 
and is associated with plaque instability and rupture, leading to blockage of the artery lumen 
and subsequent cardiovascular events e.g. heart attack or stroke149.  
The failed clearance of apoptotic cells is viewed as a key driver of atherosclerosis151, and the 
mechanisms behind this could give insights into failed clearance in other pathologies, or 
indeed ageing.  
1.4.1. The inflammatory background of Atherosclerosis 
It is now widely accepted that atherosclerosis has a largely inflammatory background, with 
involvement of immune cells and inflammatory mediators from the initial stages of plaque 
formation, through progression of the plaque, destabilisation and rupture46,58.  
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Cellularity of advanced plaques is a crowded milieu of endothelial cells (ECs), smooth 
muscle cells (SMCs), monocytes, MØ, foam cells (MØ- and SMC- derived), mast cells, T 
lymphocytes, including live, apoptotic and necrotic cells147,148. Subsequently the extracellular 
milieu within the plaque is multifarious, containing oxidised lipoproteins, Th1 and Th2 
cytokines, matrix metalloproteinases (MMPs), fibrin, collagen, proteoglycans and cellular 
debris58,147. 
Atherosclerotic plaque formation is initiated by sub-endothelial lipoprotein retention, 
inflammation, LDL modification including EC-mediated oxidation, and EC dysfunction152-155. 
This causes EC adhesion receptor upregulation, recruiting monocytes from the blood 
stream156-160. Monocytes differentiate to macrophages and accumulate in the arterial intima, 
gorging on oxidised lipoproteins, inducing foam cell (FC) formation and death by 
apoptosis45,46,153,161. Apoptotic cell accumulation attracts further monocytes into the arterial 
intima, exacerbating plaque formation, and the process continues in a cycle162, accumulating 
further immune cells and inflammatory mediators, as listed above. This process can 
eventually lead to weakening of the artery wall, due to factors such as MMP accumulation, 
plaque rupture and thrombus formation46,58,150,163.  
Studies have found inflammatory effects of oxLDL on endothelial cells and MØs, which can 
account for the origins of monocyte recruitment to the subendothelial space and 
atherogenesis164-166. Why inflammation remains unresolved is unknown, and despite the 
prominence of MØ-derived foam cells in the plaque, the inflammatory status of these cells, 
either live or apoptotic, is unclear. 
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Figure 4. The role of monocytes and macrophages in key stages of atherosclerotic 
plaque formation 1. Lipoprotein retention and resulting sub-endothelial inflammation cause 
upregulation of adhesion molecules on the endothelial cell surface 2. Following firm 
adhesion, monocytes are recruited to the subendothelial space via diapedesis, differentiating 
into MØ and gorging on lipoproteins 3. Lipid laden MØ-derived foam cells accumulate in the 
plaque, die by apoptosis and recruit further monocytes from the circulation, exacerbating 
plaque progression and inflammation 4. Non-resolving inflammatory milieu can cause plaque 
progression to arterial wall weakening, plaque rupture and thrombus formation 
 
1.4.2. Interplay between LDL and monocytes/macrophages in atherogenesis 
Low-density lipoprotein (LDL) modification, monocyte recruitment and foam cell formation are 
well characterised as the initiating events of atherosclerotic plaque formation. LDL is the 
main carrier of serum cholesterol in humans, and although cholesterol has vital physiological 
roles, including maintenance of cell membrane fluidity and signal transduction, high levels of 
LDL in the blood is associated with increased risk of atherosclerosis147,167. The single 
initiating event that leads to the formation of fatty streaks, leading on to plaque formation is 
still debated, however strong evidence supports the Response-to-Retention theory152,168-170. 
Williams and Tabas argue that although many pathological processes contribute to early 
atherogenesis, they are generally normal physiological responses that would occur in healthy 
tissue as a result of retained subendothelial lipoproteins. Without this retention, the other 
defining features of atherogenesis and plaque progression, such as EC dysfunction and FC 
formation, would not ensue. This theory is strongly supported in study by Nakashima et al. 
Media           Intima                         Lumen 
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(2007)45, which found that diffuse intimal thickening (DIT) and lipoprotein accumulation 
preceded macrophage infiltration in autopsy samples of human coronary arteries. 
Lipoproteins retained within the sub-endothelium may then become modified, including 
oxidative modification154,155. Research has shown that ECs themselves may be primarily 
responsible for LDL oxidation153.  
1.4.2.1. LDL oxidation and the effect on recognition by macrophages   
LDL particles can be described as heterogeneous in nature due to variances in size, 
composition and structure171, and because of this, and factors such as diet, LDL samples 
from different individuals can vary greatly in the state of and susceptibility to oxidation172. 
The LDL particle consists of an outer layer of phospholipid and unesterified cholesterol, with 
a single apolipoprotein B-100 (apoB100) molecule at the surface171. The core of the LDL 
particle contains more unesterified cholesterol, and also triglycerides and cholesteryl ester171. 
Hevonoja et al. (2000)171 suggested a three-layer model for LDL particle structure, consisting 
of an outer surface layer, an interfacial layer and the core. Native LDL (nLDL) is bound by the 
LDL receptor, however modification of the LDL particle will result in recognition by alternative 
receptors, including scavenger receptors CD36, SRA-1 and LOX-1. Although scavenger 
receptors recognise various modified LDL particles, e.g. acetylated LDL, it is oxidised LDL 
particles that are thought to be the most physiologically relevant173. 
Sufficient oxidation of LDL particles must occur for recognition by scavenger receptors, as 
opposed to the LDL-R; for example, at least 60 lysine residues on the apo-B100 moiety must 
be substituted with aldehydes for recognition by SRA-1174. Despite a common affinity toward 
anionic phospholipids, scavenger receptors vary in the binding site recognised on the oxLDL 
molecule175-177. CD36 binds to the lipid moiety of oxLDL, whereas SRA-1 binds the oxidised 
apo-B100 molecule178,179. Much attention has been given to the role of scavenger receptor in 
atherogenesis, so as to determine whether specific receptors can be targeted to prevent 
oxLDL uptake by MØ and subsequent plaque formation.  
1.4.2.2. LDL-R 
Many MØ cell surface receptors have been implicated in modified LDL uptake. The LDL 
receptor (LDL-R) is responsible for uptake of native LDL particles and is regulated 
homeostatically by levels of intracellular cholesterol, preventing excess intracellular lipid 
accumulation180. Following oxidation of LDL, the LDL-R is no longer able to bind the LDL 
particle, which is now a recognisable ligand for receptors including scavenger receptors type 
A and B SRA/SRB), CD68, MARCO (MAcrophage Receptor with COllagenous structure) and 
LOX-1, many of which have also been shown to have a role in apoptotic cell clearance (see 
fig. 1)181. 
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1.4.2.3. SRA-1 
Scavenger receptor A-1 (SRA-1) has been described as a principal receptor in modified LDL 
uptake182. Initially identified as an acetylated LDL receptor, known ligands include oxidised 
LDL (oxLDL), LPS, PS and apoptotic cells103,177,179,183,184. It is a trimeric transmembrane 
glycoprotein with 6 domains, including the collagen-like domain; positive residues in this 
domain form a site for modified lipoprotein interaction177,185. SRA-1 expression is confined 
mainly to MØ, and has roles in adhesion, cell-cell interaction and innate immunity, therefore 
could have multiple roles in the development of an atherosclerotic lesion177,186. A role for SRA 
in clearance of apoptotic thymocytes has also been shown103. Foam cell formation has in part 
been attributed to SRA-1 mediated uptake of oxLDL, with a 30% reduction in macrophage 
oxLDL uptake in SRAI/II knockout mice187. 
1.4.2.4. CD36 
CD36 is another oxLDL receptor with a central role in foam cell formation. Mice lacking both 
CD36 and SRA were found to have a reduction in oxLDL degradation of 70-90%, with no 
apparent foam cell formation182. Studies with CD36 blocking antibodies show that 
approximately 50% oxLDL binding is mediated by CD36178. CD36 is a class B scavenger 
receptor expressed by monocytes, MØ, platelets, ECs and adipose tissue175. CD36 has been 
shown to bind oxLDL and LDL modified by monocyte-generated reactive nitrogen 
species188,189. Apoptotic cells and native lipoproteins have also been shown as CD36 
ligands190,191. 
1.4.2.5. LOX-1 
LOX-1 is a novel oxLDL receptor which is primarily found on ECs192. Like SRA-1 and CD36, 
LOX-1 has been shown to have multiple ligands, including PS, bacteria and apoptotic 
cells176. The type II transmembrane protein receptor is shown to be expressed by MØ, and 
expression is thought to be upregulated in pro-atherogenic conditions176,193. The primary role 
for LOX-1 in atherogenesis is thought to be endothelial dysfunction and apoptosis following 
oxLDL uptake194. 
These key receptors play an important role in oxLDL uptake, foam cell formation and 
subsequent atherogenesis. 
1.4.3. Apoptotic cell clearance in a lipid-rich environment 
The atherosclerotic plaque is lipid-rich and contains persistent apoptotic cells. The 
established plaque is a complex, dynamic microenvironment consisting of numerous different 
cell types and inflammatory mediators, including ECs, SMCs, monocytes, MØ, FCs, mast 
cells, T lymphocytes, oxidised lipoproteins, Th1 and Th2 cytokines, MMPs, fibrin, collagen, 
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proteoglycans and cellular debris58,147,148. This results in high rates of apoptosis and 
secondary necrosis within the plaque195. Although all cell types play a role in plaque 
progression, monocytes, MØ and MØ-derived FCs play a central role in formation and 
progression of the plaque, including plaque rupture, making these cells a desirable target in 
controlling inflammation in this disease. 
Failed AC clearance in atherosclerosis has become widely accepted150, largely due to the 
presence of ACs in the plaque46, despite a poor understanding of the mechanisms behind 
this. ACs largely go unseen in vivo, due to efficient clearance by neighbouring non-
professional and recruited professional phagocytes41,195. At sites of high apoptosis, e.g. the 
thymus, some free ACs can be detected, and free AC numbers are increased when AC 
clearance mechanisms are interfered with, e.g. as seen in CD14-/- mice38. In the 
atherosclerotic plaque, ACs persist to the point of secondary necrosis, resulting in a necrotic 
core in advanced atheromas, leading to the hypothesis of defective AC clearance196. Whilst 
mechanisms of MØ cell death in the plaque are largely studied, clearance mechanisms post 
apoptosis are less well understood, and a small number of studies into foam cell clearance, 
and the presence of ACs in the plaque, has led to the conclusion that clearance is 
defective46,195,197.  
Previous studies looked into the causes of such a high number of AC in a localised area, and 
have shown oxLDL as an inducer of apoptosis in foam cells; this was attributed to lysosomal 
damage, with lysosomal membrane disruption causing leaking of contents into the 
cytosol161,198,199. Excess intracellular cholesterol, via acetylated LDL (acLDL) loading, has 
also been demonstrated to induce apoptosis after trafficking to the endoplasmic reticulum 
(ER), where calcium stores are depleted, resulting in death effector expression200. However 
other studies, have not found prominent oxLDL induced toxicity of MØ, demonstrating a need 
for further study197,201. 
Competition between oxLDL or oxidised red blood cells was observed to affect AC binding 
using murine peritoneal MØ, at oxLDL concentrations of 250µg/ml195. Studies have also 
found that oxLDL competes with apoptotic thymocytes for the same receptors202. It is well 
established that scavenger receptors, such as those present in this model, CD36, SRA-1 and 
LOX-1, recognise both AC and oxLDL175-177. The oxLDL receptor CD36 is thought to play an 
essential role in AC clearance in vivo via recognition of oxidised phosphatidylserine 
molecules on the AC surface, a molecule that may not be recognised if oxLDL remains 
bound to the receptor101,203. 
Varying approaches exist to investigate AC clearance within the plaque, and clarity is vital 
when defining models, to enable comparison of results across studies. The use of human 
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endartectomy samples gives a real example of the plaque environment, however the 
observation of live cellular processes is not possible, only the outcomes of such processes 
can be investigated. Sample numbers are often low depending on availability and results can 
vary greatly due to differences in genetic backgrounds and lifestyle. Murine endartectomy 
samples are popular as genetic backgrounds can be controlled and also the environment 
and diet of the mice can be controlled. The significant drawback using this method, along 
with the inability to observe live cell processes, is the comparison of results across species. 
The same drawback occurs with the use of ex vivo murine macrophages (e.g. peritoneal), 
though live cell processes can be observed, and ex vivo human macrophages are not 
available. The absence of true human macrophage cell lines also makes the use of murine 
macrophage cell lines a popular method to study macrophage behaviour. For those wanting 
maintain a human focus to research, monocyte-like cell lines can be induced to macrophage-
like cells, though the method of induction and similarity of the cells to macrophages does 
raise questions of their own. Human monocyte-derived macrophages (HM-DMØ) from 
peripheral blood monocytes are arguably the closest fit to a true human 
monocyte/macrophage model, however even within this model, methods of monocyte 
isolation vary greatly, and the chosen method of differentiation is also inconsistent between 
research groups. 
It is important to understand the basis of AC accumulation in the plaque195, especially as an 
accretion of cells undergoing secondary necrosis exacerbate the pro-inflammatory 
environment of the plaque, contributing to plaque instability149,195. The nature of mechanisms 
behind inefficient AC clearance in the plaque is unknown, and could be a result of reduced 
function, competition in response to the local microenvironment, or a physiological change in 
phagocyte function in aged or damaged cells. The ability of foam cells to eat apoptotic foam 
cells is also uncharacterised, including the specific ligand-receptor partnering, and whether 
this compares to „normal‟ cell clearance mechanisms. The persistence of inflammation within 
the plaque, despite immuno-modulatory mechanisms that usually follow AC clearance, has 
also not been addressed in human cells. Mechanisms of monocyte recruitment into the 
plaque have been partially characterised, but the impact of plaque-derived AC mediators 
have not been addressed with regards to possible over-recruitment of monocytes, and lack 
of macrophage egress in the plaque.  Full characterisation of FCs and apoptotic FCs (aFC) 
in clearance could indicate where a failure in communication or function may arise. Many 
different AC receptors have been identified on phagocytes, including many of the oxLDL 
receptors already discussed, and bridging molecules such as thrombospondin and C1q 
should also be considered (see fig. 1)204. 
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1.4.3.1. The role of necrotic cells as inducers of inflammation within the plaque 
It is the accepted phenomenon that apoptotic and necrotic (primary and secondary) cell 
death have opposing immunological outcomes. Apoptosis is associated with immunologically 
silent cell death and corpse removal, with increasing evidence of a role in dampening 
inflammation55,56. Necrosis is associated with damage or trauma-induced cell death, loss of 
membrane integrity, and release of inflammatory intracellular contents, such as the much 
referred to HMGB1205. These „danger signals‟ have been proposed to contain DAMPs 
(damage-associated molecular patterns), that like ACAMPs, mimic PAMPs for PRR 
recognition, and potential inflammation consequences206. Secondary necrosis occurs when 
apoptotic cells remain undisposed and develop features including, most importantly in the 
case of inciting inflammation, loss of membrane integrity, causing intracellular contents to 
leak from the dying cell207.  
Evidence now suggests that immune responses induced by these events are not as clear-cut 
as previously suggested. For example some ACs have been shown to induce an 
inflammatory response208-210. Persistent apoptotic (which can develop into secondary 
necrotic) or primary necrotic cells have also been shown to be non-inflammatory38,40,211 
Immunogenicity of cell death is not only predicted by the cell death pathway, other 
parameters must also be taken into account, including the intrinsic antigenicity of the dying 
cell, previous stress of activation, the cell death inducer and the availability of responding 
immune cells212.  
Anti-inflammatory cytokine release is an important stage in resolution of inflammation and 
occurs in response to AC interaction54-56. It may be that a foam cell, or an aged cell, is no 
longer capable of eliciting an anti-inflammatory response in response to AC interaction, 
contributing to the dominant pro-inflammatory environment within the plaque, and potentially 
contributing to the systemic inflammatory status of aged individuals and those with 
atherosclerosis14,58,213. 
Evidence of the inflammatory consequences of secondary necrosis is lacking. Fadok et al. 
observed anti-inflammatory signals could be induced via early apoptotic, late apoptotic or 
lysed neutrophils, however these signals were overridden by inflammatory proteases 
released by secondary necrotic cells207. Anti-inflammatory effects were overridden, however 
protease inhibitors abrogated any inflammatory response207. In support of the inflammatory 
consequences of secondary necrotic cells, Shibata et al. found that early apoptotic, but not 
secondary necrotic, neutrophils down-regulate LPS-induced pro-inflammatory cytokine 
production of murine macrophages via induction of NO production214. The study also found 
that secondary necrotic neutrophils induced TNF-α release, but both apoptotic and 
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secondary necrotic cells suppressed inflammatory IL-12p40 and IL-6 release214. This 
supports the notion that perceived immune modulation following certain mechanisms of cell 
death is not as clear-cut as often stated. 
Immunogenic factors of primary necrosis, such as HMGB1, have been shown to be released 
during primary but not secondary necrosis of primary murine cells205. In contrast to this, 
HMGB1 release by apoptotic cell lines Jurkat, HeLa and U937 has been shown, 
demonstrating the crossover between markers for different cell death mechanisms215. The 
most compelling evidence for inflammatory consequences of uncleared ACs remains to be 
the presence of persisting AC and inflammation in autoimmune disease34, but even in these 
cases, causality is not established. Examples in murine models have also been shown of 
failed AC clearance, without the expected associated inflammation or autoimmune 
disease38,39. Primary necrosis may also drive inflammatory cytokine expression in the plaque 
via release of inflammatory intracellular components, and evidence of primary necrosis in 
atherosclerosis in mice has been found216. However not all studies into necrotic cells have 
observed resulting inflammation described40.  
1.4.4. Cytokines in the atherosclerotic plaque 
The cytokine profile in the atherosclerotic plaque is extremely complex given the quantity and 
variety of immune cells present, and the combination of pro-inflammatory mediators, e.g. 
oxLDL217, and anti-inflammatory mediators, e.g. AC55,56, and the resulting autocrine and 
paracrine effects on subsequent cytokine release. Sources of cytokine production can be 
categorised as primary, e.g. cytokine response to retained subendothelial lipoproteins, and 
secondary, e.g. cytokine response following established subendothelial inflammation and 
plaque formation, sources. 
One of the key features of AC clearance is the non-inflammatory manner in which unwanted 
„self‟ cells are disposed. This is not due to a lack of reaction by the phagocyte, but rather the 
release of a balance of cytokines, which have autocrine and paracrine effects, resulting in an 
immunologically silent or, even anti-inflammatory, response to self54-56.  The interesting 
phenomenon in the atherosclerotic plaque is that despite an excess of ACs and phagocytic 
MØ, a pro-inflammatory environment persists46,58. 
Just as persistence of ACs is poorly understood, the failure of occurring phagocyte:AC 
interactions to regulate the inflammatory environment of the atherosclerotic plaque, as seen 
with other inflammatory responses56, is also unknown. Cytokines found to be expressed in 
human atherosclerotic plaques include TNF-α, interleukins 1-3, 6, 8, 10, 12, 15,18, IFN-γ, 
TGF-β1-3, macrophage colony-stimulating factor (M-CSF) and a variety of chemokines137.  
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A selection of cytokines associated with immune modulation following AC clearance, and 
also found in human atherosclerotic plaques, will be investigated as part of this study. This is 
based on the hypothesis that inapt FC responses to AC, or inappropriate tickling of MØ or FC 
by apoptotic FC, may contribute to the inflammatory environment of the plaque.  
1.4.4.1. TNF-α in atherosclerosis 
TNF-α is a classic pro-inflammatory cytokine of the TNF superfamily, which has 2 identified 
receptors, TNF-R1 and TNF-R2137,218. TNF-α is released by a broad variety of cells, but is 
primarily produced in monocytes and MØ218, and is a suggested marker of classical 
activation. Cleavage of pro-TNF-α by TNF-α converting enzyme (TACE) ADAM17, an MMP, 
results in an active form of TNF-α; ADAM17 has also been implicated in soluble CX3CL1 
shedding219. Basal levels of TNF-α production, and the ability of aFCs to suppress TNF-α 
release, may provide insight into MØ subtype following lipid-loading of a MØ model, giving 
clues as to the drivers of inflammation in the plaque. 
TNF-α has been identified in human atherosclerotic plaques, and has been classed as a pro-
atherogenic cytokine137,220-222. TNF-α has the ability to drive inflammation in the plaque, but 
was not shown to be essential for inflammation. TNF-α deficient apoe-/- mice have reduced 
levels of inflammation in the plaque and reduced lesion size, but inflammation was still 
present223. Other studies have found no effect of TNF-α on lesion size in mice. TNF-α has 
also been shown to reduce scavenger receptor expression in HM-DMØ, which could have 
athero-protective effects224. Increased plasma concentrations of TNF-α have been implicated 
as a biomarker for risk of recurrent coronary events in stable post-MI patients225. A Finnish 
study also found TNF-α was a predictor of coronary heart disease, cardiovascular disease 
events and total mortality in men226. 
AC ingestion has been shown to suppress LPS-induced TNF-α release in vitro56. It is 
unknown whether aFC have the ability to suppress inflammation in a similar manner to other 
AC models, e.g. apoptotic neutrophils. 
1.4.4.2. IL-10 and IL-12 in atherosclerosis 
IL-12 is a cytokine that is also associated with inflammation, and drives a Th1/inflammatory 
response227. IL-12 consists of 2 subunits, p35 and p40, to produce an active heterodimer, 
and is produced by phagocytes and antigen presenting cells218. The IL-12R is also made up 
of 2 subunits, IL-12Rβ1 and IL-12Rβ2. The ratio of IL-10:IL-12 release has been proposed as 
a marker for MØ activation, with high IL-10 and low IL-12 release associated with alternative 
MØ activation, and the opposite profile representing classical MØ activation49,228. In vivo the 
plaque milieu may prime or maintain monocytes, MØ and foam cells in a classically activated 
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state, which is supported by the data that pro-inflammatory Th1 cytokines are prominent 
within plaques58. 
IL-12 has been identified in human atherosclerotic plaques, and was found to be produced 
by monocytes in vitro in response to oxLDL228. It has also been found to drive anti-oxLDL 
antibody production in murine models of atherosclerosis, driving inflammation229. It has a 
cross-regulatory role with IL-10, and has been shown to be suppressed by AC ingestion55,228. 
The contribution of FC and aFC induced IL-12 production in response to pro- and non- 
inflammatory stimuli will be investigated in this study to aid understanding of the failed 
resolution of inflammation in atherosclerosis. 
IL-10 is a regulatory, or anti-inflammatory, cytokine, associated with regulatory MØ 
activation, or Th2 responses137. As discussed in the previous section, IL-10:IL-12 ratios can 
be a marker of classical or regulatory MØ activation49, and they have cross-regulatory 
roles228. 
IL-10 has been found in human atherosclerotic plaques, which in murine models was found 
to correlate with reduced iNOS expression and cell death, showing some degree of immune 
modulation within the plaque228,230, and has been designated an anti-atherogenic cytokine137. 
It has been shown to be produced following AC ingestion in some studies55, however Fadok 
et al. (1998) found suppression of IL-10 in response to AC56. Whether aFCs can regulate the 
IL-10:IL-12 balance in unknown. 
Some evidence suggests that a reparative „M2‟ phenotype may be favoured by processes 
within the plaque, such as oxLDL mediated induction of PPARγ expression231,232, however 
the overall pro-inflammatory environment and lack of AC clearance indicates an „M1-like‟ 
phenotype may predominate58,195,217,233. This has implications in further cell clearance, as 
TNF-α has been shown to inhibit clearance mechanisms57,234. Further research has 
manipulated MØ activation to an alternative phenotype to see if pathology is improved. In a 
rat model of myocardial infarction, a pathological event following atherosclerotic plaque 
rupture, repair was improved via administration of PS-liposomes, promoting a reparative 
macrophage phenotype in cardiac MØ235. 
1.5. Role of chemotaxis in clearance and plaque formation 
The continual recruitment of monocytes to the atherosclerotic plaque is a key factor in 
disease progression, and inhibition of recruitment may prove to be athero-protective. MØ 
apoptosis is thought to be athero-protective in early lesions, with successful AC clearance by 
infiltrating monocytes dampening inflammation236. MØ apoptosis, and the subsequent 
recruitment of further monocytes from the blood stream, is thought to be a key event in 
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driving pathology of late atherosclerotic lesions, with persistent ACs and inflammation 
contributing to necrotic core formation and plaque instability149. 
A lack of MØ egress out of the atherosclerotic plaque via chemotaxis is also a contributing 
factor to atherosclerosis, which likely doesn‟t occur due to the failure of resolved 
inflammation, contributing to leukocyte trapping in the plaque80,237,238. 
Much research into apoptotic cell removal focuses on the interaction and phagocytosis 
phases of clearance, with increasing interest in subsequent immune-modulation. Research 
into the „find-me‟ stages of AC clearance is lagging, however recent research has identified 
roles for CX3CL161 and ICAM-371 in attraction of monocytes to sites of cell death. Interest in 
these earlier stages of AC clearance is becoming more prominent as the potential for 
therapeutic targets at sites of inappropriate cell recruitment increases, e.g. in atherosclerosis. 
To this end, a strong model for investigating the precise mechanisms of cell recruitment 
employed in different pathological scenarios would be valuable when considering prevention 
of inappropriate or excessive cell recruitment, as seen in atherosclerosis156,239. 
1.5.1. Recruitment of monocytes to the plaque 
Chemotaxis is the directional movement of cells along a concentration gradient of an 
attractive agent, an active process which is distinct from chemokinesis, the general, non-
directional movement of cells240. Chemo-attractive agents induce cell movement via 
promotion of cell motility and upregulation of adhesion molecule expression. Chemotaxis of 
immune cells to sites of infection or damage is a vital starting point to a robust immune 
response. Circulating leukocytes continually but transiently interact with the endothelium 
during immune surveillance, rolling along the endothelium as a result of shear force and low-
affinity interaction, which is mediated by adhesion molecules known as selectins on the 
leukocyte and endothelial cell surfaces241,242. 
1.5.1.1. Selectins and selectin ligands 
Selectins are type I transmembrane glycoproteins, a subclass from the lectin family 
(reviewed in 243). Selectin expression is restricted to leukocytes, platelets and the vascular 
system, thus have a specific role in leukocyte-endothelial cell adhesion and leukocyte 
recruitment to sites infection and inflammation244. L-selectin is found on the leukocyte cell 
surface and is thought to be crucial for leukocyte rolling in vivo245. L-selectin is able to 
mediate leukocyte rolling independent of E- and P-selectin, and is important in endothelial 
cell tethering246. Secondary capture via L-selectin can also occur between circulating and 
adherent leukocytes on the endothelial cell surface, which has been shown to have particular 
importance in leukocyte tethering in arterial venules and subsequently, atherogenesis247. E-
selectin, expressed on endothelial cells, is upregulated by inflammatory cytokines including 
39 
 
TNF-α160,248, which is found in human atherosclerotic plaques222. P-selectin is expressed by 
platelets, megakaryocytes and endothelial cells249. It is expressed constitutively in endothelial 
cells, packaged intracellularly in Weibel-Palade bodies and is trafficked rapidly to the 
endothelial cell surface following activation by effector molecules including histamine249. 
P-selectin expression is increased in endothelial cells overlying active atherosclerotic 
plaques, and co-expressed with upregulated ICAM-1, which has low expression levels in 
healthy arteries157. E-selectin and ICAM-1 expression is also increased in human plaque 
endothelial cells250. ICAM-1and E-selectin were constitutively expressed on intimal 
endothelium of both normal coronary arteries and those overlying fatty streaks, but ICAM-1 is 
increased only on and around plaque macrophages251. 
Following oxLDL exposure, it was found that ECs bind an increased number of monocytes 
with a stronger binding force than non-exposed ECs, via mechanisms including increased 
expression of ICAM-1 and P-selectin158,252. Vascular cell adhesion molecule-1 (VCAM-1) was 
also found to be upregulated indirectly via oxLDL induced cytokine-activated gene 
expression159, specifically TNF-α. OxLDL has also been shown to stimulate the release of 
monocyte chemotactic protein-1 (MCP-1) from endothelial and smooth muscle cells, 
recruiting circulating monocytes253. 
All selectins recognise sialylated carbohydrates, and other modified carbohydrates and 
glycoproteins with varying avidities, including fucosylation, sulphation and glycation.243 On 
leukocytes, PGSL-1 is the dominant ligand for P- and L-selectin243,254,255. E-selectin receptors 
have been difficult to identify, but include endothelial selectin ligand-1(ESL-1)243,256,257. 
1.5.1.2. Integrins and integrin ligands 
Stable interaction is established by activation of integrins. β2 (e.g. LFA-1) and α4 integrins 
(VLA-4) are the integrins that regulate leukocyte trafficking258. LFA-1 is expressed 
constitutively on leukocytes, and interacts with ICAM-1 and 2258. VLA-4 is expressed on 
monocytes and lymphocytes with homing potential, and interacts with a number of receptors, 
including VCAM-1258. PECAM-1 was also found to promote atherogenesis, attributed to its 
mechanosensitive properties, and the role of shear stress in atherogenesis258. 
Subendothelial lipoprotein retention has been shown to induce VCAM-1 expression259. 
VCAM-1 and ICAM-1 have been found on human coronary arteries260. TNF-α also induces 
VCAM-1 and ICAM-1 expression in human umbilical vein endothelial cells (HUVECs)261.  
ICAM-1 expression was also increased by native LDL in HUVECs, enhancing monocyte 
recruitment to the endothelium262.  
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1.5.1.3. Integrin-independent leukocyte adhesion 
CX3CL1 has also been shown to mediate leukocyte adhesion in an integrin-independent 
manner68. CX3CL1 is expressed by endothelial cells in response to inflammatory mediators 
and acts as an adhesion molecule. CX3CL1 also has a role in NK-mediated endothelium 
damage263. 
1.5.1.4. Transendothelial monocyte migration 
Transendothelial migration of monocytes has been shown to promote monocyte 
differentiation to macrophages and formation of foam cells in the plaque153. Monocytes in the 
sub-endothelium can be induced to differentiate into macrophages directly via oxLDL and 
also by oxLDL stimulated release of M-CSF264,265. Macrophages then gorge on modified 
lipoproteins via receptor mediated endocytosis in an unregulated manner, becoming lipid-
laden foam cells177,266. These events further demonstrate a key role for oxLDL and 
monocytes/macrophages in plaque progression. 
1.5.1.5. Apoptotic cell-derived microparticles 
Microparticles have been widely studied in atherosclerosis, but in the context of biomarkers 
of disease and thrombus formation267. The role of MPs in inflammation and immune cell 
chemotaxis is now becoming of greater focus268, with the majority of plaque microparticles 
thought to be macrophage-derived269. 
Microparticles (MPs) are phospholipid and protein rich submicron particles, derived from cell 
membranes of activated or dying cells270. MPs range in size from 0.1-2µm, with particles less 
than 100nm termed exosomes, and those greater than 1.5µm in diameter referred to as 
apoptotic bodies270 MPs are generated following zeiosis, or blebbing, and requires 
uncoupling of the cell membrane with the underlying cytoskeleton271 271,272. This results in 
shedding of microparticles (MPs), or released blebs, which have been shown to be attractive 
to monocytes60. UV-B has been shown to induce apoptosis via intrinsic and extrinsic 
pathways, a non-specific inducer of apoptosis, with mechanisms including DNA damage, 
oxidative stress and death receptor upregulation273. These pathways culminate in caspase 
cascade activation and resultant apoptosis274. Loss of cytoskeletal integrity is a key stage of 
apoptosis that leads to the generation of blebs/MPs, and eventually larger apoptotic 
bodies275. 
Lauber et al.62, through the use of caspase-3 deficient MCF-7 cells, showed AC-mediated 
chemotaxis induction is caspase-3 dependent. Caspase-3, a cysteine-aspartic acid protease, 
is an effector caspase which is present in cell lines used in studies here. It plays a central 
role in apoptosis, and can activate ROCK-1 or PAK2 to induce membrane blebbing276,277. 
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This generates phospholipid rich MPs, which also contain a rich source of cell specific 
antigens, including proteins and lipids, which could provide a huge source of unrecognised 
„find-me‟ signals for phagocyte recruitment to dying cells278.  
MPs in human atherosclerosis have been studied to the degree of proteomic, metabolomic, 
and immunomic characterisation278, but this has been focused largely on thrombotic potential 
and as biomarkers of underlying disease269. Immunogenicity of leukocyte-derived 
microparticles on endothelial cells has been shown279,280. MPs have also been shown to 
promote monocyte recruitment to the plaque via the transfer of ICAM-1 to endothelial cells281. 
The administration of THP-1-derived MPs was also shown to contribute to atherogenesis in a 
murine model of atherosclerosis282. So overall, the ability of MPs to modulate mechanisms in 
atherosclerosis has been addressed in many areas, however the influence of MPs on 
recruitment of monocytes to apoptotic cells in the plaque has not been addressed. 
A role for MPs as a „find-me‟ mediator in AC clearance is emerging, and is of particular 
interest in a plaque-like environment as MPs are extremely heterogeneous in nature, and 
reflect the status of the parent cell. If the parent cell, e.g. a lipid loaded MØ (known as foam 
cells) has properties that enhance disease progression, MPs can confer this message to 
surrounding cells, as they bear antigens of the parent cell. MP-derived antigens may confer 
signals via ligands on the surface of surrounding cells, or MPs may behave as a vector, 
transferring antigens directly to be incorporated into surrounding cells281.  
Chemoattractants CX3CL1 and ICAM-3, have recently been associated with apoptotic B cell-
derived MPs, and blocking action of these attractants was shown to reduce monocyte 
migration to MP61,71, however this has not been studied in the context of apoptotic MØ or 
atherosclerosis, despite the known role of CX3CL1 and its cognate receptor (CX3CL1) in 
atherogenesis239,283.   As MPs are a result of membrane blebbing, they contain a high 
proportion of phospholipids, including PS, and membrane proteins284. The receptors for MP-
induced chemotaxis are not well defined, and as CD14 has been previously shown to 
mediate AC recognition in this model, it is a prime candidate for AC-derived MP recognition.  
1.5.1.6. Soluble factors 
Chemokines are a cytokine subfamily, of mediators that can induce directed migration of 
cells to points of cell stress, death or disease. They are categorised into 4 families according 
to the spacing of the cysteine residues (C,CC,CXC and CX3C) , and CX3CL1 (CX3CL1) is 
the only identified member of the CX3C chemokine subclass
238,285. The unusual 
transmembrane structure of CX3CL1 consists of an extracellular N-terminal chemokine 
domain presented on a mucin-like stalk, a transmembrane α helix and a short cytoplasmic 
tail285,286 (fig. 4). Endothelial cells express CX3CL1 in response to activation or initiation of 
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apoptosis, where it acts as an adhesion molecule, initiating firm adhesion of CX3CL1 
receptor CX3CR1 positive monocytes68. CX3CR1 is a 7 transmembrane domain GPCR 
expressed predominantly on leukocytes, NK cells and T cells64,242. 
To function as a classic chemokine, CX3CL1 is cleaved via metalloproteinases tumour 
necrosis factor-alpha converting enzyme (TACE/ADAM17) or ADAM10219,287 (fig. 4). 
Following cleavage, from the cell membrane, CX3CL1 is shed from the cell surface and 
functions as a chemokine to recruit CX3CR1 positive cells288. G-protein signalling is required 
for chemotaxis of CX3CR1 positive cells64.  
 
Figure 5. Schematic of membrane bound and soluble CX3CL1 Membrane bound 
CX3CL1 acts as an adhesion molecule in monocyte recruitment to the endothelium during 
atherogenesis. Apoptotic cells have been shown to release soluble and microparticle-
associated CX3CL1 to attract phagocytes for clearance. Adapted from Liu et al.289. 
CX3CL1 was identified by Truman et al. on microparticles released by apoptotic B cells, and 
is recognised by CX3CR1 on the phagocyte surface64. CX3CL1 was also found to increase 
expression of milk fat globule-endothelial growth factor 8 (MFG-E8), an identified bridging 
molecule between apoptotic cells and phagocytes, thus enhancing clearance69. With such a 
prominent role in recruitment to dead cells, it is only logical that CX3CR1 has a role to play in 
atherogenesis, especially considering the influence this chemokine has on other processes 
involved in plaque progression. 
CX3CL1 is also a survival signal against apoptosis. This has implications when considering 
the accumulation of potentially „sick‟ lipid-laden cells within the plaque, and may be athero-
protective, or atherogenic, according to whether plaques are in the early or late stages149. 
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Soluble CX3CL1 also influences monocyte integrin function, enhancing avidity to ICAM-1 
and VCAM-1290,291. 
Other soluble factors involved in phagocyte recruitment to AC in the plaque are likely to 
include other „find-me‟ signals discussed previously (see 1.1.2.), including chemokines IL-8 
and MCP-159, nucleotide chemoattractants ATP and UTP63 and lipid mediators LPC and 
S1P62,72,73. „Keep-out‟ signals such as lactoferrin may also be present within the plaque78,79. 
1.5.2. Modelling chemotaxis to apoptotic cells  
As interest in chemotaxis to apoptotic cells develops, modelling mechanisms must equally 
develop. Previous research into monocyte recruitment to apoptotic cells has focused on 
vertical systems including transwells and vertical chambers61-63,71, e.g. modified Boyden 
chamber,which has become the most widely used method to study mammalian cell 
chemotaxis in vitro292-294, but whilst the system has advantages, it also has many 
limitations292. 
In vertical assay systems, the concentration gradient of the attractive agent is at 100% in the 
lower wells of the vertical chamber, and 0% in the upper wells, above the microporous 
membrane, which is the starting point of the migrating cells. The exact nature of the gradient 
around the membrane is unknown and is likely affected by the migrating cells themselves292, 
which will settle onto the top of the membrane before moving through, and blocking, the 
pores. Also the nature of cell movement cannot be distinguished during migration, so 
conclusions must be made based on the final distribution of migrated cells at the end of the 
assay292. 
More recently, increasingly precise methods are being sought to enable the mechanisms of 
chemotaxis to be investigated more thoroughly, with particular emphasis on stable 
concentration gradients of attractants, greater optical features and greater sensitivity and 
reproducibility292,295,296, which traditional methods such as the vertical chambers and under-
agarose assays do not provide292,294,297. 
1.5.2.1. Advantages of a horizontal assay system 
The Dunn chamber is a horizontal assay system using modified glass slides. The optics 
using the Dunn chamber are excellent and precise movement of individual cells can be 
observed. The Dunn chamber also provides the ability to observe in detail the kinetics of cell 
movement, including velocity and distance, and the precise time frame over which individual 
cells move, rather than the time frame of the assay. It can also be deduced whether cells 
within a population are moving uniformly or within subpopulations, a key focus of study of 
monocyte migration, given the observation of monocytic subpopulations with preferential 
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migratory properties according to differential surface receptor expression50,298. The Dunn 
chamber also provides a linear concentration gradient of attractant, which is established 
quickly between inner and outer chambers following assay set up (approx. 10-30 minutes), 
with a half-life of up to 30 hours depending on the molecular weight of the attractant292.  
There are advantages of using the vertical chamber, particularly the widespread use of the 
technique in the field, resulting in a well-characterised assay61,71,293. The assay also provides 
a high throughput of assays compared to a many other methods, including the Dunn method, 
allowing statistical significance to be established in fewer assays. Clear trends can be seen 
on qualitative plots generated using the Dunn chamber in these studies, but many lack the 
power of statistical significance, indicating a need for further repeats of assays. Multiple wells 
in the vertical chamber (48) make it more efficient in this respect, though multiple fields of 
view can be used in the Dunn assay to improve statistical data. 
Dunn chambers have not been used to date to investigate migration of monocytes to 
apoptotic cells. Whether apoptotic MØ- and apoptotic FC-derived MPs play a role in 
monocyte recruitment to the atherosclerotic plaque is not known. 
 
1.6. Aims and objectives 
The current study aims to better understand the clearance of apoptotic cells by MØ in ageing 
and age-related conditions, with a particular emphasis on apoptotic cell clearance in 
atherosclerosis. It aims to address the current gaps in knowledge relating to the mechanisms 
that underpin apoptotic cell clearance and how these are affected by ageing and by the 
aged-environment (as may occur within the atheromatous plaque). 
The primary hypothesis under consideration is that AC clearance becomes defective in 
ageing.  In addressing this hypothesis, the influence of an aged environment or altered cell 
function will be assessed.  
 
The specific aims of this project are: 
 
1.  To assess the ability of MØ and foam cells to interact with apoptotic cells: 
Initial studies will assess the use of human myeloid leukaemia THP-1 cells as a model of 
monocyte and MØ function, with regards to mechanisms involved in apoptotic cell clearance. 
This will include relevant processes to the atherosclerotic plaque, with the use of lipid-loaded 
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(oxLDL) THP-1-derived MØ to create foam cells, a cell phenotype specific to the 
atherosclerotic plaque. 
The ability of MØ and foam cells (FC) to interact with apoptotic cells, including apoptotic MØ 
and apoptotic FC, will be assessed. This is a process that has not been studied using human 
MØ-derived apoptotic cells55,203. 
Human monocyte-derived MØ will also be used as a phagocyte model, to compare 
responses in immortal human cell lines versus human primary cells. The ability of HM-DMØ 
to interact with THP-1 models of apoptotic MØ and apoptotic FC will be assessed. HM-DMØ 
interaction with apoptotic MØ or FC has not previously been investigated. 
 
2.  To assess the nature of cytokine responses of MØ and foam cells to apoptotic cells: 
To further understand the drivers of inflammation in the plaque, TNF-α, IL-10 and IL-12 
profiles of THP-1 derived- and HM-DMØ following exposure to a variety of stimuli will be 
assessed. This includes cytokine release at rest, following long-term lipid loading, to deduce 
whether foam cells are hyper-inflammatory. The response to LPS will be assessed, to allow 
comparison of inflammatory responses between lipid- (FC) and non-lipid-loaded (MØ) 
phagocytes. Cytokine responses to apoptotic MØ and apoptotic foam cells will be 
investigated, as this has not been studied in human cells, so it is unknown whether a non-
inflammatory phenotype, as observed in other apoptotic cell models, is relevant to the plaque 
environment54. The subsequent immune modulation in response to apoptotic cells, will also 
be assessed. This includes the ability of apoptotic MØ and apoptotic FC to „switch-off‟ an 
inflammatory response, as seen with other apoptotic cell models55. 
Human monocyte-derived MØ will also be used as a phagocyte model, to compare 
responses in immortal human cell lines versus human primary cells. The ability of HM-DMØ 
to modulate immune responses following interaction with THP-1 models of apoptotic MØ and 
apoptotic FC will be assessed. HM-DMØ interaction with apoptotic MØ or FC has not 
previously been investigated. 
 
3.  To assess monocyte recruitment to apoptotic MØ and foam cells: 
The chemoattractive properties of apoptotic cells and apoptotic cell-derived supernatant to 
THP-1 monocytes will also be assessed in a novel manner, with the use of a horizontal 
chemotaxis chamber. This will include monocyte migration to apoptotic MØ and apoptotic 
FC-conditioned medium, as „find-me‟ signals released by apoptotic cells in the plaque have 
not previously been studied. Mechanisms of apoptotic-cell induced chemoattraction will be 
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investigated, as these have not been studied previously using MØ as an apoptotic cell 
model, by targeting candidate mediators with blocking antibodies. 
 
4.  To assess the ability of MØ from aged individuals to interact with and respond to AC: 
Finally, a small scale pilot study using young (<25) and mid-life (>40) donors will be carried 
out to assess the ability of HM-DMØ from each age group to interact with, and modulate 
inflammation in response to, apoptotic cells. 
Donor plasma will also be used to condition THP-1-derived MØ in a „young‟ or „aged‟ 
environment, and assess the effect on THP-1-derived MØ clearance of apoptotic cells. This 
will be carried out in the absence of presence of donor serum from young or mid-life donors, 
to assess the role of immediate effects, versus the long term effects, of MØ interaction with 
apoptotic cells, in the presence of a „young‟ or „aged‟ environment. Similar studies have been 
done in rodents33, but this has not previously been assessed in humans. This may also 
indicate links between failure of control of immune responses in ageing and in 
atherosclerosis. 
Results from this study will advance current knowledge of phagocyte clearance of apoptotic 
cells in ageing and in an age-related environment. This would then provide future direction 
on the improvement of control of inflammatory responses in conditions such as 
atherosclerosis and ageing. 
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Materials and Methods 
2.1. Cell culture 
2.1.1. Cell lines 
THP-1: A human monocytic leukaemia cell line which grow in suspension. THP-1 cells can 
be differentiated into macrophage-like cells using various compounds299,300.  
Jurkat: A human T cell leukaemia cell line which grow in suspension301.  
Mutu: EBV-positive Burkitt lymphoma cell line which grow in suspension302. 
HUVEC: Human umbilical vein endothelial cell line, grown according to manufacturer‟s 
instruction (ATCC, Virginia, USA) and maintained at P<6. 
2.1.2. Cell culture and differentiation  
THP-1, Jurkat and Mutu cell lines were cultured in RPMI supplemented with 10% (v/v) foetal 
call serum (FCS), 2mM L-Glutamine, 100RU/ml Penicillin, and 100µg/ml Streptomycin 
(cRPMI), all purchased from PAA (Yeovil, UK). Cells were incubated at 37C in a 5% CO2 
humidified incubator and passaged when high levels of confluence were reached, 
approximately every 2-4 days. This maintained cell densities between 2 x105 -1 x 106 
cells/ml.  
HUVECs were cultured in Endothelial Cell Growth Medium (PromoCell, Heidelberg, 
Germany). Cells were incubated at 37C in a 5% CO2 humidified incubator and passaged 
when high levels of confluence were reached, approximately every 4-5 days. Cells were 
maintained at a maximum of 80% confluence and used at a passage number of <6. 
THP-1 cells were treated with 100nm VD3 (Enzo Life Sciences, Exeter, UK), 250nm PMA 
(Sigma-Aldrich, Dorset, UK) or both (double stimulated, DS) and incubated for 72 hours to 
induce differentiation into macrophage-like cells. Phase contrast images (20x) were taken to 
observe morphology using a fully motorised Zeiss Axiovert 200 M fluorescence microscope 
(Carl Zeiss Ltd, Welwyn Garden City, Fradley, Staffordshire, UK) and Hamamatsu Orca 
camera driven by Velocity (Perkin-Elmer, Cambridge, UK). 
2.1.3. Primary cell isolation and culture 
Solutions 
Dextran solution:    6% w/v Dextran in PBS 
Isotonic Percoll stock solution: 10% v/v PBS (10X) in Percoll 
Percoll working solution:  64% v/v Isotonic Percoll stock solution in 1X PBS 
48 
 
Up to 50ml of blood was taken from healthy volunteers using 9ml K3EDTA Vacuettes 
(Greiner Bio-One, Stonehouse, Great Britain), in accordance with ethical guidelines (Aston 
University Ethics Committee). Anti-coagulated (EDTA) blood samples were centrifuged to 
separate cells from platelet-rich plasma (350g; 20mins/brake off). The plasma layer was 
removed and frozen for future use. 6% dextran in Dulbecco‟s PBS (w/v) (Pharmacosmos, 
Holbaek, Denmark; PAA), was added to the cell fraction (2:1 total cell volume:dextran 
solution) to sediment red blood cells (2h; RT), leaving a leukocyte-rich fraction resting on top 
of the red blood cell fraction. The leukocyte-rich upper layer was harvested and dextran was 
removed by washing in sfRPMI + 1% (w/v) BSA (PAA) (350g; 4mins), and the leukocyte 
pellet resuspended in approximately 1ml sfRPMI + 1% BSA. Resuspended leukocytes were 
layered onto a band of 64% Percoll working solution, and centrifuged (700g; 20mins; brake 
off), leaving a peripheral blood mononuclear cell (PBMC) band on top of a Percoll layer, and 
an uppermost layer of RPMI. The PBMC band was extracted with a 1ml Pasteur pipette and 
washed in sfRPMI + 1% BSA (w/v) (350g; 6mins). PBMCs were resuspended in specialist 
chemically-defined MØ medium (Life Technologies, Paisley, UK) (serum-free, 2mM L-
Glutamine, 100RU/ml Penicillin, and 100µg/ml Streptomycin) and seeded directly into 24 or 
96 well plates, or onto glass coverslips, for future assays. Non-adherent cells (lymphocytes) 
were removed 20-24 hours post-seeding by extensive washing. Adherent cells (monocytes) 
were allowed to differentiate to MØ for 7-14 days prior to use. Medium was replaced every 3-
5 days prior to assay use. 
2.2. Foam cell formation 
2.2.1. LDL isolation and oxidation  
Solutions 
Light solution:     15.1046g KBr in 100ml dH2O 
Heavy solution:    33.4218g KBr in 100ml dH2O 
BCA/copper sulphate working solution: 200µl copper (II) sulphate solution (4% w/v) 
      19.8mls BCA solution 
Human plasma was obtained from healthy volunteers. Native LDL (nLDL) was isolated from 
the plasma by ultracentrifugation at 32000xg (20h;16C), using light and heavy potassium 
bromide (KBr) solutions (Sigma-Aldrich) to provide a density gradient. In brief, 50mg sucrose 
(Sigma-Aldrich) and 770mg Kbr were dissolved in 2mls of plasma. 200µl ethylene glycol 
(Sigma-Aldrich) was added and 2mls of heavy solution was layered on top of the plasma. 
4mls of KBr heavy solution was then layered on top, followed by dH2O, which was added 
until 2-3mm space remained at the top of the centrifuge tube. The nLDL band was removed 
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and desalted by size exclusion chromatography using PD10 columns (GE Healthcare, 
Buckinghamshire, UK). The nLDL was then filtered through a 0.45µm filter to sterilise. Liquid 
nitrogen was used to snap freeze samples in 1 ml aliquots, aliquots were then stored at -20C 
until required. 
The BCA assay was used to measure concentration of LDL samples, which was chosen on 
the principle that there is one protein molecule per LDL particle (apo-B100). Standards of 
protein from 0-2.5mg/ml were generated using BSA diluted in PBS (PAA). Samples were 
incubated with BCA/copper sulphate (Sigma-Aldrich) working solution for 30 minutes at 37C 
before the optical density was read at 570nm using a Biotek EL800 Microplate Reader. A 
standard curve was generated, based on known concentrations of standard solutions, to 
estimate the concentration of LDL in the sample. 
Oxidised LDL samples (oxLDL) were produced by incubating nLDL with 10µM copper 
sulphate (1h; 37C). After 1 hour, 10µl (0.5M) of the chelating agent EDTA (Sigma-Aldrich) 
was added to prevent further oxidation. The oxLDL was then desalted by size exclusion 
chromatography using PD10 columns and sterile filtered at 0.45µm. Samples were snap 
frozen using liquid nitrogen and stored in 1ml aliquots at -20C until required. 
2.2.2. Carbonyl ELISA to measure protein oxidation  
Solutions:  
Coating buffer:  1 x carbonate-bicarbinate buffer capsules in 100ml dH2O 
Wash buffer:   0.9% (w/v) saline supplemented with 0.05% (v/v) Tween 20 
Block buffer:  1% (v/v) Tween 20 (Sigma-Aldrich) in PBS 
LDL samples and BSA standards (provided by Chris Dunston, Aston University, UK) were 
diluted to 20µg/ml protein and made up to 200µl in coating buffer. 50µl of each sample was 
added to wells in triplicate and incubated (1h; 37C). Wells were washed 3 times with wash 
buffer and 50µl 2,4-dinitrophenylhydrazine (DNPH), (1mM in 2M HCl), (Sigma-Aldrich), was 
added for 1 hour at room temperature to derivatise carbonyl groups. Wells were washed 3 
times with wash buffer and 50µl secondary antibody (goat anti-mouse IgE, diluted 1:5000 in 
blocking buffer) (Sigma-Aldrich) was added and the plate incubated (1h; 37C). Wells were 
washed 3 times with wash buffer and samples developed with o-Phenylenediamine 
dihydrochloride (OPD) (100µl/well) (Sigma Aldrich). The reaction was stopped with 50µl of 
1M HCl (Sigma-Aldrich) per well and the plate read at 490nm using a Biotek EL800 
Microplate Reader. A standard curve was generated, based on known concentrations of 
standard solutions, to estimate the carbonyl content in each sample. 
50 
 
2.2.3. Foam cell generation 
THP-1 cells were seeded in 24 well tissue culture plates and differentiated into macrophage-
like cells as above (see 2.1.2.). Unstimulated, VD3 stimulated, PMA stimulated and double 
stimulated (DS) THP-1 cells were then incubated for a further 72 hours at 37C with desired 
concentrations of nLDL and oxLDL (diluted in cRPMI). Phase contrast images (20x) were 
taken to observe morphology using a fully motorised Zeiss Axiovert 200 M fluorescence 
microscope (Carl Zeiss Ltd) and Hamamatsu Orca camera driven by Velocity (Perkin-Elmer). 
2.2.4. Visualising lipid droplets with light microscopy – Oil Red O staining 
THP-1, VD3 stimulated, PMA stimulated and double stimulated cells were treated with nLDL 
and oxLDL as above (2.2.3.), fixed with 1% w/v formaldehyde (Sigma-Aldrich) solution 
(diluted in PBS) and stored at 4C until staining. Immediately prior to staining, Oil Red O 
working solution (Cayman Chemical, Michigan, USA) was prepared by adding 6 parts stock 
solution to 4 parts dH2O and filtered through a 0.4µm filter to remove precipitate prior to 
staining. Fixative was removed and each well washed with dH2O. 60% isopropanol (Sigma-
Aldrich) was then added to each well for 5 minutes. The isopropanol was removed and Oil 
Red O working solution was added to each well for 30 minutes at room temperature. Wells 
were then washed with dH2O, lipid accumulation observed in cells and phase contrast 
images (10x, 20x) were taken to observe morphology using a fully motorised Zeiss Axiovert 
200 M fluorescence microscope (Carl Zeiss Ltd) and Hamamatsu Orca camera driven by 
Velocity (Perkin-Elmer). 
2.2.5. Visualising lipid droplets with fluorescence microscopy – Nile Red staining 
In order to observe lipid accumulation in cells, double stimulated cells (following LDL 
treatment) were fixed with 1% (w/v) formaldehyde solution (diluted in PBS) and stored at 4C 
until staining. Oleic acid treatment was used as a positive control for staining (1:5000 dilution 
in cRPMI). Staining was carried out as per manufacturer‟s instructions (Lipid Droplets 
Fluorescence Assay Kit, Cayman Chemical). In brief, cells were washed with provided assay 
buffer before Nile Red staining solution was added (1:1000 dilution in assay buffer) for 15 
minutes at room temperature. Cells were then washed with assay buffer and lipid droplet 
staining observed via fluorescence microscopy (excitation/emission = 485/535) (40x). Lipid 
droplets appear as green round spots. Images (20x) were taken to observe morphology 
using a fully motorised Zeiss Axiovert 200 M fluorescence microscope (Carl Zeiss Ltd) and 
Hamamatsu Orca camera driven by Velocity (Perkin-Elmer). 
2.2.6. Quantifying lipid droplet accumulation – assay optimisation 
A black opaque 96 well plate (Cat. No. DPS-134-070R, Fisher Scientific, Loughborough, UK) 
and a clear 96 well tissue culture plate (Cat. No. CC015, Appleton Woods, Birmingham, UK) 
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were loaded with varying concentrations of goat anti-mouse-FITC (Sigma-Aldrich) to 
compare overspill of emitted light between wells. Additionally, cells were cultured in a clear 
96 well tissue culture plate, then lysed with 2% SDS (Sigma-Aldrich). Whole cell lysate was 
then transferred to corresponding wells in a black 96 well plate for Nile Red staining (see 
2.2.5.). 
2.2.7. Quantifying lipid droplet accumulation – fluorescence plate reader assay 
Double stimulated cells were treated with oxLDL as above (2.2.5.), at a density of 5 x 103 
cells per well, in a black, clear bottomed 96 well tissue culture plate (Cat. No. DPS-130-
010N, Fisher Scientific, Loughborough, UK). Oleic acid treatment was used as a positive 
control for staining (1:5000 dilution in full culture medium). Staining was carried out as per 
manufacturer‟s instructions. In brief, cells were washed with provided assay buffer and fixed 
with fixative solution (diluted 1:10 in assay buffer) for 10 minutes. The plate was centrifuged 
and washed with assay buffer before Nile Red staining solution was added (1:1000 dilution in 
assay buffer) for 15 minutes at room temperature. Cells were then washed with assay buffer 
and lipid droplet staining observed with a Spectramax Gemini EM fluorescence plate reader 
(Molecular Devices) (excitation/emission = 485/535). Results showed that this protocol was 
not efficient at predicting foam cell formation (data not shown). 
2.3. Assessment of cell viability 
Levels of apoptosis were continually monitored across all cell lines using light microscopy to 
assess the presence of morphological features of apoptosis, such as cell shrinkage, nuclear 
condensation and blebbing. Cells were also routinely analysed via flow cytometry to assess 
proportions of the population that were displaying live or dead morphology. 
2.3.1. Annexin V/Propidium iodide staining  
Solutions 
Binding buffer:  150mM NaCl, 10mM HEPES (pH7-7.5), 2.5mM CaCl2 in dH2O 
To assess cell viability, cells were washed in binding buffer and stained with 2µl (1:50 in 
binding buffer) Annexin V-FITC (AxV-FITC) (Bender MedSystems, Vienna, Austria) for 15 
minutes on ice and washed once with, and resuspended in, 1ml binding buffer. Immediately 
prior to flow cytometric analysis of each sample, 5µl of stock propidium iodide (PI) from the 
AxV-FITC Apoptosis Detection Kit was added to reveal the proportion of cells with a leaky 
cell membrane, a marker of cell necrosis. Cells were analysed using a Beckman Coulter 
Quanta SC flow cytometer. Unstained cells were used as a negative control.  
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2.3.2. Assessing toxicity induced by native and oxidised LDL 
To assess toxicity of LDL treatment on monocyte-like cells, THP-1 were seeded in 6 well 
tissue culture plates in a total volume of 5mls. Cells were treated with nLDL and oxLDL 
diluted in cRPMI. Following LDL treatment, 500µl samples were taken from each well daily 
for up to 7 days to assess levels of apoptosis and necrosis induced by LDL treatment, as in 
2.3.1. 
To assess toxicity of LDL treatment on macrophage-like cells, THP-1 cells were seeded in 6 
well tissue culture plates. Cells were treated with nLDL and oxLDL diluted in cRPMI and one 
tissue culture plate was sampled each day. Immediately prior to staining, cells in all wells of 
one plate were incubated in 5mM EDTA in PBS for 1 hour at 37C to bring adherent cells into 
suspension. Cells were then washed twice in binding buffer before AxV/PI staining as above, 
as on 2.3.1. Unstained cells were used as a negative control.  
2.3.3. Apoptosis induction 
To induce apoptosis with minimal secondary necrosis, Jurkat, Mutu, THP-1 macrophages 
and THP-1 foam cells were treated with 100mJ/cm2 UV radiation (typically 2-4 minutes 
treatment), using a UVP UXV Chromato-Vue C-71 light box, and incubated for 18-24 hours 
at 37C. To confirm induction of apoptosis, cells were stained for flow cytometry according to 
the protocol in section 2.3.1. UV dose was monitored using a UXP UVX Radiometer. 
Induction of apoptosis was also confirmed using light microscopy, as discussed above. 
To confirm levels of apoptosis in cells for individual assays, a sample of the apoptotic cells 
were fixed with 1% (w/v) formaldehyde in PBS for flow cytometry and side scatter and 
forward scatter evaluated. The smaller, granular population appear in the „dead‟ zone, 
whereas the larger, healthy cell population appear in a distinct „live‟ zone303. 
All apoptotic cells used in these studies were human cell-line derived. 
2.3.4. Isolation of cell-free supernatant 
Viable cells were seeded at 2x106 cells/ml in chemically-defined macrophage medium + 
2mM ʟ-glutamine + 100IU/ml penicillin. Medium was also replaced prior to UV treatment. 
Apoptosis was induced by UVB irradiation (see 2.3.3.) and supernatants harvested following 
18-24 hours incubation at 37C. Large cell debris was removed by centrifugation at 350xg for 
6 minutes to generate cell-free supernatant (CFS), which contains microparticles and soluble 
factors (e.g. cytokines and chemokines). 
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2.4. Immunofluorescence staining of cell surface proteins 
Cells were washed with 0.1% w/v BSA in PBS and 2 x 105 cells were added to each tube for 
staining. Cells were stained for 45 minutes on ice with the relevant primary antibodies, to a 
final volume of 100µl, using 20% v/v normal human serum (NHS) (PAA) in PBS as a diluent. 
All primary antibodies were titrated and concentrations chosen according to saturation of 
receptor staining. Control antibody concentrations were chosen to match maximum antibody 
concentrations of the same isotype. Following primary antibody staining, cells were washed 
twice with 5% v/v NHS (in PBS) and tubes were stained with secondary antibody goat anti-
mouse-FITC (GAM-FITC) for 30 minutes on ice, including cells with no primary antibody 
staining (secondary/FITC control). GAM-FITC was diluted 1/2000 in 20% v/v normal goat 
serum (NGS) (PAA) and 100µl was added per well. Following staining, cells were washed 
twice with 5% v/v NGS and fixed with 1% w/v formaldehyde. Cells with no primary or 
secondary antibody staining were also analysed (unstained control). Cells were stored at 4C 
until analysis via flow cytometry. 
2.4.1. Surface receptor expression of THP-1 models 
Unstimulated and VD3, PMA and double stimulated THP-1 cells were stained with mouse 
anti-human monoclonal antibodies targeting CD36 (Abcam, Cambridge, UK), LOX-1 [clone 
331212] (R&D Systems, Abingdon, UK), SRA-1 (R&D Systems), CD14 (clones 61D3/63D3, 
made in house) and ICAM-3 (clone MA4, made in house). THP-1 cells were seeded in 6 well 
plates and differentiated for 72 hours as above. Following differentiation, PMA and DS cells 
were treated with 5mM EDTA in PBS (1h; 37C) to bring adherent cells into suspension. Cells 
were stained with primary antibody as above (2.4.). The following final concentrations were 
used for each antibody: CD36 (20µg/ml), LOX-1 (50µg/ml), SRA-1 (50µg/ml), CD14 (neat 
supernatant), ICAM-3 (1/100 dilution), IgG1 control [clone MOPC21] (20 µg/ml) (Sigma-
Aldrich), IgG2b control (50µg/ml) (Abcam). All primary antibodies were titrated and 
concentrations chosen according to saturation of receptor staining. Receptor saturation could 
not be reached with LOX-1 and SRA-1 antibodies, so concentrations were chosen with 
positive receptor staining and low background staining. The staining of these antigens would 
not be useful for quantifying cell surface protein expression, but can be used for semi-
quantitative/qualitative staining. Control antibody concentrations were chosen to match 
maximum antibody concentrations of the same isotype. Cells were then stained with 
secondary antibody as above (2.4.) Cells were fixed with 1% w/v formaldehyde and stored at 
4C until ELISA analysis. 
In order to assess cell surface receptor expression in cells following oxLDL treatment, 
indirect immunostaining of cells of interest was carried out with monoclonal antibodies 
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targeting CD36, LOX-1, SRA-1, CD14 and ICAM-3, according to the protocol above. Cells 
were fixed with 1% w/v formaldehyde and stored at 4C until analysis via flow cytometry. 
To support chemotaxis studies, the anti-CX3CL1 [clone 51637] (R&D Systems) and anti-
ICAM-3 antibodies were used for indirect immunostaining of cell surface CX3CL1 and ICAM-
3 in live and apoptotic MØ and foam cells, to gather evidence for loss of expression via 
membrane shedding, as in section 2.4. Cells were fixed with 1% w/v formaldehyde and 
stored at 4C until analysis via flow cytometry. 
2.4.2. Endothelial cell phenotyping following treatment with live and apoptotic MØ/FC-
conditioned medium 
Human umbilical vein endothelial cells (HUVECs) were cultured in 6 well plates and 
incubated in the presence of live MØ/FC CFS and apoptotic MØ/FC CFS, set up as in 2.3.4., 
or medium control (24h; 37C). Following incubation, conditioned medium was removed and 
cells washed with PBS and incubated in trypsin/EDTA (PAA) to lift adherent cells into 
suspension (20min; 37C). Direct immunostaining was carried out with FITC-labelled anti-
CD62E, or FITC-labelled control, and results analysed by flow cytometry (see 2.4.). 
2.5. Phagocyte interaction with, and responses, to apoptotic cells and other mediators 
2.5.1. Interaction of phagocytes with apoptotic cells 
THP-1 cells were seeded at 2x104 cells per well in 24 well tissue culture plates in cRPMI with 
250nm PMA or 100nm VD3 + 250nm PMA (DS) (72h; 37C). Following differentiation, cells 
were treated with (FC) or without (MØ) oxLDL (indicated concentrations) (72h; 37C). Culture 
medium was removed and 2 x 105 apoptotic jurkat, THP-1 macrophage or THP-1 foam cells 
were added per well, in 500µl serum free RPMI + 1% P/S + 0.2% BSA. A 10:1 ratio of 
apoptotic cells: macrophages was chosen to provide excess ACs for interactions. Plates 
were incubated (1h; 37C) and wells were then washed with 1ml cold PBS to prevent further 
interactions and remove unbound apoptotic cells. Cells were fixed with 1% formaldehyde 
(w/v in PBS) and stored at 4C until staining. To stain, 2-3 drops of Diff-Quik (made in house) 
were added to each well to visualise cells. Macrophages (THP-1 derived) appear as large 
adherent light-blue cells, and apoptotic cells appear as small dark blue spots. Interactions 
were counted as number of macrophages interacting with apoptotic cells per 200 cells 
counted in each well. 
Primary human monocytes were seeded as above and allowed to adhere overnight in 
chemically-defined macrophage medium (CD-MØ medium). The culture medium was 
replaced, removing non-adherent cells (lymphocytes) and adherent monocytes left to 
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differentiate for 7-14 days in CD-MØ medium, which was replaced every 3-5 days until the 
time of the assay. Interaction assays were then carried out as above in chemically defined 
macrophage medium with apoptotic THP-1 derived macrophages/foam cells. 
2.5.2. Interaction of oxLDL treated cells with E.coli  
THP-1 cells were seeded in 6 well tissue culture plates. Following differentiation and oxLDL 
treatment, the culture medium was removed and cells washed in complete or serum-free 
medium. In dark conditions, dilutions of fluorescein conjugated E. coli (Life Technologies) in 
either complete or serum-free medium were added to relevant wells and plates incubated 
(40min; 37C).  Wells were then washed with 1ml cold PBS to prevent further interactions and 
remove unbound E. coli. Differentiated THP-1 cells were then treated with 5mM EDTA in 
PBS (30min; RT) to bring adherent cells into suspension. Cells were washed in 0.1% BSA in 
PBS then fixed with1% w/v formaldehyde and stored at 4C until analysis via flow cytometry. 
Following optimisation, a 1/1000 dilution of fluorescein conjugated E. coli in SF RPMI was 
chosen. After samples were analysed by flow cytometry, trypan blue (Sigma-Aldrich) was 
used to quench fluorescence of E. coli particles bound to the THP-1 macrophage/foam cell 
surface, and samples re-analysed by flow-cytometry. This enables differentiation between 
bound and internalised E.coli, highlighting any physiological differences between function of 
THP-1 macrophages and THP-1 foam cells. This may highlight whether any decreases in 
apoptotic cell binding is a result of altered function, or whether a general decrease in activity 
may be associated with foam cells as they were „sick‟. 
2.5.3. AC inhibition of inflammatory response 
THP-1 cells were seeded at 5x105 cells per well in 24 well tissue culture plates in cRPMI with 
250nm PMA or 100nm VD3 + 250nm PMA (DS) (72h; 37C). Following differentiation, cells 
were treated with (FC) or without (MØ) oxLDL at a concentration appropriate to the 
experiment (72h; 37C). Culture medium was removed and 1.5x106 apoptotic jurkat (see 
2.3.3.), THP-1 macrophage, THP-1 foam cells (6h post UV) or medium control were added 
per well, in 500µl sfRPMI containing 1% P/S + 0.2% BSA, and plates incubated (20h; 37C). 
0.5ng/ml LPS (from E. coli O111:B4, Sigma-Aldrich), diluted in sfRPMI, or sfRPMI alone was 
then added to wells with or without the presence of ACs, with normal human serum (10% 
final conc.) and incubated (4h; 37C). Supernatants were harvested and stored at -20C until 
ELISA analysis. 
Primary human monocytes were seeded at 8.3x104 in 96 well tissue culture plates and 
allowed to adhere overnight in chemically-defined macrophage medium (CD-MØ medium). 
The culture medium was replaced, removing non-adherent cells (lymphocytes) and adherent 
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monocytes left to differentiate for 7-14 days in CD-MØ medium, which was replaced every 3-
5 days until the time of the assay. Interaction assays were then carried out as above in 
chemically defined macrophage medium with apoptotic THP-1 derived macrophages/foam 
cells. 
2.5.4. Measurement of cytokine release via indirect Enzyme-Linked Immuno-Sorbent 
Assay (ELISA) 
Solutions 
ELISA diluent:  0.05% (v/v) Tween 20 (Sigma-Aldrich), 0.1% (w/v) BSA in PBS 
ELISA wash buffer: 0.9% (w/v) sodium chloride (Sigma-Aldrich), 0.05% (v/v) Tween 20 
ELISA block buffer: 1% (w/v) BSA, 5% (w/v) sucrose in PBS  
To detect cytokine release by THP-1-derived MØ (PMA) and HMDM at basal levels, and in 
response to ACs and LPS, stored supernatants from section 2.5.3. were analysed via indirect 
ELISA. 
TNF-α, IL-10, IL-12 (Peprotech, New Jersey, USA) and CX3CL1 (R&D Systems) ELISAs 
were carried out according to manufacturer‟s instructions (PeproTech). Briefly, ELISA plates 
were coated in 1µg/ml (or otherwise recommended) relevant capture antibodies in PBS 
(100µl/well) and stored at room temperature overnight. ELISA plates were washed (wash 
buffer; three times) and 200µl block buffer added per well (1h; RT). ELISA plates were 
washed and serial dilutions (in ELISA diluent) of recombinant TNF-α, IL-10, IL-12 or CX3CL1 
added, or harvested supernatants (100µl/well)                                                                                                                            
(neat or diluted in sfRPMI according to the individual experiment) (2h; RT). ELISA plates 
were washed and 0.5µg/ml (or otherwise recommended) TNF-α, IL-10, IL-12 and CX3CL1 
detection antibody (in ELISA diluent) added (100µl/well) (2h; RT). ELISA plates were washed 
and streptavidin-HRP added at 1:2000 dilution in ELISA diluent (100µl/well) (30m; RT). 
ELISA plates were washed and 100µl OPD added per well. Following a colour change, the 
reaction was stopped with 1M HCl (50µl/well) and ELISA plates read at 490nm. A standard 
curve was generated for each plate, based on known concentrations of recombinant 
proteins, to estimate the cytokine concentration in each sample. 
2.5.5. Effect of PMA on inflammatory response of human monocyte-derived 
macrophages 
Primary human monocyte-derived macrophages were seeded in 24 well tissue culture plates 
and allowed to adhere overnight in chemically defined macrophage medium (CD-MØ 
medium). The culture medium was replaced, removing non-adherent cells (lymphocytes) and 
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adherent monocytes left to differentiate for 7-14 days in CD-MØ medium, which was 
replaced every 3-5 days until the time of the assay. HMDM were co-cultured with apoptotic 
Jurkat (10:1 AC:MØ), (see 2.3.3.), (24h; 37C), in the presence or absence of indicated PMA 
concentrations.  
2.6. Models of phagocyte chemotaxis  
2.6.1. Vertical monocyte chemotaxis model - the Boyden Chamber 
Initial experiments were carried out using the modified Boyden Chamber method, utilising a 
NeuroProbe 48 well vertical chemotaxis chamber (Fig. 9). This was to ascertain chemotactic 
properties of apoptotic cell-derived microparticles and soluble factors. 
 
Figure 6. Assembly of NeuroProbe 48-well vertical migration chamber Image of an 
assembled vertical migration chamber (top left). Chamber design (top right) consists of lower 
wells for chemoattractant loading (d), sealing gasket (a) which supports a polycarbonate 
membrane, upper wells for monocyte loading (b) and metal fittings to ensure minimal spaces 
between components (c). Bottom figure depicts direction of monocyte migration from upper 
wells (b) to chemoattractant in lower wells (d), through a polycarbonate membrane which is 
supported by a gasket (a). Images adapted from supplier website (NeuroProbe.com). 
A 48 well vertical chemotaxis chamber was used according to manufacturer‟s instructions 
(NeuroProbe Inc., Gaithersburg, Madison, WI, USA). In brief, 25µl control or chemoattractant 
was loaded into the lower chambers (Fig. 9; d.), followed by a PVP-free polycarbonate 
membrane (pore size: 5µm; pore density: 4 x 103 pores/mm2) and assembly of the upper 
chamber. VD3 stimulated THP-1 cells were suspended in assay medium (RPMI + 0.2% BSA 
+ 2mM ʟ-glutamine + 100IU/ml penicillin) at 2x106 cells/ml. 50µl per well of THP-1 
suspension was added to the upper chambers (1x105 cells/well) (Fig. 9; b.). Chambers were 
incubated for 4 hours at 37C before cell migration was assessed. Membranes were washed 
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and stained with Diff Quik solution; migrated monocytes remained stuck to the underside of 
the membrane or embedded in the microporous membrane, whilst monocytes that had 
settled on top of the membrane were removed by washing and scraping on a proprietary 
blade. Total migrated cells (5 fields of view per well) were counted using light microscopy 
(40X). 
2.6.2. Horizontal monocyte chemotaxis model optimisation - Dunn Chamber 
A true chemoattractant gradient is not established in the vertical models of chemotaxis, 
rather a step gradient of chemoattractant is located immediately below a microporous 
membrane. In order to establish a true chemotactic gradient, without having to factor in 
the effects of gravity on chemotactic activity, a horizontal assay system was established 
using the Dunn chemotaxis chamber. 
 
Figure 7. Schematic of the Dunn chemotaxis chamber Image (left) depicts 
chemoattractant loading area (a), viewing bridge (gradient) (b), inner well (medium) (c), 
outer well (chemoattractant) (d), and placement of coverslip with adherent monocytes 
(underside) (e). Right image shows direction of monocyte migration towards 
chemoattractant (arrow), across the viewing bridge (b), following establishment of a 
chemoattractive gradient from the outer well (d) to the inner well (c). 
MCP-1, first isolated from THP-1-conditioned medium, is an established 
chemoattractant for monocytes304-306. MCP-1 was used as an attractant to establish a 
horizontal chemotaxis assay for this model, using the Dunn chemotaxis chamber, 
adapted from methods outlined by Zicha et al.292. This group deduced that proteins with 
a molecular weight of 350-750Da will produce a stable linear gradient within 10 minutes 
and that decay to half will take 10 hours292. Large proteins (10-20kDa) form a linear 
gradient within 30 minutes, with decay to half in 30 hours292. At 8-9kDa, an MCP-1 
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gradient should be established at an early time point in the assay, and be stable 
throughout the time course of the assay. 
THP-1, VD3, PMA and DS cells were cultured on glass coverslips (24mmx24mm) in 
cRPMI, with or without differentiating agents, in 6 well plates. Human PBMCs, human 
peripheral blood monocytes and human monocyte-derived MØ were also cultured on 
glass and plastic coverslips to assess migration. sfRPMI or CD-MØ medium was added 
to both wells of the Dunn chemotaxis chamber. Using sterile forceps, coverslips with 
cultured cells were placed face down (cell-side down) on top of the wells, leaving a gap 
for addition of chemoattractant in the outer well (Fig. 10). Edges and the top of the 
coverslip were dried using filter paper, and 3 edges were sealed with hot paraffin wax 
using a small paintbrush. The gap left on the fourth edge for chemoattractant loading 
was used to drain the outer well of medium using filter paper, with care taken not to 
make contact with the underside of the coverslip, where cells should be present. 
100ng/ml MCP-1 in either sfRPMI or CD-MØ medium was promptly added to the outer 
well and the edge sealed with hot wax using a small paintbrush. Cells were observed 
over the bridge area of the chamber, where the gradient between wells will be 
established. 
Assays had to be optimised to provide an area with optimal cell density, which needed 
to be chosen as too many cells made tracking difficult, and too few gave less powerful 
statistics. Tutorials by Ibidi on use of bespoke chemotaxis tracking software Chemotaxis 
and Migration Tool v.2.0 recommended 40 cells per assay should be tracked for 
powerful statistical data. Seeding densities had to be adjusted per cell differentiation 
method due to varying adherence levels. Initial assays were observed for 48 hours, 
however following observation they were cut down to 2 hours, which was the time at 
which monocyte migration had ceased. It was interesting to note that apoptotic cell-
derived CFS proved a more robust chemoattractant than the positive control MCP-1. 
Quantitative assessment was carried out using Image J and the Ibidi Chemotaxis and 
Migration Tool (version 2.0, standalone software), which provided measures of 
directness (Euclidean/accumulated distance), distance, velocity, forward migration index 
(FMI) and the Rayleigh test. A further assessment was utilised using the provided 
measurement of angle of the end points, and quantifying the average standard deviation 
of angle endpoints (SDoA). This should indicate a level of uniformity of migration of the 
monocyte population. 
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2.6.3. Monocyte chemotaxis to apoptotic cells - modelling in the Dunn chamber 
To assess the chemoattractive properties of apoptotic cells and apoptotic cell-derived 
mediators, whole cell cultures, and cell free supernatants, were harvested from live and 
UV-induced apoptotic cells. Apoptotic cells were generated as in 2.3.3. Live cell cultures 
were prepared under the same conditions, with the exception of UV exposure. Assays 
were carried out as above (2.6.2.), with CD-MØ medium in the inner well, and apoptotic 
whole cell culture (WC) (2.3.3.) or cell-free supernatant (2.3.4.) (CFS) in the outer well. 
The addition of blocking antibodies targeting CX3CL1 (5ng/ml), ICAM-3 (1/10 dilution of 
tissue culture supernatant) and CD14 (1/10 dilution of tissue culture supernatant) were 
added to WC or CFS preparations immediately prior to loading. 
2.7. Function of aged macrophages; a pilot study 
Up to 50ml of blood was harvested from an age range of healthy donors in accordance 
with Aston University Ethics Committee, and age and gender recorded alongside 
anonymised sample reference numbers. PBMCs were isolated (as in section 2.1.3.) and 
seeded in 24 well plates (AC interactions assays; see 2.5.1.) or 96 well plates (cytokine 
responses to AC; see 2.5.3.) in CD-MØ medium. Non-adherent cells (lymphocytes) were 
removed after 24 hours culture, and adherent cells (monocytes) allowed to differentiate 
to MØ over a period of 7-14 days. AC interaction assays with UV-induced apoptotic 
Jurkat cells (see 2.3.3.) were carried out as previously (see 2.5.1.), with the use of CD-
MØ medium instead of RPMI. Cytokine responses following co-culture with UV-induced 
apoptotic Jurkat cells were carried out as previously (see 2.5.3.), with the use of CD-MØ 
medium instead of RPMI. TNF-α ELISA was carried out as per manufacturer‟s 
instructions (PeproTech) (2.5.4.). 
For plasma-conditioning assays, THP-1 cells were seeded at 2x104 cells per well in 24 
well tissue culture plates in cRPMI with 250nm PMA + 100nm VD3 (DS) (72h; 37C). 
Following differentiation, cells were treated with plasma derived from young or mid-life 
donors (10%v/v in sfRPMI) (72h; 37C). Culture medium was removed and 2 x 105 
apoptotic jurkat added per well, in the presence or absence of serum from the same 
donor. This assay was designed to show functional differences in the effects of long 
term exposure of cell line MØ to an „aged‟ environment, and the impact of the „aged‟ 
environment on functions occurring in the immediate local microenvironment, i.e. AC 
clearance. 
  
61 
 
Modelling apoptotic foam cell clearance in vitro 
3.1. Introduction 
The atherosclerotic plaque continues to provide a unique and interesting area of 
investigation in the field of apoptotic cell (AC) clearance. Research has shown that a 
highly inflammatory environment persists within advanced atherosclerotic lesions58. At 
these sites, monocytes are recruited to the arterial sub-endothelium, where they 
differentiate into macrophages (MØ) and gorge on modified lipoproteins, resulting in the 
formation of lipid-laden „foam cells‟162. These foam cells undergo apoptosis, recruiting 
further monocytes and the process repeats46. Given the high number of localised ACs 
being cleared by macrophages, the plaque microenvironment contradicts evidence that 
AC clearance dampens inflammatory responses55,56. 
In this chapter, a THP-1 MØ-derived foam cell model is developed and characterised. 
Data is presented that addresses phenotype and function of macrophages within an 
environment with plaque-like features. Viability is assessed, and expression of receptors 
relevant to modified lipid uptake and apoptotic cell clearance is shown. The ability of 
foam cells to recognise and interact with apoptotic cells is investigated, as is the ability 
of apoptotic foam cells to be recognised by „normal‟ non-foam cell phagocytes. 
Current research suggests defective AC clearance, or efferocytosis, may be a leading 
cause of plaque progression, leading to plaque instability and pathological 
outcomes149,150,195,197. This has been attributed to loss of function of lipid-laden MØ, 
known as foam cells195,197, however the contribution of apoptotic foam cells to defective 
clearance has had very little focus. Indeed, the clearance of apoptotic MØ has attracted 
little attention. 
The hypothesis for the work in this chapter is that MØ from a lipid-laden environment 
may be defective in their capacity to interact with apoptotic cells, and thus promote 
resolution of inflammation. In order to address this, the THP-1 model established in this 
chapter will be used to answer the research questions listed in the following table. 
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Phagocyte 
 
Apoptotic cell 
 
 
Macrophage 
(MØ) 
Foam cell 
(FC) 
Apoptotic MØ 
(aMØ) 
How well do non-lipid-laden 
MØ and non-lipid-laden aMØ 
interact? 
Do FC have the ability to 
recognise, interact with and 
phagocytose aMØ? 
Apoptotic FC 
(aFC) 
Do aFC upregulate „eat-me‟ 
and downregulate „don‟t-eat-
me‟ signals to MØ, enabling 
recognition, interaction and 
phagocytosis? 
Does the combination of 
FC/aFC result in defective 
clearance in this model? 
 
Table 1. Summary of key research questions addressed in Chapter 3 
3.2. Results 
3.2.1. Morphology of monocyte and macrophage models 
In order to assess macrophage (MØ) function, it was necessary to establish a MØ model for 
analysis. A number of models are available ranging from primary human and mouse MØ, 
through to cell lines and their stimulated derivatives. THP-1 cells have been used extensively 
as multiple monocyte-MØ models can be obtained from the same originating cell line 307-311. 
These cells and their stimulated derivatives are functional for apoptotic cell clearance, 
inflammatory responses, and show representative changes in lipid metabolism-gene 
expression throughout differentiation, important for a representative foam cell model300,307,312. 
THP-1 cells can be differentiated into more MØ-like cells using various differentiation 
strategies; no treatment (THP-1), vitamin D3 (VD3) treatment, PMA treatment or double 
stimulation (DS) with both agents310,311. In order to establish successful differentiation 
strategies for use in the foam cell model, morphology was examined following 72 hours 
differentiation.  
In order to follow the differentiating effects of VD3 and PMA, THP-1 cells were stimulated to 
differentiate with VD3, PMA or both agents. Using light microscopy and flow cytometry, 
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morphological changes were assessed relative to unstimulated THP-1 cells (Fig. 8). 
Morphologically, VD3 cells remain similar to THP-1 cells in their monocytic appearance. Both 
cell types show weak adherence to tissue culture plastic (i.e. they are easily removed with 
washing) and spreading is not apparent. They remain homogeneous in nature, with a defined 
population observed on flow cytometry histograms, with equivalent cell size (forward scatter) 
and granularity (side scatter) to unstimulated THP-1 cells, indicating a monocytic phenotype. 
PMA and DS cells differ greatly in morphology in comparison to THP-1 and VD3 cells, with 
visible spreading and strong adherence to tissue culture plastic (i.e. few cells are removed by 
washing). PMA and DS cells are also larger in appearance and more granular than THP-1 
and VD3 cells, as observed when comparing forward scatter (FS) and side scatter (SS) by 
flow cytometry (Fig. 8). Of the adherent cells, two phenotypes became apparent, MØ that 
spread in an elongated manner (fig. 5, circled cell a), and rounder MØ (fig. 5, circled cell b). 
THP-1 and VD3 cells were both observed to proliferate, which was apparent when counting 
cells for antibody staining, as supported by Thomas et al. (2013)312. PMA and DS cells 
decreased in number, suggesting terminal differentiation and some cell death or cell fusion. 
Results suggest unstimulated THP-1 and VD3 stimulated cells may be a suitable monocyte 
model, whereas PMA and DS stimulated cells could better represent a MØ model. 
 
 
THP-1 VD3 
PMA DS a 
b 
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Figure 8. Alternative differentiation methods produce varying phenotypes in THP-1 
cells THP-1 cells were either undifferentiated or differentiated with VD3, PMA or both VD3 
and PMA (DS) as indicated (72h; 37C), and examined by light microscopy and flow 
cytometry to compare morphology. Scale bars represent 100µm in THP-1 and VD3, 200µm 
in PMA and DS. 
3.2.2. Surface receptor expression of monocyte and macrophage models 
The surface receptor expression profiles for oxLDL receptors CD36, SRA-1 and LOX-1, for 
the multifunctional receptor CD14 and the adhesion molecule ICAM-3 (a leukocyte-restricted 
IgSF member) were investigated using indirect immune-fluorescence staining and flow 
cytometry (Fig. 9) CD36, SRA-1 and LOX-1 are key receptors in oxLDL uptake and foam cell 
formation and are also known to bind apoptotic cells103,176,182,190,192. By immunophenotyping 
each model for expression of these receptors, the likelihood of each THP-1 model to produce 
foam cells may be predicted. CD14 expression is also investigated in order to predict the 
ability of each model to tether apoptotic cells, a function which is potentially defective in foam 
cells as part of defective AC clearance31,46. ICAM-3 has also been implicated in AC 
clearance71,84. 
In THP-1 cells, CD36 expression was high, and CD14 and ICAM-3 expression present but 
low (Fig. 9). This would indicate the ability to uptake oxLDL, and theoretically some ability to 
bind AC. SRA-1 and LOX-1 expression appears undetectable on frequency histogram plots, 
however a small increase in mean fluorescence intensity was detected with LOX-1 staining, 
compared to isotype control, should be noted. What levels of oxLDL receptor expression, 
and the required combination of various oxLDL receptors, are necessary for function should 
also be considered, as very low levels may still be relevant and functional. In VD3 
differentiated cells, CD36 and ICAM-3 expression was high, with very high expression of 
CD14 also present, suggesting comparable likelihood of THP-1 and VD3 cells to form foam 
cells in the presence of oxLDL, but perhaps an increased ability in AC binding following VD3 
differentiation (Fig. 9). SRA-1 and LOX-1 expression was undetectable, with a small increase 
in MFI with LOX-1 staining, as in THP-1 cells.  
Forward Scatter 
Side  
Scatter 
THP-1 VD3 PMA DS 
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PMA and DS cells show expression of all receptors, indicating oxLDL uptake and 
subsequent susceptibility to foam cell formation, and also improved AC interaction efficiency 
(Fig. 9). PMA and DS cells show increased SRA-1 and LOX-1 expression compared to THP-
1 and VD3 cells, however VD3 cells show the highest expression levels of CD14. Staining of 
LOX-1, and to some extent SRA-1, in PMA and DS cells, revealed dual populations within 
these models. This suggests upregulation of receptors only in a subpopulation of cells as 2 
distinct peaks were observed on frequency histogram plots, whereas CD36 was expressed 
across the whole cell population. ICAM-3 expression is also upregulated in PMA and DS 
cells compared to THP-1, however VD3 cells showed the highest levels of ICAM-3 
expression. Results point towards PMA and DS differentiated THP-1 cells as strong 
candidates for foam cell modelling.  
 
 
 
 
 
 
 
 
Cell 
No. 
Cell 
No. 
THP-1             CD36     SRA-1      LOX-1   CD14     ICAM-3 
MFI            7.58/32.62    5.07/4.98      5.07/10.94  1.93/7.26    9.22/8.96 
%Gated         2.89/67.97   3.06/2.81      3.06/4.23  1.72/9.52    12.04/19.9 
VD3              CD36     SRA-1        LOX-1    CD14     ICAM-3 
MFI            7.42/58.11    6.61/7.79      6.61/11.39  3.74/185.5    7.42/32.52 
%Gated         2.76/78.82   2.63/2.61      2.63/3.11  3.12/78.98     2.76/67.19 
PMA              CD36     SRA-1        LOX-1    CD14     ICAM-3 
MFI            6.00/59.06    6.06/35.1        6.06/28.4  6.00/16.7    6.00/8.14 
%Gated         9.71/61.65  14.37/43.79      14.37/25.48  9.71/25.61     9.71/25.19 
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Figure 9. Phenotyping THP-1 models for key oxidised LDL and apoptotic cell receptors 
Undifferentiated or VD3, PMA or DS (VD3+PMA) differentiated THP-1 cells were stained with 
primary monoclonal antibodies targeting CD36, SRA-1, LOX-1, CD14 and ICAM-3 (black) or 
isotype matched control antibodies (grey), and displayed as log fluorescence intensity. 
Expression levels were compared using flow cytometry. Results are also shown as mean 
fluorescence intensity and % gated (solid black line represents positive gating). A 
representative example of at least 3 experiments is shown. 
3.2.3. Oxidation of LDL 
Subendothelial retention of modified LDL, including oxidised LDL (oxLDL), is the origin of 
vascular cell damage and foam cell formation, therefore plays a key role in 
atherogenesis45,169,170. In order to create foam cells for the model, LDL must first be isolated 
from donors and oxidised. It is important to be aware of the variance in levels of oxidation in 
native LDL (nLDL), as this can be influenced by LDL particle size and diet171. LDL from 
different donors is also susceptible to oxidation at different levels, so it is also important to 
establish differences in oxidation levels between samples following the same oxidation 
method172. Various methods can be employed to oxidise and measure oxidation levels of 
LDL. Carbonyl ELISA measurement is popular as carbonylated proteins remain stable and 
the ELISA method provides sensitivity313. 
Carbonyl ELISA results (tab. 3) demonstrate an increase in carbonyl content, and therefore 
protein oxidation, following exposure to copper sulphate (tab. 3). Also to note, is that the fold 
increase in carbonyl content is much greater in LDL#1, which had lower basal carbonyl 
Cell 
No. 
Cell 
No. 
Log Fluorescence Intensity 
DS              CD36     SRA-1        LOX-1   CD14      ICAM-3 
MFI           10.18/72.34   7.69/32.76       7.69/42.48            10.18/21.49    10.18/8.25 
%Gated        10.63/68.85 17.59/29.96      17.59/33.08            10.63/28.96     10.63/29.4 
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content, and therefore oxidation. Results also show how basal levels of LDL oxidation can 
vary between donors, as seen in previous research314. Also to note, the fold increase in 
carbonyl content is much greater in the LDL#1, which had lower levels of basal oxidation 
(tab. 3). It is therefore important that steps should be taken to minimise variation of LDL 
oxidation levels between assays.  
 Carbonyl content (nmol/mg protein) 
 
 Native Oxidised 
LDL #1 0.31 4.65 
LDL #2 2.69 6.91 
 
Table 2. Copper sulphate treatment results in LDL oxidation Native LDL (nLDL) samples 
from 2 donors (#1 and #2) were oxidised with 10µM copper sulphate (1hr; 37C). The reaction 
was stopped with 10mM EDTA and samples desalted. Carbonyl content before and after 
copper sulphate treatment was estimated using an ELISA to indicate basal levels of protein 
oxidation (native) and oxidation levels following exposure to oxidant copper sulphate 
(oxidised). n=2. 
3.2.4. Generation of foam cells 
3.2.4.1. Oil Red O staining of foam cells 
In order to establish the best differentiation method for foam cell formation, THP-1, VD3, 
PMA and DS cells were all treated with oxLDL and observed after 24, 48 and 72 hours 
treatment to assess intracellular lipid accumulation, a key morphological marker of foam cell 
generation. It can then be investigated whether there is any correlation between receptor 
expression on each cell type and subsequent lipid uptake and accumulation. 
Droplet formation within PMA and DS cells, but not THP-1 or VD3 cells, was observed 
following 72 hours of native LDL (nLDL) or oxidised LDL (oxLDL) treatment (0-50µg/ml), 
however droplet formation was much more robust, and seen at lower concentrations, with the 
use of oxLDL. Following 24 hours of oxLDL exposure, droplet formation was observed from 
concentrations as low as 5µg/ml oxLDL, and increased numbers of droplets were observed 
after 48 hours. After 72 hours, droplet formation seemed to have stabilised. Various 
qualitative methods can be used to assess foam cell formation, however Oil Red O, a neutral 
lipid dye, is commonly chosen as a cheap qualitative method, and results can be seen easily 
using light microscopy195,315-317. Nile Red staining can be used to assess the amount of 
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intracellular neutral lipid qualitatively and quantitatively, however it is a more expensive 
method. 
Following 72 hours treatment of cells with oxLDL, foam cell formation was confirmed by 
staining for intracellular neutral lipid with Oil Red O (Fig. 10). Lipid accumulation is not 
detectable in monocytic THP-1 and VD3 cells, although red areas can be seen due to 
extracellular precipitation of the dye. Intracellular staining of lipid droplets is much more 
defined in the PMA and DS models, showing intracellular lipid has been accumulated in 
these macrophage-like cell types, as shown by arrows.  
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Figure 10. Oil Red O staining shows intracellular lipid accumulation in macrophages 
Undifferentiated or VD3, PMA or VD3+PMA (DS) differentiated THP-1 cells were treated with 
0, 10 or 50µg/ml oxLDL (72h; 37C). Cells were stained with Oil Red O for intracellular lipid 
accumulation (seen as red/darkly stained regions) and observed via light microscopy. Phase 
contrast images (20x) are shown. Images are representative of 3 independent experiments. 
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3.2.4.2. Nile Red staining of foam cells for fluorescence microscopy 
Foam cell formation was confirmed using a second assay of lipid accumulation, staining for 
intracellular neutral lipid with the fluorescent stain Nile Red (Fig. 11). This method confirms 
previous results that lipid has not accumulated in monocytic THP-1 cells when compared to 
basal levels of fluorescence. Fluorescence appears slightly increased following oxLDL 
treatment in VD3 cells, representing possible neutral lipid accumulation, though it is much 
less apparent than in PMA and DS cells, where formed droplets can be distinguished. 
Intracellular staining of lipid droplets can again be seen in the PMA and DS models, showing 
intracellular lipid has been accumulated in these more MØ-like cell types, as seen with Oil 
Red O staining. Basal levels of fluorescence are also higher in the PMA and DS models, 
which may be improved if lipid levels in growth medium can be reduced, however increased 
levels of autofluorescence have been shown previously in macrophages compared to 
monocytes311. 
 
THP-1 
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  DS 
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Figure 11. Nile Red staining shows intracellular lipid accumulation in MØ 
Undifferentiated or VD3, PMA or VD3+PMA (DS) differentiated THP-1 cells were treated with 
0 or 10µg/ml oxLDL (72h; 37C). Cells were stained with Nile Red for intracellular lipid 
accumulation (bright green vesicles) and observed via fluorescence microscopy (40x). Scale 
bars (white) represent 100µm. Images are representative of 2 independent experiments. 
3.2.5. Assessing toxicity of nLDL and oxLDL 
It is important to establish a balance between sufficient LDL concentrations to induce foam 
cell formation, whilst having minimal effect on viability of the cells, for successful investigation 
of foam cell function. Cell death would be the final phase of LDL induced toxicity, so it is 
logical to use this end point to determine any overall toxic effects of LDL treatment. This will 
also provide a useful indicator of whether it is possible to induce apoptosis throughout the 
monocyte or MØ population using nLDL or oxLDL alone, as this would provide a source of 
apoptotic foam cells for future experiments, in a physiologically relevant manner. 
THP-1 cells and DS cells were used to represent monocytes and macrophages MØ 
respectively. Following oxLDL exposure, levels of apoptosis and necrosis were low in the 
monocyte model, with fluctuations at 4 days likely to be due to experimental design (Fig. 12). 
Higher apoptosis and necrosis levels were found in MØ after 5 days, however this was not 
higher than control cells. 
Control over cell death is required to maintain experimental feasibility, therefore for further 
experiments, cell death was induced by UV following foam cell generation, so more 
synchronous cell death is achieved when comparing foam cell and non-lipid loaded cell 
models. 
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Figure 12. Oxidised LDL does not induce significant apoptosis or necrosis in 
monocyte and macrophage models THP-1 cells (monocytes) were treated with or without 
(C) 150µg/ml oxLDL, and sampled over 7 days to monitor levels of apoptosis (AxV positive 
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cells) and necrosis (PI positive cells) using flow cytometry. This was repeated with DS cells 
(MØ) which were treated with or without 50µg/ml oxLDL following differentiation. Results are 
representative of 3 independent experiments. 
3.2.6. Effect of oxidised LDL treatment on surface receptor expression 
Changes in surface receptor expression for CD36, SRA-1, LOX-1, CD14 and ICAM-3 were 
investigated using flow cytometry following 0, 10 and 50µg/ml oxLDL exposure (Fig. 13). 
CD36, SRA-1 and LOX-1 are key receptors in oxLDL uptake and foam cell formation, and 
are also known to bind apoptotic cells103,176,182,190,192. By phenotyping each model for 
expression of these receptors following oxLDL exposure, the implications of changes in 
receptor expression in apoptotic cell removal and therefore plaque progression may be 
assessed. CD14 expression is also investigated in order to predict changes in the ability of 
each model to tether apoptotic cells within the plaque environment, a function which is 
potentially defective31,46.  
An increase in CD36 expression was found in THP-1, VD3 and PMA cells, but not DS cells 
(Fig. 13). CD14 expression was increased in VD3 cells following oxLDL treatment. No overall 
increase in LOX-1 and SRA-1 expression is observed following oxLDL treatment, and ICAM-
3 levels remain consistent apart from a potential increase in expression in DS cells. CD14 
expression is upregulated following 50µg/ml oxLDL treatment in VD3 cells. Results in THP-1, 
VD3 and PMA models indicate the presence of a positive feedback loop of CD36 expression 
following oxLDL exposure, supporting previous research318,319. This was not found with SRA-
1 and LOX-1 following exposure to oxLDL over 72 hours, therefore increased SRA-1 and 
LOX-1 expression following exposure to oxLDL may not have a prominent role in foam cell 
formation in these models, as found previously with LOX-1318. 
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Figure 13. Modest changes in surface receptor expression of some 
monocyte/macrophage models following oxidised LDL treatment THP-1, VD3, PMA and 
DS cells were treated with 0, 10 or 50µg/ml oxLDL (72h; 37C) and were stained with primary 
antibodies targeting CD36, SRA-1, LOX-1, CD14 and ICAM-3. Expression levels were 
compared with indirect immunostaining, followed by flow cytometry. Results are shown as 
mean fluorescence of FITC secondary antibody. Results are representative of 3 independent 
experiments. 
3.2.7. Foam cell interaction with apoptotic cells 
Despite a high proportion of localised monocytes and macrophages, the atherosclerotic 
plaque contains a high proportion of apoptotic and necrotic cells, including apoptotic 
macrophages and T cells, suggesting impaired clearance mechanisms46,195. To investigate 
whether oxLDL treatment affects the ability of macrophages to interact with apoptotic cells 
(ACs), PMA and DS cells were treated with indicated concentrations of oxLDL for 72 hours 
prior to co-culture with AC to permit lipid-loading, and foam cell formation (Fig. 14). UV-
induced apoptotic Jurkat (aJK) were used as they are a well-established AC model, often 
used in such studies54,210. In the DS MØ model oxLDL did not significantly reduce MØ ability 
to interact with aJK compared to untreated control. The PMA model shows a significant 
reduction in AC interaction following oxLDL treatment when compared to untreated control, 
with reductions in interaction with aJK apparent from as low as 5µg/ml oxLDL treatment 
(P<0.01), and becoming more significant at concentrations of 10µg/ml oxLDL and above 
THP-1 VD3 
PMA DS 
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(P<0.001). Results suggest that PMA differentiated THP-1 cells may be a useful tool in 
modelling defective clearance within the atherosclerotic plaque. 
 
0 1 5
1
0
2
5
5
0
0
1 0
2 0
3 0
4 0
5 0
o x L D L  p re -tre a tm e n t  (µ g /m l)
%
 P
h
a
g
o
c
y
te
s
 i
n
te
r
a
c
ti
n
g
 w
it
h
 A
C
**
***
   
0 1 5
1
0
2
5
5
0
0
5
1 0
1 5
2 0
2 5
o x L D L  p re -tre a tm e n t  (µ g /m l)
%
 P
h
a
g
o
c
y
te
s
 i
n
te
r
a
c
ti
n
g
 w
it
h
 A
C
A C
n o  A C
 
Figure 14. Oxidised LDL treatment reduces macrophage interaction with apoptotic 
Jurkat cells PMA or DS differentiated THP-1 were treated with oxLDL (72h; 37C) to promote 
lipid loading of MØ and to drive foam cell formation. aJK were added to each well (10:1 
aJK:MØ ratio) and unbound aJK removed after co-culture (1h; 37C). The number of MØ 
interacting with aJK was counted out of 200 cells per well. Data shown are mean % 
interaction ± S.E of 4 independent experiments. ** P<0.01, *** P<0.001 2way ANOVA with 
Tukey’s post-hoc test. 
One simple explanation of reduced AC (aJK) binding by lipid-loaded PMA cells is that MØ 
pre-treatment with oxLDL results in persistent blocking of receptors, by oxLDL, that are 
required in AC tethering or engulfment, post oxLDL removal. If oxLDL-receptor binding 
persisted following removal of unbound oxLDL, and addition of ACs for co-culture, receptors 
required for AC interaction would be blocked, e.g. SRA-1, LOX-1 and CD36. Also, if residual 
unbound oxLDL remained in the assay system, competition for the same receptors may 
occur, reducing binding in those models with higher concentrations of oxLDL pre-treatment. 
To investigate whether straight forward competition between oxLDL and ACs for shared 
phagocytic receptors contributes to reduced aJK binding in the PMA model, PMA MØ were 
treated with indicated concentrations of oxLDL for 1 hour, to allow interactions to take place. 
After 1 hour, supernatants were replaced with medium with or without aJK. This was either in 
the presence or absence of oxLDL at indicated concentrations, to account for any impact of 
unbound oxLDL competing for receptors during co-culture of phagocytes with aJK (Fig. 15). 
No significant decrease in percent of MØ interacting with aJK was found following 1hr oxLDL 
treatment of PMA MØ cells compared to untreated control, either in the presence or absence 
of oxLDL during co-culture. This supports the hypothesis that physiological changes following 
PMA DS 
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lipid-loading, not just receptor competition, are at play in defective interaction of lipid-laden 
MØ and aJK. 
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Figure 15. Reduction in apoptotic Jurkat cell interaction is not due to receptor 
competition with oxidised LDL PMA differentiated THP-1 were pre-treated with oxLDL (1h; 
37C), medium was removed and aJK were added to each well, in the presence or absence 
of indicated oxLDL concentrations. Cells were co-cultured (1h; 37C) and unbound aJK 
removed by washing. The number of MØ interacting with aJK was counted out of 200 cells 
per well. Data shown are mean % interaction ± S.E of 3 independent experiments. 2way 
ANOVA with Tukey’s post-hoc test showed no statistical significance between oxLDL 
treatment groups. 
To investigate whether reduced interaction of PMA-derived MØ with aJK is a result of 
general reduced binding/phagocytic ability of the phagocyte following lipid-loading, an 
alternative phagocytic target was utilised. Following differentiation with PMA, MØ were 
treated with (FC) or without (MØ) 50µg/ml oxLDL (72h; 37C) for MØ/FC generation. The 
ability of MØ and FC to bind and phagocytose dead fluorescently labelled Escherichia coli 
(K-12 strain) was compared (Fig. 16). MØ and FC were exposed to fluorescent E. coli (or 
medium control) for 40 minutes at room temperature, unbound E. coli removed by washing, 
and cells analysed via flow cytometry. Mean fluorescence intensity was compared before 
(black bars) and after (grey bars) quenching of fluorescence of surface bound E. coli to 
determine whether differences in binding or uptake of E. coli could be observed between 
lipid-loaded and non-lipid-loaded cells. Results show no significant differences between MØ 
and FC ability to bind and phagocytose fluorescently labelled E. coli. Following quenching 
with trypan blue, a similar, but not significant, decrease in overall fluorescence of cells 
exposed to fluorescently labelled E. coli was observed. This supports the hypothesis that 
there may be a change in physiological function following lipid-loading when comparing 
ability to clear some apoptotic cells, and not solely an overall decline in health of cells, or 
overall binding/phagocytic ability. 
76 
 
M
Ø
 
M
Ø
 +
 E
.c
o
li
F
C
F
C
 +
 E
.c
o
li
0
1 0
2 0
3 0
4 0
M
e
a
n
 F
lu
o
r
e
s
c
e
n
c
e
 I
n
te
n
s
it
y
P re -q u e n c h
P o s t-q u e n c h
 
Figure 16. Reduction in apoptotic Jurkat cell interaction is not due to reduced 
phagocytic ability MØ and FC were incubated with fluorescently labelled E. coli, or cRPMI 
control (40min;37C) and MØ/FC washed to remove unbound E. coli. MØ/FC were detached, 
fixed and samples stored at 4C until flow cytometry (black bars). Following analysis via flow 
cytometry, trypan blue was added to quench fluorescence of surface bound E. coli, MØ/FC 
washed and samples re-analysed (grey bars). Data shown are mean % interaction ± S.E of 3 
independent experiments. 2way ANOVA with Tukey’s post-hoc test showed no statistical 
significance between oxLDL treatment groups. 
3.2.8. Interaction with apoptotic foam cells 
It is not fully understood whether perceived defects in AC clearance within the atherosclerotic 
plaque150,195,197 originate from failed functionality of phagocytic cells to interact with AC, or 
whether apoptotic foam cells fail to attract/elicit the correct response from phagocytes 
entering the plaque. It was investigated whether oxLDL treatment affects the ability of 
phagocytes to interact with lipid-loaded apoptotic cells (aFC) in this model. Also shown was 
the effect of lipid-loading on the ability of MØ to interact with aMØ and aFC. PMA MØ were 
treated with (FC) or without (MØ) oxLDL for MØ/FC generation, and subsequently co-
cultured with MØ/FC induced to apoptosis by UV exposure (aMØ/aFC) (Fig. 17a). HMDM 
were also used as a phagocytic cell (no oxLDL exposure) (Fig. 17a). Data show no 
significant differences in the ability of all phagocyte types to interact with aMØ compared to 
aFC. Interestingly, lipid-loaded MØ (i.e. foam cells) show no reduction in ability to interact 
with aMØ or aFC when compared to non-lipid-loaded MØ, differing from results found using 
aJK as an apoptotic cell model. This may be a result of cell type variations in phagocyte:AC 
interaction, with regards to mediating ligands/receptors. Both AC models represent cell types 
found in the plaque46, so are relevant to atherosclerotic plaque research. 
When comparing phagocyte interaction levels with aJK (Fig. 14), versus aMØ and aFC (Fig. 
17a), combined data show a significant reduction in MØ interaction with aMØ and aFC when 
compared to aJK (Fig. 17b). A significant reduction in FC interaction with aFC compared to 
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aJK was also observed, but the reduction was not significant when comparing FC interaction 
with aMØ. A general reduction in clearance rates of apoptotic foam cells compared to other 
AC types could have implications in plaque progression and further investigation into the 
mechanisms of AC clearance between differing phagocyte and AC types would be of benefit. 
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Figure 17. Recognition of apoptotic macrophages and apoptotic foam cells is not 
affected by lipid loading in THP-1 or primary cell model MØ and FC were induced to 
apoptosis (100mJ/cm2) to generate apoptotic MØ and FC (aMØ/aFC). MØ, FC and HMDM 
were co-cultured with a 10:1 ratio of AC:phagocyte. Unbound aMØ/aFC were removed by 
washing and samples fixed. The number of phagocytes interacting with AC was counted out 
of 200 cells per well. Data shown are mean % interaction ± S.E of 3 independent 
experiments. * P<0.05 2way ANOVA with Tukey’s post-hoc test. 
3.3. Discussion 
The ageing population, especially in the „oldest old‟, will cause an increase in the incidence 
of age-related disease320. As the average age of the population increases, the range of 
„healthy ageing‟ lags behind. Research into age-related disease is becoming ever prominent 
as researchers endeavours to broaden the healthy age-range and therefore improve quality 
of life for the oldest old. 
Atherosclerosis becomes more prominent as we age321, so improving understanding of the 
disease is a key research target given the ageing population322. Atherosclerosis also 
provides a paradoxical environment of great interest to the field of AC clearance, given the 
inflammatory environment despite the presence of localised monocytes and MØ and dead 
cells46, a combination largely thought to dampen inflammation55,56. 
Results in this chapter show that oxLDL treatment of MØ, but not monocytes, induces 
intracellular lipid droplet accumulation and foam cell formation. This does not lead to 
constitutive upregulation of scavenger receptor expression in this foam cell model. 
a b 
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Comparison of non-lipid-loaded MØ and foam cell function showed equal ability to interact 
with bacteria, aMØ and aFC. Interestingly, foam cells showed a reduced capacity to interact 
with apoptotic Jurkat cells compared to MØ. Optimal rates of interaction with aJK by MØ 
were not reached with MØ or FC interaction with aMØ or aFC. This result could mean that 
even under optimal conditions, aMØ/aFC are cleared at sub-optimal rates when compared to 
maximum possible rates of AC clearance. The consequence of this at sites with large 
numbers of aMØ/aFC could go some way to explain the persistence of AC within the plaque. 
  
Phagocyte 
 
Apoptotic cell 
 
 
Macrophage 
(MØ) 
Foam cell 
(FC) 
Apoptotic MØ 
(aMØ) 
Non-lipid-laden MØ and non-
lipid-laden aMØ were found 
to interact but rates of 
interaction were 1/3 lower 
than rates of MØ interaction 
with aJK 
FC have the ability to 
recognise, interact with and 
phagocytose aMØ and rates 
of interaction were 
comparable to the rates of 
MØ interaction with aMØ 
Apoptotic FC 
(aFC) 
aFC were recognised by MØ 
to the same degree as aMØ 
therefore it is likely that aFC 
upregulate „eat-me‟ and 
downregulate „don‟t-eat-me‟ 
signals to MØ, enabling 
recognition, interaction and 
phagocytosis 
The combination of FC/aFC 
does not result in defective 
clearance in this model 
compared to the MØ/aMØ 
interaction, however 
interaction is more 
successful with aJK 
interaction 
Table 3. Summary of results from key research questions addressed in Chapter 3 
 
3.3.1. Oxidised LDL in the foam cell model 
It is important to be aware of how differences in oxidation levels of LDL particles can affect 
the method of oxLDL binding and internalisation to ensure experimental consistency when 
setting up a foam cell model. The use of varying methods of LDL modification, e.g. 
acetylated or aggregated LDL, or varying methods of LDL oxidation, are likely to add difficulty 
to interpretation and comparison of results across studies and research groups195,199,200.  
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Sufficient oxidation of LDL particles must occur for recognition by scavenger receptors, as 
opposed to the LDL-R; Mild oxidation produces minimally modified LDL (mmLDL) which may 
still be recognised by the LDL-R, but is not sufficiently modified to be recognised by 
scavenger receptors201. Further characterisation of modified LDL used in this study would be 
required to define whether it is minimally or extensively oxidised. A more recent study (2010) 
used LDL oxidised in the same manner, and for the same length of time, as the present 
study, and defined it as mmLDL323, however other studies have cultured native LDL with 15-
lipoxygenase expressing fibroblast cell lines201,324. mmLDL induced MØ spreading, via CD14, 
was found to inhibit phagocytosis of ACs201 . In this model, despite presence of CD14 (figs. 
5/6/7), spreading is not observed in THP-1 and VD3 models. Spreading is already induced 
by PMA and DS differentiation (Fig. 8), and phagocytic ability is present (Fig. 14/12/14). 
Whilst it is important to be aware of the implications of different oxidation states of LDL and 
the biological effects they can elicit, it must also be noted that terms such as mmLDL are 
subjective. In order to allow for comparison of results with oxLDL across studies, it is 
important to be explicit regarding oxidation methods used and to clearly define terms such as 
mmLDL. 
Various methods can be employed to oxidise and measure oxidation levels of LDL. 
Physiologically relevant methods can be used to mildly oxidise LDL, however oxidation by 
metal ions is a common method employed to oxidise LDL and produces similar results in in 
vivo oxidation201,325,326, and was the method of choice in this study. Carbonyl formation as a 
result of protein oxidation was used to confirm LDL oxidation via the chosen method of metal 
ion oxidation. Carbonyls are a popular choice of marker for oxidation measurement due to 
the stability of carbonylated proteins313. The ELISA method employed is also highly sensitive 
and minimal protein is required to complete the assay313. Results demonstrate the 
aforementioned donor variability in oxidation levels of basal and modified LDL samples (tab. 
3). It is therefore important to minimise variability of protein oxidation levels to ensure 
differences in LDL oxidation status between experiments does not skew results and impact 
conclusions formed. One method that can be used to combat variation in oxidation levels 
between samples collected on different days or from different donors is to pool LDL samples 
from a number of donors and use the pooled LDL across experiments, a method adopted for 
the rest of these studies.  
3.3.2. Morphology, surface receptor expression and foam cell formation of THP-1 
models 
Human cell lines are an important tool in atherosclerotic plaque research, due to the limited 
availability of human plaque samples, and the species variability of the often used murine 
and lapine models.  
80 
 
The advantages of using the monocytic THP-1 cell line is that various methods can be 
employed to differentiate cells into a MØ-like phenotype, resulting in cells that appear to be 
at different stages of differentiation310,311; VD3 cells appear more monocytic than PMA and 
DS cells, which show MØ-like characteristics. This can be used as a tool to determine at 
which point during monocyte-MØ differentiation do cells become susceptible to oxLDL 
induced changes to phenotype and function. It also allows modelling of the plaque in vitro, 
from infiltrating monocytes through to lipid-loaded foam cells. This provides a 
comprehensive, straightforward model, without the need to cross over between species, e.g. 
as in Schrijvers et al., an important paper in the field, which drew conclusions based on 
human endarterectomy samples, rabbit endarterectomy samples, murine thioglycollate 
elicited peritoneal MØ (phagocyte model in AC clearance assays), murine MØ cell line J774 
(foam cell model), human monocyte cell line U937 (AC model), and human platelets and 
RBC from fresh blood195. Also to note is the use of apoe-/- murine models, knocking out  
Apolipoprotein E (ApoE), resulting in alterations in lipid trafficking, and resulting 
atherosclerosis, which is not readily found in mice327. However care should be taken to draw 
conclusions on AC clearance in the plaque of these experimental models as ApoE has been 
identified as having a role in AC clearance, and knockout of this molecule results in a 
persistence of ACs and an inflammatory state in vivo328.  
Monocyte-like THP-1 cells show some adherence but do not spread and are easily removed 
from tissue culture plastic by washing (Fig. 8). Presence of CD36 on THP-1 cells has been 
shown in previous studies329, however despite high levels of CD36 in this model (Fig. 9), 
evidence of oxLDL uptake in the form of intracellular accumulation of lipid droplets, and 
therefore foam cell formation, is not observed via Oil Red O or Nile Red staining (figs. 7/8). 
An explanation for this could be the comparatively low expression levels of oxLDL scavenger 
receptors SRA-1 and LOX-1 compared to PMA and DS models (Fig. 9), however CD36 is 
thought to account for at least 50% of oxLDL binding178. Previous research has found low 
levels of SRA mRNA expression in isolated human monocytes, which was upregulated 
during differentiation177. Undetectable levels of LOX-1 mRNA expression was observed 
previously in THP-1 MØ and human PBMCs, and LOX-1 mRNA expression was upregulated 
with differentiation330, as seen in the THP-1 model (Fig. 9). Priming or activation of 
monocytes may be required before active endocytosis of oxLDL266. Monocyte-like THP-1 
phenotypes (unstimulated/VD3) may also have more efficient mechanisms of cholesterol 
efflux compared to MØ-like models, PMA/DS THP-1 cells, so although oxLDL uptake could 
be occurring, it is not being accumulated in the form of neutral lipid droplets. This could be 
achieved by measuring MØ uptake of DiI (1,1'-dioctadecyl-3,3,3'3'-tetra-methylindocyanide 
percholorate) labelled oxLDL, or measuring labelled oxLDL concentration in media before 
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and after exposure to cells317. Despite a lack of foam cell formation, the presence of 
monocytes in the atherosclerotic plaque may make unstimulated THP-1 cells a relevant part 
of the model being established331. 
Vitamin D3 (VD3) has been described as having a functional role in the hemopoietic 
system332, and induces differentiation of cells via the vitamin D receptor (VDR)333. 
Morphological changes following VD3 induced differentiation are minimal; cells continue to 
proliferate, show some adherence but little spreading and are easily removed from tissue 
culture plastic by washing (Fig. 8). Previous studies have shown that VD3 treated cells are a 
more representative monocyte model than unstimulated THP-1 cells, with upregulation of 
CD14 expression, as confirmed in the present study, enhanced phagocytic activity and 
superoxide production310,312,332,334. Terminal differentiation is not reached following VD3 
stimulation and upon removal of the stimulant, cells may revert to the THP-1 phenotype310,334. 
Calcium priming by VD3 may explain why functionally, VD3 stimulated cells appear further 
along the differentiation pathway than THP-1 cells, despite still phenotypically appearing 
THP-1 like334, as shown by FS and SS on flow cytometry histograms (Fig. 8). Expression of 
CD36 is comparable to THP-1 cells (summarised in table 4). LOX-1 and SRA-1 expression 
levels are also low, and given that CD36 and SRA-1 are thought to account for up to 80% of 
total oxLDL binding, it could be predicted that VD3 stimulated cells would not be the most 
efficient model for active oxLDL uptake335. This was confirmed by Oil Red O and Nile Red 
staining in figures 7 and 8 respectively. Expression of CD14 is at its highest in this model, 
which may predict enhanced phagocytic ability in response to ACs compared to both 
unstimulated and PMA stimulated cells, however the monocytic nature of VD3 cells makes 
this difficult to test in our system. It may also suggest that any reduction in oxLDL uptake is 
not due to insufficient oxidation of LDL as mmLDL would bind CD14201. Miller et al. (2003) 
found reduced apoptotic thymocyte uptake by murine J774 MØ following mmLDL induced 
MØ spreading201. 
Treatment with the phorbol ester PMA results in a more prominent MØ-like phenotype; cells 
become much more adherent and spreading can be observed (Fig. 8). PMA is a potent 
activator of protein kinase C (PKC) and is thought to mimic the second messenger signalling 
lipid diacyl-glycerol (DAG)310. Basal expression of SRA-1 and LOX-1 was higher than the 
THP-1 and VD3 models (Fig. 9; summarised in table 4). Histograms revealed two 
populations of cells following PMA differentiation in terms of LOX-1, and to some extent 
SRA-1, expression, with 2 peaks observed on the histograms, unlike CD36 expression, 
which is upregulated in all cells when comparing MFI to that in the THP-1 model (Fig. 9). This 
supports previous findings in PBMCs that PMA treatment upregulates CD36 mRNA 
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expression, and that PMA also stimulates upregulation of LOX-1 mRNA in THP-1 cells330,336. 
As CD36 and SRA-1 receptors account for up to 80% of total oxLDL binding and 
degradation, it is reasonable to anticipate that use of this model will result in foam cell 
formation178,335. Cell surface CD36 protein expression was high in all models, however the 
combined receptor profile following PMA stimulation correlated with high uptake of oxLDL, as 
detected by Oil Red O and Nile Red staining of accumulated neutral lipid (figs. 7/8). CD14 
levels were also increased in this model compared to unstimulated THP-1, though did not 
reach levels of VD3 stimulated cells (summarised in table 4). This supports previous 
studies312, and would indicate good potential ability to uptake ACs, especially considering the 
ability of scavenger receptors in AC interaction102-105. 
DS cells have a similar level of CD14 to that of cells treated with PMA alone, despite also 
being treated with VD3, therefore the pathway activated by PMA stimulated differentiation 
may override that of VD3 (fig 6; summarised in table 4). Like cells treated with PMA alone, 
DS cells have a typically MØ-like phenotype, with strong adherence and spreading (Fig. 8). 
Thomas et al. reported differences in LPS response in these THP-1 models that were not 
directly linked to CD14 expression, with high TNF-α release in response to LPS in DS cells, 
and to a lesser extent, PMA cells. LPS stimulation resulted in a very small amount of TNF-α 
release by comparison, and unstimulated THP-1 response was negligible312. DS cells also 
had similar levels of oxLDL receptor expression when compared to the PMA model, with high 
levels of CD36 and lower levels of SRA-1 and LOX-1, however SRA-1 and LOX-1 expression 
was higher than expression observed in the THP-1 model. CD14 expression was also 
detected (Fig. 9; summarised in table 4). Uptake of both oxLDL and apoptotic cells should be 
apparent in this model, and foam cell formation as indicated by lipid accumulation was shown 
by Oil Red O and Nile Red staining (figs. 7/8).  
In summary, despite the prominent role of CD36 in oxLDL uptake178, expression of this 
receptor alone is not predictive of foam cell formation. It may be that SRA-1 and LOX-1 
presence is also essential, or upregulation of signalling molecules is required alongside 
differentiation to MØ. 
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THP-1 
models 
Surface Receptors Foam cell 
formation 
CD36 SRA-1 LOX-1 CD14 ICAM-3 
THP-1 ++ +/- +/- + + N 
VD3 +++ +/- +/- ++++ +++ N 
PMA +++ ++ ++ ++ ++ Y 
DS +++ ++ ++ ++ ++ Y 
Table 4. Summary of expression of key surface receptors and foam cell formation in 
THP-1 models Summary of surface receptor expression of each THP-1 model as analysed 
by flow cytometry – Mean fluorescence intensity was examined and expression scored as 
follows: +/- little or no detectable expression, + low expression, ++ medium expression, +++ 
high expression, ++++ very high expression. Foam cell formation was also analysed by Oil 
Red O staining and scored as either presence (Y) or absence (N) of foam cells after 72hr 
oxLDL exposure at 50µg/ml. 
3.3.3. Effects of oxidised LDL treatment on THP-1 models 
3.4.3.1. Toxicity 
The upregulation of scavenger receptors in PMA and DS models, and the accumulation of 
lipids in these models, implies that PMA and DS cells may be more susceptible to toxic 
effects of oxLDL, however once cells are of a foam cell phenotype, induction of apoptosis 
may be altered. For example, expression of SRA-1 was found to reduce oxLDL induced 
apoptosis, a mechanism which may contribute to prolonged life of MØ in the plaque and the 
production of foam cells337. 
Previous studies have found oxLDL induces apoptosis in foam cells, however other studies, 
including the present work (Fig. 12), have not found prominent oxLDL induced toxicity of 
MØ197,201. Miller et al. (2003)201 found no difference in murine peritoneal or cell-line MØ 
function between 10-50µg/ml oxLDL treatment when investigating actin response. Khan et al. 
also found that oxLDL at 100µg/ml did not induce MØ cell death in rat MØ197. Conversely, 
significant levels of apoptosis in PBMC-derived MØ (PBMC-DMØ) were found from 50µg/ml 
oxLDL treatment198, however LDL samples were extensively oxidised (24 hours copper 
sulphate oxidation, versus 1 hour in this study). Contradictory results are likely due to the 
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varying extent of LDL oxidation across studies, with results by Bjorkerud & Bjorkerud (1996) 
showing oxLDL can induce cell growth or apoptosis depending on oxidation levels and cell 
types studied199. 
Minimal toxicity of oxLDL was found in both monocyte-like THP-1 cells and MØ-like DS cells 
(Fig. 12). As monocytes seem less susceptible to the effects of oxLDL, higher concentrations 
were tested than in MØ models. The lack of observed toxicity allows use of a broad range of 
oxLDL concentrations without the concern of toxicity, however further investigation will need 
to be carried out to make sure cells are still fully functional following oxLDL treatment (e.g. 
standard cell viability assays such as the MTT assay, or functional assays such as E.coli 
phagocytosis, e.g. Fig. 16, and cytokine responses to basic stimuli such as 
lipopolysaccharide, e.g. Fig. 21; Chapter 4). 
As oxLDL induced apoptosis is not readily detected in this model using annexin V versus PI 
staining, an alternative way of apoptosis induction was chosen in order to further investigate 
the full spectrum of AC clearance within the plaque. UV induction was chosen as a well-
established method of apoptosis induction, with a comparable outcome to other apoptosis 
induction methods62. This also allows a good level of control over apoptosis induction across 
assays. 
3.4.3.2. Receptor expression in THP-1 models following oxLDL exposure 
Expression of the LDL receptor (LDL-R) is regulated homeostatically by the presence of free 
intracellular cholesterol266. Unlike the LDL-R, scavenger receptor expression is independent 
of the level of free intracellular cholesterol, accounting for the failure of cellular homeostasis 
mechanisms within the atherosclerotic plaque, and the subsequent production of foam 
cells177. The LDL-R becomes downregulated when free intracellular cholesterol levels are 
high as a result of high quantities of available ligand266. Conversely, expression of the 
scavenger receptor CD36, in response to the ligand oxLDL, is increased in the THP-1, VD3 
and PMA models (Fig. 13), as found in previous studies with murine J774 and RAW 264.7 
MØ319,338. CD36 upregulation has been shown to occur via oxLDL induced PPAR-γ 
expression232,339. In contrast to the effect on CD36, PPAR-γ activation has been found to 
suppress SRA-1 expression340. This may explain why an upregulation of SRA-1 following 
oxLDL treatment was not found in any of the models used in this study (Fig. 13). 
OxLDL also upregulates CD14 expression in VD3 cells (Fig. 13), which in vivo may 
exacerbate the pro-inflammatory environment found within the plaque. Pasini et al., (2007)341 
found that enhanced levels of oxLDL upregulated CD14 and toll-like receptor 4 (TLR4) 
expression in circulating monocytes. This was then suggested to cause cytokine 
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overproduction due to the resulting priming of monocytes341. The upregulation of CD14 and 
TLR4 is comparable to that of pro-inflammatory ligands such as LPS342. It is possible that 
oxLDL treatment primes monocytes to skew towards the pro-inflammatory M1, rather than 
reparative M2, phenotype. A study by Nagornev and Maltseva (1996)233 found a proportion of 
MØ within human atherosclerotic plaques had not transformed into foam cells. These MØ 
were associated with pro-inflammatory cytokine interleukin-1 (IL-1) and TNF-α production, 
which is unusual due to the close proximity of ACs233. Priming of MØ into an M1-like 
phenotype may also cause inefficient AC clearance within the plaque, or a lack of anti-
inflammatory cytokine release in response to ACs56. 
Human monocyte and macrophage interaction with mmLDL via CD14, TLR4 and TLR2 was 
also found to exacerbate an inflammatory response via increased IL-1β, IL-6 and IL-10 
release. A combination of CD14 upregulation and mmLDL could therefore exacerbate the 
inflammatory environment in the plaque323. Cytokine profiling of MØ pre-treated with (FC) or 
without (MØ) oxLDL will be investigated in the next chapter.  
3.4.3.3. Interaction with apoptotic cells 
It is generally perceived based on a small number of studies, and the presence of uncleared 
ACs in the plaque, that AC clearance is defective within the plaque via unknown 
mechanisms46,195,197. This has been demonstrated in this differentiated THP-1 model with 
regards to foam cell interaction with apoptotic T lymphocytes (Fig. 14), which are a major 
component of plaque ACs46. However foam cell interaction with apoptotic macrophages 
(aMØ) or apoptotic foam cells (aFC), the prominent AC type in the plaque46, was not 
impaired when compared to interaction rates of the same AC types with MØ (Fig. 17a).  
A straightforward explanation for decreased aJK binding in the THP-1 model could be that 
oxLDL treatment is toxic to PMA and DS MØ, however, toxicity testing (see section 3.4.3.1.) 
revealed little apoptosis or necrosis. Schrijvers et al. (2006)195 and Khan at al. (2003)197 also 
ruled out toxicity as a mechanism behind reduced AC phagocytosis. This does not mean that 
the cells are healthy, as this is a very late marker of toxicity. However further research into 
cytokine responses in this model (see Chapter 4) seems to show comparable ability to 
produce cytokines between MØ and FC. This implies that rather than all functions of foam 
cells being affected due to oxLDL induced toxicity, only some functions are affected due to 
an alteration in MØ phenotype following foam cell formation. 
Another reported mechanism of defective AC clearance is direct receptor competition 
between ACs and oxLDL. Looking at PMA and DS cells, the ability to bind aJK, although still 
functional, appears to be impaired following oxLDL treatment (Fig. 14). This occurs despite 
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an upregulation of receptors which have been shown to recognise ACs, such as CD36 (Fig. 
13). Conversely, in the current study, using a short time period of oxLDL exposure, direct 
competition between oxLDL and aJK was not found to affect aJK binding by a human cell 
line (Fig. 12). The method employed in the THP-1 system involves replacing medium 
containing oxLDL with fresh medium before adding ACs, decreasing the likelihood that 
oxLDL is competing directly with ACs for particular receptors in this model. Additionally, Khan 
et al. (2003)197 found no effect on AC interaction in the presence of oxLDL in a Balb/c mouse 
(thioglycollate elicited) peritoneal MØ model. The system used in Khan‟s study used LDL that 
was oxidised by the same method as in the THP-1 model, but LDL was exposed to the 
oxidising agent for 24 hours, compared to 1 hour in the THP-1 model, which will significantly 
alter oxidation levels, and potentially dictate whether ACs and oxLDL are competing for the 
same binding site on MØ surface receptors. Miller et al. (2003)201 found reduced 
phagocytosis of ACs by resident peritoneal MØ following exposure to mmLDL, supporting 
results found using aJK in the THP-1 model. It is unclear whether oxLDL was removed from 
the medium before addition of ACs, therefore direct competition for CD14 between mmLDL 
and ACs may be the cause of reduced phagocytosis31,201. Alternatively, relevant to defective 
clearance in the plaque, but not the THP-1 model, monoclonal antibodies targeting oxLDL 
have been found to bind to ACs, inhibiting phagocytosis343. However, the same antibodies 
have been found to facilitate clearance of ACs in another study344. 
Following binding, ACs are engulfed by phagocytes. In the presence of oxLDL, it was 
previously found that rather than reduced binding, engulfment of ACs was delayed, which 
may exacerbate the pro-inflammatory environment found within the plaque197. The assay 
used here did not distinguish between binding and engulfment of ACs as it was carried out at 
37C, and both bound cells, and cells being engulfed, are observed. However, methods in 
Khan‟s study did not involve pre-incubation of macrophages with oxLDL and subsequent 
foam cell formation. OxLDL was present in the model system and introduced at the same 
time as the ACs, and interactions observed over 72 hours. Thus, it is unclear whether 
delayed engulfment was due to the altered phenotype of the MØs over time or the influence 
of the environment on MØ or AC behaviour, e.g. competition for binding sites. In contrast, Li 
et al. (2006)210 found no change in ability of peritoneal MØ from female C57BL6/J mice to 
engulf ACs when monitored over 60 minutes. 
If physiological changes in phagocyte or AC function following lipid loading are the cause of 
defective clearance, rather than an inflammatory or competitive local microenvironment as 
found in the plaque, then any of the multiple stages of AC clearance could be affected43. 
Effective clearance of dying cells requires the orchestration of a complex multi-stage 
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process, and it is important to note that any defects could occur on the side of the phagocyte, 
the target AC, or a combination of both. This could include changes at the level of phagocyte 
recruitment to AC, AC recognition, tethering (binding), tickling (signalling) and AC 
engulfment43. Immune modulation following clearance is also a key research focus due to the 
paradoxical inflammatory environment found in the plaque58. The model of AC interaction 
used in these studies focuses on the recognition, interaction and phagocytosis of apoptotic 
cells, as with many models of clearance.  
 
Figure 18. Foam cell phagocytosis of apoptotic cells Differentiated THP-1-derived foam 
cell interacting with apoptotic Jurkat cell. Macrophages were treated with 10 x ACs and 
incubated for 1 hour at 37C. Unbound ACs were removed by washing with PBS and the cells 
stained with Diff Quik. ACs appear as small, dark, round cells. 
If phagocyte cell death or direct receptor competition do not account for reductions in aJK 
binding following lipid loading of MØ, as with aJK binding (Fig. 14) a physiological change in 
phagocyte function may be the cause. Schrijvers et al. (2005)195 reported defective clearance 
in the plaque following observation of a 19-fold increase in the ratio of free versus 
phagocytosed ACs in human endarterectomy samples, compared with human tonsils. This 
could initially be attributed to overwhelming AC numbers in the plaque compared to the 
tonsil, or insufficient phagocyte numbers, however comparable rates of apoptosis in both 
environments were reported, and a greater number of MØ in plaques versus tonsils. This 
method gives a snapshot of clearance in both environments, and a physiological change in 
MØ function was investigated. Further investigations into mechanisms and kinetics of 
defective clearance are done in an alternative murine model, using platelets or aggregated 
LDL to produce foam cells. Using separate in vitro studies, lipid loading with platelets or 
aggregated LDL did not affect uptake of apoptotic monocytes (U937 human monocytic cell 
line), only preloading of inert beads or induction of oxidative stress reduced AC uptake. This 
did not affect uptake of further beads or E.coli. This supports data in this study that function 
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between MØ and FC to clear cells of a myeloid lineage, and to phagocytose E.coli, was 
comparable (figs. 13/14a). 
Also to consider is whether aMØ and aFC are a favourable substrate for ingestion compared 
to popular AC models such as aJK. This study found that interaction with aMØ and aFC was 
functional, but levels of interaction by MØ were reduced compared to aJK interaction (Fig. 
17b). When observing MØ interaction rates, a healthy phagocyte, with aJK, a standard AC 
model, and comparing with aMØ or aFC interaction, interaction could be deemed less 
efficient with the latter AC types (Fig. 17b). It may therefore not just be lipid loading 
phagocytes, or clearing lipid-loaded ACs, that is the fundamental issue, but a less effective 
clearance process when MØ have to clear up after themselves. Li et al. found similar results, 
with the percentage of mouse-peritoneal MØ ingesting mouse peritoneal-derived aFCs at 
20–30%, compared with 40–50% for UV irradiated Jurkat cells210. In the Schrijvers et al. 
model of AC clearance, MØ clearing apoptotic B cells in tonsil specimens contained more 
ACs than MØ clearing dead cells (prominently aMØ) within the plaque195. Given that high 
densities of aMØ requiring clearance is not common, and it is not a straightforward cell type 
to study due to adherence, research into aMØ clearance is limited. 
As clearance mechanisms become better elucidated, they are being linked with defective 
clearance mechanisms in the plaque. For example the role of the TAM receptor Mer, which 
recognises PS on the AC surface, both directly and indirectly, is gradually being elucidated, 
with roles found in both AC clearance and atherosclerosis108,109,126. In a murine model of 
atherosclerosis, Thorp et al. (2008) found Mer receptor mutation reduces efficiency of AC 
clearance, promoting AC accumulation and plaque necrosis108. Defects in Mer are also 
associated with reduced AC clearance and development of autoimmunity in mice109,110. 
Soluble Mer, cleaved from the cell surface under inflammatory conditions, has also been 
shown to inhibit AC clearance by competition with ACs for bridging molecule Gas6, an 
interesting result if you consider the inflammatory environment of the plaque345. A role for 
Mer has also been found in immune modulation following „tickling‟ by apoptotic foam cell 
membranes210. Further research into Mer in human cell lines and primary human cells would 
be beneficial to elucidating failed clearance mechanisms in human atherosclerotic lesions. 
Cell stress may also alter phagocytic efficiency. For example, autophagy, induced in stressed 
cells, in macrophages undergoing apoptosis was found to enhance their recognition by 
phagocytes346. Oxidative stress was also found to inhibit phagocytosis of apoptotic cells, 
including apoptotic Jurkat347. All AC models in the current study were induced to apoptosis 
using the same method, so if oxidative stress levels are enhanced at this point, it is likely that 
they are equally exacerbated in all AC models.  
89 
 
Subsequent immune-modulation following AC interaction may also have knock-on effects on 
further AC uptake in the plaque as differing signals may enhance or reduce further uptake 
ability. Defective immune-modulation could originate from the phagocyte, if lipid loading 
alters the ability of MØ to switch between M1 and M2 phenotypes. Also to consider is the role 
of the apoptotic cell, and whether it has the ability to confer the correct signal to the 
phagocyte. This will be investigated further in Chapter 4. 
Another consideration is whether in vivo chemotactic factors are still released by apoptotic 
foam cells, and whether phagocytic foam cells have the ability to recognise and migrate 
towards apoptotic cells within the plaque. This may not be relevant in this model of AC 
interaction (figs. 11/12/14) due to the direct and excess placement of ACs on phagocytes. It 
also may not be relevant within the plaque itself if there is such a concentration of ACs in the 
plaque that movement would not be required to contact the AC, however when considering 
the continuous recruitment of monocytes into the plaque, exacerbating the pathological 
features atherosclerosis, chemotactic factors may play a key role in plaque progression and 
are an important area of study. Mechanisms of monocyte chemotaxis to apoptotic cells will 
be further studies in Chapter 5.  
Mediators in the local environment may also play a pivotal role in clearance in the plaque, at 
which point the effects of an aged environment may come into play. For example, 
established phagocyte:AC bridging molecules MFG-E8348, C1q349 and Gas6107  knockout 
models have recently been shown to impact atherosclerosis progression in mice. Similar 
trends are found in autoimmune disease and ageing, where links have been found between 
reduced function of bridging molecules, and persistent apoptotic cells or inflammation34,350. 
Interestingly murine models of SLE, an autoimmune disease driven by defective AC 
clearance, show accelerated atherosclerosis351. This also demonstrates a pivotal role for 
bridging molecules, including Gas-6, levels of which could alter in ageing and pathology. 
Local inflammation is also likely to exacerbate is also likely to drive pathology. TNF-α, a 
classic inflammatory cytokine, has been shown to inhibits AC clearance by MØ, via cytosolic 
phospholipase A2 and oxidant-dependent mechanisms57. The effects of ageing on AC 
clearance will be further explored in a Pilot Study, detailed in Chapter 6. 
Understanding the underlying molecular mechanisms behind defective clearance of, or 
response to, ACs would be an important development for research into atherosclerosis due 
to the consequences of secondary necrosis of uncleared cells and subsequent plaque 
instability150. 
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3.4. Conclusions and future work 
Results demonstrate THP-1, a well-established human monocytic cell line, is a useful tool for 
investigating all stages of apoptotic cell clearance, which can be applied to research into 
potentially defective mechanisms of apoptotic cell clearance in the atherosclerotic plaque. 
VD3 differentiated THP-1 will be used in further studies into chemotaxis, as a monocyte 
model with adherent properties. PMA differentiated THP-1 cells have proved robust in 
macrophage and foam cell formation, and will be taken forward to investigate further aspects 
of AC clearance relevant to the plaque environment.  
Further characterisation of oxLDL utilised in these studies would help define levels of 
oxidation, and whether these are comparable to minimally modified LDL, as this has 
implications on receptor interaction, phagocytic activity and immunological outcome201,323. As 
mmLDL has been reported to be inflammatory, studies detailed in Chapter 4 may provide 
evidence to support minimal or extensive oxidation levels. Although different physiological 
outcomes have been reported following treatment of MØ with mmLDL and oxLDL, set 
parameters for oxidation levels have never been established. 
Results in this study support previous research that foam cells are in some cases defective in 
clearance of some AC lineages195,197. Further study into the mechanisms of overall reduction 
in phagocyte interaction with aMØ and aFC, compared to aJK, could be of importance, given 
the composition of ACs within the plaque. 
The involvement of Mer in AC clearance in a plaque environment in human cells would also 
bolster current research in the area, and could be done using the THP-1 model, which has 
been shown to express Mer352. 
Research into other phases of AC clearance relevant to the plaque environment will be 
investigated in the following chapters. 
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Cytokine profiling of foam cell model 
4.1. Introduction 
It is the accepted theory that efficient AC clearance is necessary, before secondary necrosis 
and subsequent inflammation ensues35, though contradictory evidence illustrates that 
mechanisms are poorly understood38,40. Clearance of apoptotic cells has also been shown to 
directly influence immune modulation in an anti-inflammatory manner55,56. 
Macrophage plasticity is well recognised, with phenotype altering between pro-inflammatory 
„M1-like‟ MØ, and „M2-like‟ MØ which have more of a reparative/janitorial role353. MØ 
phenotypes vary according to the local microenvironment, and inflammatory responses, 
associated with „M1‟-like MØ, have been shown to be dampened in the presence of ACs56. 
AC interaction is associated with an „M2‟-like phenotype, and has been shown to induce anti-
inflammatory mediators release, including TGF-β1, IL10, PGE2, PAF55,56. The release of pro-
inflammatory mediators has also been shown to be supressed following AC interaction, 
including TNF-α, IL-1, IL-12 and IL-855,56 
Following phagocyte recruitment, AC clearance has been proposed to comprise of 4 stages; 
recognition of the AC by the phagocyte, tethering of the AC (binding), tickling of the 
phagocyte by the AC (signalling) and phagocytosis. Subsequent modulation of immune 
responses in the phagocyte follows on from this. The previous chapter investigated 
recognition, tethering and phagocytosis of apoptotic foam cells by non-lipid laden and lipid 
laden MØ. Whilst defective clearance of AC has been proposed to promote plaque 
progression150,195, the immunological responses of lipid-laden phagocytes to human lipid-
laden ACs is unknown and altered phagocyte responses to apoptotic cells within the plaque 
environment may also help drive disease. This chapter will focus on the tickling/signalling 
phase, and post phagocytosis responses, by investigating the immunological outcome of 
lipid-loading MØ, and the ability of these MØ to respond to ACs in a non- or anti-
inflammatory manner. The ability of foam cells to switch between an „M1‟ and „M2‟ output will 
be investigated, and also the ability of apoptotic foam cells to tickle lipid- and non-lipid laden 
MØ into a non- or anti-inflammatory phenotype.  
There remain a number of unanswered questions addressing issues fundamental to the 
inflammatory environment within the plaque, including those relating to the immunological 
response post AC ingestion within a plaque environment. 
The hypothesis underlying this chapter is that control of regulating appropriate immune 
responses is lost by MØ in an aged (e.g. lipid-laden) environment, resulting in failure to 
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resolve inflammation. Some of the research questions used to address this are listed in the 
table below.  
  
Phagocyte 
 
Apoptotic cell 
 
Macrophage 
(MØ) 
Foam cell 
(FC) 
 
Apoptotic MØ 
(aMØ) 
What is the immunological 
outcome of interaction 
between non-lipid laden MØ 
and non-lipid laden aMØ? 
Can FC respond to aMØ in a 
non- or anti-inflammatory 
manner? 
Apoptotic FC 
(aFC) 
Can aFC tickle MØ into a 
non- or anti-inflammatory 
phenotype? 
Does the combination of 
FC/aFC cause/exacerbate 
defective immune response? 
 
Table 5. Summary of key research questions addressed in Chapter 4 
4.2. Results 
4.2.1. THP-1-derived macrophage and foam cell cytokine responses to apoptotic T 
cells 
To establish whether foam cells (lipid-laden MØ) respond to apoptotic cells in a comparable 
manner to non-lipid-laden MØ, we used an established apoptotic cell model, UV-induced 
apoptotic Jurkat (aJK). 
TNF-α is a key driver of inflammation and had been found in human atherosclerotic 
plaques221,222. TNF-α release by phagocytes has also been shown to be dampened following 
AC interaction55,56. TNF-α release was measured at basal levels (i.e. without treatment of 
macrophages) to examine whether lipid-loading of MØ induces an inflammatory cytokine 
output. Cytokine production in response to aJK was examined to establish whether MØ and 
FC both respond to aJK in a non- or anti-inflammatory manner. The addition of LPS allowed 
observation of a classical activation, and aJK-mediated switch off of an immune response, 
indicating a switch of a classical to a regulatory phenotype in MØ. 
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Figure 19. Apoptotic Jurkat reduce LPS-induced TNF-α production from both 
macrophages and foam cells MØ and FC were co-cultured with aJK (harvested 6h post 
UV) or sfRPMI control (20h; 37C). 0.5ng/ml LPS or sfRPMI control was added to relevant 
wells with normal human serum (10% v/v final conc.) and incubated (4h; 37C). TNF-α ELISA 
was carried out according to manufacturer’s instructions (PeproTech Ltd). Data shown is 
mean ± SEM of 3 independent experiments. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, 
two-way ANOVA with Tukey’s post-hoc analysis. 
Figure 19 shows MØ (no oxLDL treatment) and FC (50µg/ml oxLDL, 72h) released low and 
comparable basal levels of TNF-α, and similarly low levels following co-culture with aJK. 
Cytokine production in response to LPS, an established pro-inflammatory mediator, was also 
measured to compare the ability of MØ and FC to produce an inflammatory/‟M1-like‟ 
response, and whether this can be inhibited by co-culture with aJK. TNF-α secretion was 
significantly increased in MØ following LPS treatment (P<0.01), and was increased, but not 
significantly so, in FC, compared to basal levels. FC appeared to show reduced TNF-α 
release compared to MØ in response to LPS, but this difference was not significant. TNF-α 
release in response to LPS was significantly increased in MØ and FC compared to aJK alone 
(P<0.001 and P<0.05 respectively). TNF-α release in response to LPS was inhibited 
significantly in MØ following co-culture with aJK (P<0.05), and in FC levels were reduced but 
not significantly so. Results show FC are perhaps less inflammatory than their non-lipid-
laden counterparts, and that increased basal levels of TNF-α release may not be responsible 
for the inflammatory environment within the plaque. 
IL-12 can also drive inflammation, and had been found in human atherosclerotic plaques228. 
IL-12 and anti-inflammatory cytokine IL-10, have been found to cross-regulate, and the 
secreted IL-10: IL-12 ratio has been proposed as a marker for classical versus regulatory MØ 
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activation49,228. IL-12 release by phagocytes has also been shown to be dampened following 
AC interaction, however IL-10 release in response to ACs is less clear, with some studies 
finding upregulation, and others downregulation, of this cytokine55,56. IL-10 and IL-12 release 
was measured at basal levels (i.e. without treatment of macrophages) to examine  the effect 
of lipid-loading MØ on cytokine output. IL-10 and IL-12 production in response to aJK was 
examined to establish whether MØ and FC both respond to aJK in a non- or anti-
inflammatory manner. The addition of LPS allowed observation of a classical activation, and 
aJK-mediated switch off of an immune response, indicating a switch of a classical to a 
regulatory phenotype in MØ. 
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Figure 20. IL-10 and IL-12 response to apoptotic Jurkat by live macrophages and live 
foam cells MØ and FC were co-cultured with aJK, LPS or sfRPMI as in Fig. 19. Samples 
were diluted 1/5 in sfRPMI prior to ELISA analysis. IL-10 and IL-12 ELISAs were carried out 
according to manufacturer’s instructions (PeproTech Ltd). Data shown is mean ± SEM of 3 
independent experiments. Data analysed using two-way ANOVA with Tukey’s post-hoc 
analysis. 
Results show that despite the same methods being employed as in investigation of TNF-α 
responses, IL-10 and IL-12 responses are much more variable, and the trends associated 
with LPS response and AC clearance are not apparent (Fig. 20).  
4.2.2. THP-1-derived macrophage and foam cell cytokine responses to apoptotic 
macrophages and apoptotic foam cells 
MØ and FC models were used to investigate the ability of foam cells, compared to MØ, to 
respond to non-lipid-laden apoptotic macrophages (aMØ) and apoptotic foam cells (aFC). 
This also would address whether aMØ and aFC have the ability to „tickle‟ MØ and FC into the 
appropriate regulatory phenotype. Figure 21 shows that both MØ and FC release low basal 
levels TNF-α, consistent with data in Figure 19. Figure 21 also shows low TNF-α release by 
MØ and FC when co-cultured with aMØ or aFC, at comparable levels to basal TNF-α 
release. This would suggest that foam cells are not hyper-inflammatory, and that neither 
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aMØ nor aFC elicit an inflammatory response. This is despite co-culture up to 24 hours post 
UV treatment, by which time cells induced to apoptosis may be secondarily necrotic. The 
TNF-α response to LPS is identical in MØ and FC, and significantly higher than both basal 
and aMØ/aFC co-cultured treatment groups (P<0.0001). This indicates comparable 
functionality, or „health‟ of FC compared to MØ, given similar levels of cell death shown in the 
previous chapter (Chapter 3; Fig. 12). 
MØ co-culture with aMØ significantly inhibited LPS-induced TNF-α release (P<0.05). MØ co-
culture with aFC also significantly reduced LPS-induced TNF-α release (P<0.01), indicating 
aFC are equally capable of switching off an inflammatory response by THP-1 MØ, compared 
to aMØ (Fig. 21). 
Similar trends were observed when measuring FC TNF-α responses to LPS in combination 
with aMØ and aFC co-culture (Fig. 21). FC co-culture with aMØ significantly inhibited LPS-
induced TNF-α release (P<0.01). LPS-induced TNF-α release by FC was inhibited even 
more significantly by aFC (P<0.0001), indicating, as above, that aFC are equally, if not more, 
capable of switching off an inflammatory response by FC, compared to aMØ. Interestingly, 
the FC inflammatory response appears to be switched off more effectively by aMØ and aFC 
than the MØ inflammatory response, although these differences are not significant (ns; Fig. 
21). 
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Figure 21. Apoptotic macrophages and apoptotic foam cells reduce LPS-induced TNF-
α production from both MØ and FC MØ and FC were co-cultured with aMØ/aFC 
(harvested 6h post UV) or sfRPMI control (20h; 37C). 0.5ng/ml LPS or sfRPMI control was 
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added to relevant wells with normal human serum (10% v/v final conc.) and incubated (4h; 
37C). Supernatants were diluted 1/5 in sfRPMI prior to ELISA analysis. TNF-α ELISA was 
carried out according to manufacturer’s instructions (PeproTech Ltd). Data shown is mean ± 
SEM of 4 independent experiments. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, two-way 
ANOVA with Tukey’s post-hoc analysis. 
MØ and FC IL-10 and IL-12 responses were again variable, therefore any trends in response 
to AC and LPS were not exposed (Fig. 22).  
B
a
s
a
l
a
M
Ø
a
F
C
L
P
S
a
M
Ø
 +
 L
P
S
a
F
C
 +
 L
P
S
0 .0
0 .5
1 .0
1 .5
IL
-1
0
 (
n
g
/m
l)
B
a
s
a
l
a
M
Ø
a
F
C
L
P
S
a
M
Ø
 +
 L
P
S
a
F
C
 +
 L
P
S
0 .0
0 .2
0 .4
0 .6
0 .8
IL
-1
2
 (
n
g
/m
l)
M Ø
F C
 
Figure 22. IL-10 and IL-12 response to apoptotic macrophages and apoptotic foam 
cells by live macrophages and live foam cells MØ and FC were co-cultured with 
aMØ/aFC, LPS or sfRPMI as in Fig. 21. Supernatants were diluted 1/5 in sfRPMI prior to 
ELISA analysis. IL-10 and IL-12 ELISAs was carried out according to manufacturer’s 
instructions (PeproTech Ltd). Data shown is mean ± SEM of 3 independent experiments. 
Data analysed using two-way ANOVA with Tukey’s post-hoc analysis. 
4.2.3. Human monocyte-derived macrophage cytokine response to apoptotic cells 
THP-1 cells have proved to be a valuable model MØ system for assaying MØ function with 
regards to AC clearance312. In order to establish the relevance of cytokine responses noted 
above in THP-1-derived MØ and FC models, human monocyte-derived macrophages 
(HMDM) were employed as a primary human cell system and TNF-α responses to the same 
stimuli as in THP-1-derived MØ and FC were measured. 
Results in HMDM show low TNF-α release at basal levels, and comparably low TNF-α 
release when with aJK co-culture. This is in direct agreement with the results obtained with 
THP-1-derived MØ/FC models. However, in contrast to results in THP-1-derived MØ/FC 
models, HMDM showed significantly higher levels of TNF-α release in response to co-culture 
with THP-1 derived aMØ and aFC when compared to basal levels and aJK co-culture 
(P<0.01). TNF-α release was higher in response to aMØ/aFC than in response to LPS, but 
not significantly so. TNF-α response to LPS appeared to be inhibited a small amount with 
aJK co-culture, but not to a significant degree. TNF-α release in response to LPS was not 
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inhibited by co-culture with aMØ/aFC, in contrast to the THP-1 MØ/FC model. The TNF-α 
response to LPS in the presence of aMØ/aFC was significantly higher than basal levels 
(P<0.0001) and levels in LPS alone treatment group (P<0.01). Levels of TNF-α release by 
HMDM (Fig. 23) are lower than in the THP-1 model (Fig. 21), which is likely due to 
differences in live cell numbers following culture. 
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Figure 23. Primary human monocyte-derived macrophages produce TNF-α in 
response to apoptotic macrophages and apoptotic foam cells HMDM were co-cultured 
with aJK/aMØ/aFC (6h post UV) or CDMØ-medium control (20h; 37C). 5ng/ml LPS or 
CDMØ-medium control was added to relevant wells and incubated (4h; 37C). Samples were 
diluted 1/5 in sfRPMI prior to ELISA analysis. TNF-α ELISA was carried out as per 
manufacturer’s instructions (PeproTech). Data shown is mean ± SEM of multiple 
independent experiments. Basal n=20, LPS n=20, aJK (+/-LPS) n=17, aMØ (+/-LPS) n=17, 
aFC (+/-LPS) n=14. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 one way ANOVA with 
Tukey’s post-hoc analysis. 
One possible trivial explanation of these divergent results in HMDM could be the presence 
TNF-α in AC preparations. This could be derived from intracellular cytokine release induced 
passively via membrane disruption, e.g. secondary necrosis, or actively via contamination 
prior to apoptosis induction, e.g. bacterial contamination, which is not considered to be likely. 
All other assay components are present in basal wells, including NHS, apart from LPS, which 
is expected to be inflammatory. It is unlikely to be oxidised LDL contamination as aMØ elicit 
a TNF-α response as well as aFC. To ensure detected TNF-α was not already present in 
assay preparations, aMØ, or NHS and LPS, preparations alone were assayed for TNF-α 
following full incubation times, in the absence of phagocytes (Fig. 24). Wells did not contain 
HMDM, but contained the same working solutions of NHS, LPS and aMØ in CD-MØ medium 
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as used in the HMD-MØ assays. Results showed very low/negligible levels of TNF-α in 
control assays. 
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Figure 24. Measured TNF-α is not NHS, LPS or AC-derived aMØ (6h post UV) were 
resuspended in CDMØ-medium, and either CDMØ-medium or AC added to relevant wells 
and incubated (20h; 37C). 10% NHS (v/v, final conc.), 5ng/ml LPS or CDMØ-medium was 
added to relevant wells and incubated (4hours; 37C). Samples were diluted 1/5 in sfRPMI 
prior to ELISA analysis. TNF-α ELISA was carried out as per manufacturer’s instructions 
(PeproTech Ltd). Data shown is mean ± SEM of 3 independent experiments. 
One of the variables between the generation of apoptotic Jurkat cultures and apoptotic 
MØ/FC cultures is the use of PMA to differentiate monocyte-like THP-1 to MØ-like cells prior 
to inducing apoptosis. Although PMA containing medium is replaced at 96 hours pre-UV 
exposure, it possible that residual PMA in preparations of THP-1 derived apoptotic cells 
(aMØ/aFC) may be the cause of increased TNF-α release following HMDM exposure to aMØ 
or aFC. HMDM were cultured in the presence of PMA at 250nm (concentration used to 
generate MØ), 25nm and 2.5nm. In case PMA in the presence of AC induces TNF-α release, 
HMDM were cultured in the presence of PMA at 250nm, 25nm and 2.5nm and non-
inflammatory aJK. Preliminary results (Fig. 25) suggest that assay relevant concentrations of 
PMA do not cause TNF-α release in HMDM in the presence or absence of aJK, and thus 
suggest that the pro-inflammatory responses of HMDM to aMØ or aFC are the result of 
HMDM:AC interaction. 
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Figure 25. Preliminary data: TNF-α response to apoptotic macrophages and foam cells 
is not due to residual PMA exposure HMDM generation were co-cultured with CDMØ-
medium + PMA (indicated concs.) or aJK (6h post UV) + PMA (indicated concs.) (20h; 37C). 
10% v/v NHS (final conc.) was added to relevant wells and incubated (4h; 37C). Samples 
were diluted 1/5 in sfRPMI prior to ELISA analysis. TNF-α ELISA was carried out as per 
manufacturer’s instructions (PeproTech Ltd). Data shown is mean ± SD of 2 independent 
experiments. 
To dissect the source of increased HMDM TNF-α release in response to aMØ/aFC, 
preliminary work investigated whether apoptotic cells, or released microparticles/soluble 
factors induced TNF-α release. Culture medium was replaced at the point of UV exposure 
and HMDM were treated with either AC-derived cell-free supernatants (CFS) or ACs 16-20 
hours post UV. Preliminary data show that both AC and EVs or soluble factors in AC 
supernatants are capable of inducing TNF-α release by HMDM (Fig. 26). Further study is 
required to confirm initial findings.    
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Figure 26. Preliminary data: HMD-MØ TNF-α response to apoptotic cell-derived CFS 
HMDM were co-cultured with CDMØ-medium, aMØ and aFC whole culture or aMØ and FC 
cell-free supernatant (CFS) (centrifugation 350g; 6m) (16-20h; 37C). 10% v/v NHS (final 
conc.) was added to relevant wells and incubated (4h; 37C). Samples were diluted 1/5 in 
sfRPMI prior to ELISA analysis. TNF-α ELISA was carried out as per manufacturer’s 
instructions (PeproTech Ltd). Data shown represents 1 experiment. 
4.3. Discussion 
Trying to establish the main drivers of inflammation in atherosclerosis is a key target when 
considering future therapy and disease management. Inflammation within the plaque is now 
an established component of atherosclerosis, and evidence also points towards systemic 
inflammatory markers as indicators of disease58,354,355. Persistence of apoptotic cells could be 
exacerbating inflammation, as uncleared cells can become secondary necrotic110,356, causing 
autolysis and outflow of inflammatory intracellular components207. 
The results in this chapter show that in the THP-1 model, basal levels of pro-inflammatory 
cytokine production (TNF-α) are the same in MØ and FC, indicating that FC are not 
constitutively pro-inflammatory. Responses to pro-inflammatory stimulus LPS were also the 
same in MØ and FC, indicating that FC have functional cytokine responses. Neither aMØ nor 
aFC initiated an inflammatory response when interacting with THP-1 MØ or FC, and both AC 
types had the ability to switch of an inflammatory response. MØ and FC retained the ability to 
switch from an LPS-induced pro-inflammatory phenotype, to an anti-inflammatory phenotype 
following AC interaction.  
Conversely, HMDM responded in an inflammatory manner to aMØ and aFC, but not to aJK. 
aMØ and aFC also exacerbated LPS-induced TNF-α release in HMDM, whereas this 
response was dampened with aJK interaction. Preliminary studies suggest that both 
interaction with aMØ/aFC and aMØ/aFC-derived MPs and soluble material can induce 
inflammatory responses in MØ/FC. This could be an important inducer and driver of 
inflammation in the atherosclerotic plaque, where aFC and aMØ are abundant.      
  
Phagocyte 
 
Apoptotic cell 
 
THP-1 macrophage 
(MØ) 
THP-1 foam cell 
(FC) 
 
HMDM 
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Apoptotic MØ 
(aMØ) 
aMØ do not induce an 
inflammatory response 
in MØ and aMØ can 
switch off a TNF-α 
response in the THP-1 
model 
aMØ do not induce an 
inflammatory 
response in FC and 
aMØ can switch off a 
TNF-α response in the 
THP-1 model 
aMØ strongly 
induce TNF-α 
release in HMDM, 
and exacerbate 
LPS-induced TNF-α 
release 
Apoptotic FC 
(aFC) 
aFC do not induce an 
inflammatory response 
in MØ and aFC can 
switch off a TNF-α 
response in the THP-1 
model 
aFC do not induce an 
inflammatory 
response in FC and 
aFC can switch off a 
TNF-α response in the 
THP-1 model 
aFC strongly induce 
TNF-α release in 
HMDM, and 
exacerbate LPS-
induced TNF-α 
release 
Table 6. Summary of results from key research questions addressed in Chapter 4 
4.3.1. Inflammatory status of foam cells 
Few studies have addressed mechanisms behind the persistence of inflammation from the 
point of the macrophage/foam cell, either live or apoptotic, despite the heavy presence of 
apoptotic cells and phagocytes, a combination shown to dampen inflammation in a non-
plaque environment54-56.  
Secretion of pro-inflammatory cytokines TNF-α and IL-12, markers of classical MØ activation, 
and IL-10, a regulatory cytokine and proposed marker for alternative MØ activation, was 
investigated at basal levels in the THP-1 model, with and without oxLDL pre-treatment49. This 
was to determine whether lipid-loading MØ induces an inflammatory phenotype in the THP-
1-derived MØ model. Inflammatory cytokines drive macrophages to an „M1-like‟ phenotype, 
which can increase pro-inflammatory cytokine output and reduce the rate of apoptotic cell 
uptake, or efferocytosis234,357. TNF-α has the ability to drive inflammation, and has been 
found in human atherosclerotic lesions137,220-222. Results shown here (figs. 16/18) indicate that 
macrophages and foam cells secrete comparable basal levels of cytokine TNF-α, suggesting 
similar basal levels of inflammation when comparing macrophages before and after lipid 
loading. 
IL-12 is another inflammatory cytokine and is a suggested marker for classical MØ activation 
in conjunction with IL-10, which is a regulatory cytokine and suggested marker of alternative 
MØ activation49. Trends in IL-10 and IL-12 release could not be determined due to variability 
in results (figs. 17/19). IL-12: IL-10 dysregulation in foam cells could be a point of further 
study. Studies in primary human monocytes found oxLDL could induce IL-10 and IL-12 
release, and that these cytokines were cross-regulatory228. Studies with murine bone 
marrow-derived MØ showed apoptotic neutrophils could inhibit LPS-induced IL-10 and IL-12 
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release, however secretion was not detected after 4 hours LPS exposure, which is the time 
period used in these studies358.   
A further hypothesis is that foam cells are hyper-inflammatory in the presence of an inducer 
of inflammation (i.e. a pro-inflammatory stimulus, e.g. LPS), when compared to non-lipid-
laden MØ, as previous studies have implicated infection as a contributor of inflammation in 
atherosclerosis359. LPS and minimally modified LDL (mmLDL) have also been shown to 
cooperatively activate MØ to produce pro-inflammatory cytokines in murine models360. 
Experiments undertaken here to address this hypothesis reveal TNF-α secretion in response 
to LPS was comparable (Fig. 21) or lower (not significant; Fig. 19) in FC compared to MØ, 
suggesting FC are not hyper-inflammatory in the presence of immunogenic stimuli. IL-10 and 
IL-12 secretion was very low in comparison, and variability of results was high (figs. 17/19). A 
larger sample size or more sensitive detection method may be required. In conclusion, the 
mechanism driving the inflammatory status within the atherosclerotic plaque is either not the 
result of inappropriate phagocyte stimulation or it cannot be modelled in this THP-1-derived 
phagocyte model. 
Interestingly, minimally modified LDL (mmLDL), often referring to mild oxidation methods 
including short-term copper sulphate oxidation, or fibroblast co-culture, is a potent inducer of 
inflammation via TLR2/4 activation, resulting in IL-1β, IL-6 and IL-10323,324,360. mmLDL is an 
subjective term that has not been given a solid definition, however it would be interesting to 
question whether mmLDL is a more or less physiologically relevant model of subendothelial 
LDL accumulation, or whether is a likely to be a combination of various LDL modifications 
present. oxLDL in this model could be better defined, however a lack of modified LDL-
induced inflammation would suggest the oxLDL in this model is truly oxidised, and not 
„minimally modified‟, LDL. 
At a technical level, it is possible that differences in live cell numbers between macrophages 
and foam cells could mask true differences in cytokine output, but taken together with oxLDL 
toxicity results (Chapter 3; Fig. 12) and microscopic observation this is not thought the be the 
case in this model. 
4.3.2. Cytokine responses by THP-1-derived macrophage and foam cell models to 
apoptotic cells 
An unanswered question is whether foam cells and non-lipid-laden MØ respond to apoptotic 
cells in the same manner. Experiments in this chapter aim to address whether lipid-loading of 
phagocytes affects the resulting immune modulation seen in response to apoptotic cells. 
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In this model, results have shown that MØ-derived THP-1, a human immortal cell line, 
respond in a non-inflammatory nature to UV-induced apoptotic Jurkat, a well-established 
model for apoptotic cell clearance54, with regards to TNF-α release (Fig. 19). aJK also had 
the ability to dampen an LPS induced TNF-α release (Fig. 19). This supports data by Voll et 
al.55, which demonstrated  reduced TNF-α, IL-12 and IL-1β secretion by peripheral blood 
monocytes in response to LPS in the presence of apoptotic peripheral blood lymphocytes, 
and an increase in IL-10 secretion, a regulatory chemokine. Fadok et al.56 also found 
reduced inflammatory mediator release in response to apoptotic neutrophils, including IL-1β, 
IL-8, GM-CSF, leukotriene C4, thromboxane B2 and TNF-α, but conversely found a reduction 
in IL-10 secretion by human monocyte-derived macrophages. Upregulated secretion of TGF-
β, PGE2 and PAF were also found56.  
Foam cells also responded in a non-inflammatory manner to apoptotic Jurkat cells, as seen 
with MØ, when observing TNF-α release, indicating a „normal‟ phagocyte response to 
apoptotic Jurkat (Fig. 19). Interestingly, FC-mediated TNF-α release in response to LPS 
appeared to be switched off less effectively than in MØ when co-cultured with apoptotic 
Jurkat (Fig. 19), however only non-lipid-laden macrophages showed a significant reduction in 
TNF-α secretion in response to LPS with AC pre-treatment. This could be to the apparent 
reduction in TNF-α secretion in response to LPS by FC, a difference which was not 
significant. Increased sample size may clarify these results. FCs appear to be switched off 
more easily than MØ by aMØ and aFC with regards to LPS-induced TNF-α response. 
Little research has focused on the role of the apoptotic cell in studies on defective AC 
clearance, and a variety of AC models have been utilised. It is unclear whether aMØ and 
aFC are both able to induce an anti-inflammatory response in phagocytes, or if lipid-loading 
prior to apoptosis affects subsequent modulation of immune responses. The THP-1 cell line 
provides a good human MØ model, which can be lipid-loaded and induced to apoptosis to 
investigate cytokine responses as may occur within the plaque environment. 
Using the THP-1 model, MØ and FC TNF-α release is low, and comparable to responses 
with aJK co-culture, following co-culture with apoptotic MØ (aMØ) and apoptotic FC (aFC) 
(Fig. 21). aMØ and aFC were both able to suppress LPS-mediated TNF-α release on MØ 
and FC. This suggests that FC are able to switch between classical and alternative 
activation, and equally that aFC are capable of switching off an inflammatory response, as 
observed with aJK interaction (Fig. 19). Li et al. 210 observed TNF-α and IL-1β production, but 
not IL-10 or TGF-β, by murine peritoneal MØ following interaction with free cholesterol-
induced apoptotic macrophages (acetylated LDL + ACAT inhibitor), rather than the anti-
inflammatory response associated with AC clearance. The same study investigated 
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interaction and immune modulation following ox-LDL induced aMØ and non-lipid-loaded UV-
induced aMØ; comparable interaction was reported with all 3 AC types, however anti-
inflammatory responses were observed with oxLDL and UV-induced aMØ, but data was not 
shown210. 
Results in the current study were variable with regards to MØ and FC IL-10 and IL-12 
release, so clear trends could not be distinguished (figs 17/19).  
4.3.3. Cytokine responses by primary human macrophages to apoptotic cells 
Previous studies have used primary human monocytes to investigate the effects of oxLDL on 
inflammatory cytokine output228, however studies of human cytokine responses to apoptotic 
cells, particularly apoptotic foam cells, are lacking. To investigate whether results are 
applicable to a primary human cell model, monocytes were isolated from peripheral blood 
from healthy volunteers and allowed to differentiate to human monocyte-derived MØ 
(HMDM) over a period of 7-14 days. HMDM were co-cultured with or without AC models 
used in the THP-1 model, and stimulated with LPS to look at AC-induced knockdown of an 
inflammatory response. 
Results showed the same non-inflammatory response observed in primary MØ as in the 
THP-1 model with aJK co-culture (Fig. 23), and a reduction in LPS-induced TNF-α release 
following co-culture with aJK. However, primary MØ interaction with aMØ and aFC resulted 
in TNF-α release much greater than LPS-induced responses (Fig. 23). This also meant a 
lack of knockdown, only exacerbation, of an LPS-induced TNF-α response. This supports 
aspects of the study by Li et al., discussed briefly above, which observed TNF-α and IL-1β 
release from murine peritoneal MØ following interaction with cholesterol-induced apoptotic 
macrophages, rather than the anti-inflammatory response associated with AC clearance210. A 
murine study also found that apoptotic T cells release TGF-β, which may account for 
modulation of immune responses here361. In contrast, anti-inflammatory effects were reported 
with oxLDL-induced and UV-induced murine peritoneal MØ (data was not shown)210. This 
further demonstrates a potential role for the AC-induced inflammation within plaque, and also 
the role of persistent ACs in driving inflammation should plaque ACs prove to be 
inflammatory. Khan et al.197 also found pro-inflammatory cytokine release by murine 
peritoneal MØ following exposure to UV-induced apoptotic vascular smooth muscle cells 
(VSMCs) in the presence of oxLDL, so a combination of oxLDL and ACs may trigger a pro-
inflammatory response in MØ, however the mechanisms are yet to be elucidated. Studies in 
this chapter only involve oxLDL pre-incubation, without oxLDL presence during 
phagocyte:AC co-culture. Studies on primary murine cells and human coronary artery 
endothelial cells (HCAECs) found that ACs with oxidation-specific epitopes were 
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inflammatory209. Thus the results presented here are consistent with previous work that lipid-
laden apoptotic cells may represent a pro-inflammatory stimulus to primary macrophages 
and that this may contribute to the inflammatory nature of the plaque.   
Further studies were undertaken to try and dissect the true physiological response of HMDM 
to aMØ and aFC, and to attempt to rule out other influencing factors. The obvious variable in 
Jurkat culture and THP-1-derived aMØ generation is the use of PMA. To ensure PMA is not 
the driver of inflammatory responses observed with HMDM: aMØ/aFC co-culture, HMDM 
were co-cultured in the presence or absence of non-inflammatory aJK, with relevant dilutions 
of PMA (Fig. 25). Preliminary data shows PMA does not induce TNF-α release in HMDM in 
the presence or absence of non-inflammatory ACs. Another possible explanation of these 
divergent results, compared to the THP-1 model, in HMDM could be the presence TNF-α in 
AC preparations. This could be derived from intracellular cytokine release induced passively 
via membrane disruption, e.g. secondary necrosis, or actively via contamination prior to 
apoptosis induction, e.g. bacterial or PAMP contamination. It is unlikely to be oxidised LDL 
contamination as aMØ elicit a TNF-α in HMDM to the same extent as aFC, and limulus assay 
testing was negative on a random selected oxLDL sample (data not shown). Contamination 
is also less likely if you consider non-inflammatory results in THP-1 MØ in response to the 
same preparations (Fig. 21). To ensure detected TNF-α was not already present in assay 
preparations, aMØ, or NHS and LPS, preparations were assayed for TNF-α following full 
incubation times, in the absence of HMDM, and presence of TNF-α was not at significant 
levels (Fig. 24). 
The presence of secondary necrosis has not been ruled out in this model of aMØ and aFC, 
however an inflammatory reaction was not seen in co-culture with THP-1-derived MØ. 
Simple studies on membrane integrity would provide supporting evidence on the presence or 
absence of secondary necrosis in this model.  
The opposing results found when comparing THP-1 MØ and HMDM TNF-α response to 
THP-1 derived aMØ and aFC models shows the care that needs to be taken when defining 
models and comparing results not only across species, but between immortal cell lines and 
primary cells of the same species. Models of atherosclerosis vary widely, without much 
consensus on the best way to observe processes within the plaque. It could be argued that 
the use of human primary cells may be the closest model we can use when trying to 
understand failures in this disease.  
It is of interest to note that as such an effect is not seen with THP-1-derived MØ/FC, 
suggesting that comparison of THP-1-derived and primary macrophages may identify key 
mediators that underlie the undesirable pro-inflammatory responses.  Such mediators may 
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represent attractive targets for potential therapeutic intervention in atherosclerosis. A 
drawback of the primary cell research in this chapter, is that cell line-derived ACs were used 
due to the large numbers of ACs required for assays compared to phagocytes (10X). 
However it is a key starting point in human cell-orientated research into aFC modulation of 
immune responses in the atherosclerotic plaque, as current research has only been shown in 
murine models. 
4.3.4. Further considerations  
To further dissect the source of increased HMDM TNF-α release in response to aMØ/aFC, 
preliminary work investigated whether apoptotic cells, or released microparticles/soluble 
factors, induced TNF-α release. HMDM were co-cultured with whole aMØ/aFC cultures, or 
cell free supernatants from the same cultures (CFS), over the same time course as previous 
assays. Preliminary results (Fig. 26) suggest that aMØ/aFC cell free supernatant (CFS) 
induces more TNF-α release than aMØ/aFC whole cell culture in HMDM. This could suggest 
than aMØ/aFC could still have some anti-inflammatory properties, as the presence of AC in 
the culture reduces TNF-α release, but mediators in cell-free supernatant cause an 
inflammatory response (Fig. 26). Further research is required to confirm these observations, 
and to dissect which mediators are causing an inflammatory response. The effects of AC-
derived microparticles (MPs), or blebs, on immune-modulation in the plaque would be an 
interesting angle, as MPs they are individual to the originating cell, and can confer 
messages, e.g. inflammatory/anti-inflammatory mediators, to surrounding cells268. MPs have 
been found in human atherosclerotic plaques, and are thought to be primarily derived from 
leukocytes269. MPs also have a role in monocyte chemoattraction, another pathological 
feature in plaque progression60,61,71. It is unknown whether aFCs for example, confer „find-me‟ 
signals, for phagocytic clearance. This may not be relevant in the models of interaction used 
in this chapter as a large excess of ACs are loaded onto phagocytes, however 
consequences in the plaque environment should be considered. If aFCs are inflammatory, 
persistence in the plaque would exacerbate inflammation. 
It is important to note that although the plaque contains many MØ and MØ-derived foam 
cells, as is the definition of foam cells in this model, the complex plaque environment 
includes a variety of cell types including  endothelial cells (ECs), smooth muscle cells 
(SMCs), monocytes, mast cells, T lymphocytes and SMC-derived foam cells, including live, 
apoptotic and necrotic cells56,57.  It is also important to consider if apoptotic foam cells elicit 
the same response in phagocytes as do non-lipid-loaded ACs. Do foam cells release 
comparable find-me signals? This may not be relevant in the model of interaction used in this 
chapter as a large excess of ACs are loaded onto phagocytes.  
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4.4. Conclusions and future work 
In conclusion, evidence in this chapter shows that lipid-loading does not induce TNF-α 
release in THP-1-derived MØ, but this needs to be confirmed by generation of foam cells 
using HMDM, especially given the opposing results observed following AC interaction. Foam 
cells may be hyper-inflammatory with regards to IL-10 and IL-12 release, however this 
requires further study with an increased sample size or more sensitive detection method, e.g. 
via multiplex assays. This would allow a full spectrum of cytokine release to be established in 
cell line and primary cell models of foam cells. Broader cytokine profiling may also provide 
further evidence as to whether alternative or classical MØ activation is favoured in these 
conditions, including TGF-β, which was the aim with the range of cytokines chosen in these 
studies.  
That aMØ can induce inflammation in HMDM is a key observation that, with further 
investigation, could advance understanding of the persistent inflammatory environment in 
human atheroma. As clearance of a high density apoptotic MØ is not a common occurrence, 
and MØ are not an easy AC type to model due to adherence, they are an understudied AC 
type. It would be interesting to further dissect the differences in THP-1-derived MØ and 
HMDM responses to apoptotic MØ and apoptotic FC. Generation of human monocyte-
derived FC, aMØ and aFC would further complete the model. It could then be established 
whether immortal cell line-derived AC models are physiologically relevant, or whether it is 
just a quirk of the assay in question. 
Profiling of aMØ/aFC supernatants could also advance knowledge in the area, to further 
dissect the roles of human cytokine and MP release by apoptotic foam cells. THP-1 derived 
microparticles were recently shown to promote inflammation and atherogenesis in a murine 
model of atherosclerosis282. 
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Mechanisms of chemotaxis to apoptotic cells 
5.1. Introduction 
Chemotaxis is the directional movement of cells up a concentration gradient of an attractive 
agent240. Chemotaxis is important in recruitment of immune cells to points of damage, 
inflammation and, of particular interest to this project, pathological sites such as the 
atherosclerotic plaque362,363. Here, circulating monocytes are recruited from the blood stream 
by upregulated expression of adhesion molecules, such as selectins, on endothelial cells 
overlying the plaque157,250. The plaque is a highly inflammatory environment58 with a lot of cell 
death46, both factors which are known to result in monocyte recruitment43,362. Torr et al. 
showed a role for find-me signal ICAM-3 in recruitment of THP-1-derived monocytes to 
apoptotic cells, with evidence strongly suggesting ICAM-3 release via shedding of AC-
derived MPs71. Another find-me signal, CX3CL1, has been demonstrated to recruit HMDM to 
apoptotic cells, with MP association also shown61. 
The role of apoptotic cell-derived ICAM-3 in recruitment of phagocytes to apoptotic cells has 
only recently been shown71, and was initially identified as a mediator in intercellular adhesion 
between viable cells364. In AC clearance, ICAM-3 is thought to be modified, in as yet an 
undefined manner, to act as an „eat-me‟ flag on the surface of apoptotic cells84. As a murine 
homologue has never been identified, studies of ICAM-3 are restricted to human cells, 
hampering the understanding of the functions of this molecule80. This chapter aims to further 
dissect the role of ICAM-3, which has currently been shown in monocyte recruitment to 
apoptotic lymphocytes (i.e. B and T cells)71, in the recruitment stages of apoptotic cell 
clearance. It is not currently known whether ICAM-3 plays a role in recruitment to other 
leukocytes undergoing cell death, or in other pathological situations. 
Since identification of the role of CX3CL1 in monocyte capture, adhesion to endothelium and 
activation under flow conditions68, and discovery of expression in the plaque365, this 
chemokine has been implicated heavily in development and progression of atherosclerosis. 
CX3CL1 expression has been found in atherosclerotic plaques365,366 and has been implicated 
in CX3CR1-positive monocyte recruitment to the plaque239. Recruitment of monocytes is one 
of the key pathological events in plaque progression, with blockade of recruitment shown to 
improve disease state156. This chapter will further investigate the role apoptotic cell-derived 
CX3CL1 in monocyte recruitment to dying cells, with emphasis on CX3CL1 derived from 
„plaque relevant‟ cells, apoptotic macrophages (aMØ) and apoptotic foam cells (aFC). 
CD14 is a tethering receptor shown to mediate AC clearance31, however its role in „find-me‟ 
signal detection and subsequent monocyte migration towards apoptotic cells has not been 
assessed. CD14, the prototypic LPS receptor367, has also been implicated in AC clearance31, 
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suggesting it has the ability to produce opposing ligand-dependent immunological outcomes. 
Alongside signalling partner TLR4368, CD14 interaction with LPS results in a pro-inflammatory 
immune response, whereas interaction of CD14 with ACs results in a non- or anti-
inflammatory outcome312. MPs are important in monocyte/MØ recruitment to dying cells, but 
whether effects are exerted via binding to known tethering receptor CD14 is not known. 
Tethering of MPs via CD14 may result in MØ activation and migration toward dying cells, 
therefore the role of CD14 in plaque-associated monocyte recruitment will be investigated in 
this chapter. 
This chapter will address the establishment of a horizontal chemotaxis model to be used to 
observe chemotaxis towards agents including AC-derived MPs and soluble factors. Blocking 
antibodies against target molecules with known roles in AC clearance will be utilised to 
establish some of the key molecular players in aMØ and aFC clearance. In previous studies, 
vertical chamber models have been used61,71, but this project seeks to establish a model that 
is not influenced by gravity, and that measures chemotaxis along a true gradient rather than 
migration down a step gradient to a pool of attractant. Horizontal models of chemotaxis could 
therefore be more physiologically relevant. 
In order to develop the model further from a physiological perspective, a vertical transwell 
system was used but with the additional barrier of endothelial cells. HUVECs were used as 
the model endothelial cells of choice. The downstream effects AC-derived MPs exert on 
endothelial cells in the form of selectin expression was also investigated. 
The hypothesis covering this chapter is that in an aged environment (e.g. lipid-laden), 
monocytes are inappropriately recruited to sites of cell death. Research questions posed in 
the table below will be addressed in order to investigate this hypothesis. 
  
Phagocyte 
 
Apoptotic cell 
 
 
Monocyte 
Apoptotic MØ 
(aMØ) 
How well do non-lipid laden MØ attract monocytes via „find-
me‟ signals? 
Are these mechanisms, CD14, ICAM-3 or CX3CL1 
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mediated? 
Apoptotic FC 
(aFC) 
Does lipid-loading enhance or reduce attractiveness of „find-
me‟ signals to monocytes? 
Are these mechanisms, CD14, ICAM-3 or CX3CL1 
mediated? Does lipid-loading alter effector molecules? 
Table 7. Summary of key research questions addressed in Chapter 5 
5.2. Results 
5.2.1. Modelling chemotaxis using a vertical chamber system 
To establish whether microparticles (MPs) from plaque-relevant apoptotic cells (AC) induced 
monocyte migration, a vertical 48 well chemotaxis chamber (Neuroprobe Inc., Gaithersburg, 
Madison, WI, USA) was used in preliminary experiments (Fig. 27). In this assay, monocytic 
VD3 stimulated THP-1 migration was measured from an upper chamber, towards a pool of 
sfRPMI (Control), apoptotic macrophage (aMØ)-derived cell-free supernatant (CFS), or 
apoptotic foam cell (aFC)-derived cell-free supernatant (CFS). CFS is generated by 
centrifugation of whole cell supernatants for 6 minutes at 350xg, pelleting any cell bodies or 
large cell debris. 
Figure 27 shows minimal migration towards medium alone (control), and comparatively 
increased migration towards aMØ-derived CFS, however this was not significant when 
compared to control wells (P>0.05). THP-1 cells migrated toward aFC-derived CFS in a 
significant manner when compared to migration toward control and aMØ-derived CFS 
(P<0.05). 
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Figure 27. Apoptotic foam cell-derived cell-free supernatants induce 
monocyte migration VD3 stimulated THP-1 in sfRPMI were allowed to migrate 
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to aMØ and aFC cell-free supernatants (CFS) or sfRPMI control (4h; 37C). 
Following migration, the polycarbonate membrane was stained and migrated 
cells per high power field (HPF)(40X) on the underside of the membrane 
quantif ied by light microscopy. Four replicate wells and five HPFs of view per 
well were assessed. Data shown are mean migrated cell number per HPF ± S.E. 
of 3 independent experiments. *P<0.05 one way ANOVA with Tukey’s post-hoc 
test. 
5.2.2. Dunn chamber optimisation 
aFC-derived CFS was shown to induce significant monocyte migration in a vertical assay 
system. Next, a horizontal system was established to observe monocyte migration along a 
true chemotactic gradient, based on methods outlined by Zicha et al.292.  
THP-1, VD3, PMA and DS cells were cultured on glass coverslips at a range of cell densities 
and mounted onto Dunn chambers containing sfRPMI or chemically defined (CD)-MØ 
medium in the inner well, and 100ng/ml MCP-1 diluted in sfRPMI or CD-MØ medium 
subsequently added to the outer well. This concentration was chosen as VD3 stimulated 
monocyte chemotaxis to 100ng/ml MCP-1 was observed in preliminary studies using the 
vertical assay system. Dunn chambers were sealed and placed in a humidified chamber at 
37C, and cell migration visualised using time-lapse video microscopy. Images were taken 
every 10 minutes over a 48 hour time period.  
Results showed that although THP-1 adhered to coverslips, adherence was weak and few, if 
any, THP-1 cells remained on coverslips following mounting onto Dunn chambers, despite 
increasing seeding density. More VD3 cells remained on coverslips following transfer onto 
Dunn chambers and some migration was observed in the presence of protein-free CD-MØ 
medium, though cell numbers were very low. Chemotaxis was not observed when sfRPMI 
was used in the assay and as a diluent for MCP-1. PMA and DS differentiated THP-1, and 
human peripheral blood monocytes, are strongly adherent and remained on coverslips 
following transfer onto Dunn chambers, however migration was not observed in either cell 
type. Interestingly, PMA and DS cells appeared to show signs of attempted migration 
towards MCP-1, but appeared to be anchored too firmly to enable migration (Fig. 28). PMA 
and DS cells were cultured on plastic coverslips to investigate whether this would result in 
weaker adherence but the same results were observed. Peripheral blood monocytes were 
mounted on coverslips and used in the Dunn chambers between 20 minutes and 24 hours 
post isolation but were also too strongly adherent for migration.  
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Figure 28. Migration of PMA cells towards MCP-1 THP-1 monocytes were cultured with 
PMA on glass coverslips (72h; 37C). Chemically-defined (CD)-MØ medium was placed in the 
inner well of the Dunn chamber and 100ng/ml MCP-1 in CDMØ-medium was placed in the 
outer well, providing an MCP-1 gradient between the wells. Coverslips were mounted over 
the wells and monocyte migration monitored using time-lapse video microscopy. Arrows 
represent predictive direction of movement based on MCP-1 gradient (low to high). Individual 
cells are circled for comparison at 1h and 24h. 
Taking these results forward, the VD3 model was chosen for future migration studies due to 
their monocytic phenotype and ability to adhere and migrate, and adherent cell numbers 
were increased by raising the seeding density of cells and coating the coverslips in poly-D-
lysine (PDL) prior to seeding of cells. Preliminary studies were carried out to investigate a 
range of concentrations of MCP-1 to promote maximal migration by VD3 stimulated THP-1 
cells and 100ng/ml was found to induce robust monocyte migration (data not shown). 
5.2.3. Modelling horizontal THP-1 chemotaxis to MCP-1 
VD3 stimulated monocytes cultured on PDL-coated glass coverslips were visualised moving 
across a bridge between the inner well (no attractant) and outer well (attractant) of a Dunn 
chemotaxis chamber. Migration was recorded using the manual tracking plugin in Image J. 
This plugin records coordinates from each cell and data can be imported into the Ibidi 
Chemotaxis and Migration Tool (V2.0) to obtain normalised plots. This tool normalises cells 
to the same starting point (centre of plot), and allows mapping of cell migration from this 
point. All axis on qualitative migration plots in this chapter are set to the same units 
(470x470µm). The Chemotaxis and Migration Tool generates plots and also extracts 
statistical data, which include directness, distance, velocity, angle, and a bespoke measure 
of migration termed forward migration index (FMI)369.  
The Chemotaxis and Migration Tool also incorporates the Rayleigh Test as a statistical test, 
which measures uniformity of a circular distribution of points, in this case the cell endpoints, 
0h 24h 
  
  
  
1 1 
2 
3 
2 
3 
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and takes into account distance from the origin369. The null hypothesis, that cells move in a 
uniform manner, is rejected when P>0.05. 
Figure 29 shows non-directional movement to medium alone (C), also referred to as 
chemokinesis, whereas assays with MCP-1 (indicated plots) show directional migration 
towards MCP-1. Rayleigh test results (P values on plots) show cells move in a uniform 
manner toward MCP-1 in all assays. One control assay shows uniform movement, but in this 
case distance of cell migration was low. P values (on plots) using the Rayleigh test were 
extremely low in MCP-1 assays compared to control. 
 
Figure 29. Monocytes migrate towards MCP-1 in the Dunn chamber chemotaxis model 
VD3 stimulated THP-1 in chemically-defined (CD)-MØ medium were allowed to migrate to 
100ng/ml MCP-1 or CD-MØ medium control (2h; 37C), with plots labelled MCP-1 and C 
respectively. Monocyte migration was monitored using time-lapse video microscopy. 
Migration of 40 cells per assay was measured using Image J and analysed using the Ibidi 
Chemotaxis and Migration Tool (V2.0). Data shown are representative of multiple 
independent experiments. Control n=3, MCP-1 n=4. P values for individual assays were 
obtained using the Rayleigh test, with a null hypothesis of non-uniform movement rejected at 
P<0.05.  
In order to assess statistical significance of movement across multiple assays, rather than 
individually, basic statistical data of assays (i.e. Euclidian distance, total/accumulated 
P=0.162 P=0.155 P=0.002 
P=3.91x10
-10
 P=5.65x10
-6
 P=1.49x10
-4
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distance, velocity and directness) shown in Figure 29 was extracted using the Chemotaxis 
and Migration Tool (Fig. 30). This data failed to show significant quantitative differences 
between control and MCP-1 directed migration, despite clear differences seen qualitatively 
(Fig. 29). This is because some monocytes moved in a kinetically similar manner in MCP-1 
and control studies, however the direction the cells were travelling in was markedly different.  
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Figure 30. Quantitative measurement of monocyte migration Extraction of quantitative 
data relating to monocyte directness, velocity, accumulated distance and Euclidean distance 
of assays shown in Fig. 29. Migration of 40 cells per assay was measured using Image J and 
analysed using the Ibidi Chemotaxis and Migration Tool (V2.0). Data shown mean ± SEM 
and are representative of multiple independent experiments. Control n=3, MCP-1 n=4. Data 
analysed using unpaired t test. P>0.05 in all parameters. 
5.2.4. Defining directionality 
The measure of directness above (Fig. 30) shows how directly cells move between two 
points, i.e. from A to B, regardless of the location of „B‟ in relation to the attractant. To show 
directionality towards an attractant, forward migration index (FMI) can be utilised. 
FMI, an index provided in the Chemotaxis and Migration Tool, represents the efficiency of the 
forward migration of cells parallel (in this case the y axis; yFMI) and perpendicular (x axis; 
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xFMI) to the direction of the attractive gradient, according to variables including the distance 
travelled from the starting point and the location of the endpoint in relation to each axis (Fig. 
31). Data is always set up so the chemoattractive gradient runs along the y axis. A high yFMI 
value (movement parallel to the attractive gradient), and a low xFMI value (perpendicular to 
the attractive gradient) indicates a powerful chemotactic effect369. This measurement takes 
into account positive and negative migration. 
Figure 31. Schematic of monocyte 
migration plots showing cell 
endpoints in relation to forward 
migration index (FMI) Cell endpoints 
are allocated an xFMI and a yFMI 
value according to variables including 
distance from starting point and 
location in relation to each axis. The 
left plot represents a high xFMI value and a low yFMI value (poor chemotaxis). The right plot 
represents a low xFMI value and a high yFMI value, indicating strong chemotaxis movement, 
parallel to the concentration gradient. 
An alternative method has also been utilised to extrapolate how well cells move toward an 
attractant. This method measures uniformity of movement of the monocyte population based 
on the location of the endpoint. This was calculated by extracting the statistical data from the 
Chemotaxis and Migration Tool based on the angle measurement. The angle measurement 
gives the location of each end point of each tracked migrating cell, where the attractant is 
placed at 0 degrees (top), and cells are normalised as migrating from the centre of the circle 
(Fig. 32). The standard deviation of the angle was used to show variability in each assay of 
the final destination of each migrating cell (SDoA). The more the end point of individual cells 
deviate from the other end points, the higher the SD value (Fig. 32a. and 29c.). This was 
used as a measure of uniform migration, as the more closely the monocytes move toward an 
attractant as a population, the lower the standard deviation will be of the angle of the end 
points. This was a means of showing quantitatively that cells move toward MCP-1 in a 
significant (P<0.05) uniform and directional manner (Fig. 33), corresponding with qualitative 
data (Fig. 29). Data show mean SD of angle measurements across at least 3 assays (± 
SEM), where a high value indicates more variability, and therefore less uniformity. 
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Figure 32. Schematic of monocyte migration plots showing cell endpoints in relation 
to angle values Plots a) and b) show small and similar distances travelled, however based 
on angle measurements, plot a) will have high SD of angle (SDoA) measurement, and plot b) 
a low SDoA, as cell end points are less variable. Plot c) will have a comparable SDoA to plot 
a), and plot d) will have a comparable SDoA value to plot b). Plot e) will have the same SDoA 
value as plot d), as variability of endpoint values, rather than endpoint values themselves, 
are measured. This measure is a powerful tool to extrapolate uniformity of movement via 
variability of cell end points, but it does not take into account distance moved or whether 
direction is positive or negative, so measurements must be observed in conjunction with 
qualitative plots. 
Figure 33 shows extrapolated statistical data from plots shown in Figure 29. Using the 
forward migration index (FMI) (left hand graph), xFMI shows that the amount of directional 
cell migration perpendicular to the attractive gradient is comparable between control (no 
attractive gradient) and MCP-1 assays. yFMI values, the amount of directional migration 
parallel to the attractive gradient, are higher in MCP-1 assays, however this was not shown 
to be significant compared to control (P>0.05, 2 way ANOVA with Tukey‟s post hoc test for 
multiple comparisons).  
When investigating variability of movement using SDoA of end points of cells (Fig. 33; right 
hand graph), results show statistically significant differences in variability between control 
and MCP-1 assays. SDoA is more variable in control assays, showing less uniform, or more 
direct, migration of cells. In assays with MCP-1, variability according to SD of angle is 
significantly lower (P<0.05), indicating more uniform migration (unpaired student‟s t test).  
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Figure 33. Monocytes migrate directionally towards MCP-1 Extrapolating 
data from plots in Fig. 29, the left hand graph shows FMI values perpendicular 
(xFMI) and parallel (yFMI) to the attractive gradient, where present. FMI values 
were analysed using 2 way ANOVA with Tukey’s post hoc test. The angle of 
each end point of migrating cells was assessed using an unpaired student’s t 
test, P<0.05. Data shown are mean ± SEM of the deviation of migrations of 
multiple independent experiments. Control n=3, MCP-1 n=4. 
5.2.5. Characterising chemotaxis to apoptotic cell models 
5.2.5.1. Chemotaxis to apoptotic Jurkat cells 
The Dunn Chamber was used to assess horizontal migration of monocytes (VD3 stimulated 
THP-1) along a concentration gradient toward plaque-relevant (MØ and FC) conditioned 
medium. Initially, assays were carried out using an established model of cell death, UV-
induced apoptotic Jurkat cells. Apoptotic Jurkat cells are an established inducer of monocyte 
attraction54,63, therefore were used to set-up, and ensure robustness of, the assay. 
Figure 34 shows representative plots of monocyte migration toward medium conditioned (16-
20h) with live jurkat (whole culture; JK WC), live JK conditioned medium with cell bodies 
removed, leaving MPs and soluble factors (jurkat cell-free supernatant; JK CFS), UV-induced 
apoptotic jurkat conditioned medium (aJK WC), and UV-induced apoptotic jurkat conditioned 
medium with cell bodies removed (aJK CFS). All four plots show directional movement 
towards an attractive factor. 
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Figure 34. Monocytes migrate towards medium conditioned with live or apoptotic 
Jurkat cells VD3 stimulated THP-1 in chemically-defined (CD)-MØ medium were allowed to 
migrate to live JK or aJK whole cell (WC) or cell-free supernatant (CFS) (2h; 37C). Monocyte 
migration was monitored using time-lapse video microscopy. Migration of 40 cells per assay 
was measured using Image J and analysed using the Ibidi Chemotaxis and Migration Tool 
(V2.0). Qualitative plots and FMI and SD of angle measurements are also shown. 
Quantitative data shows mean values ± SEM of 3 independent experiments. *P<0.05, 
**P<0.01 one way (SD of angle) or two way (FMI) ANOVA with Tukey’s post hoc test. 
To look at directional migration quantitatively, forward migration index (FMI) and SD of angle 
measurements are compared using the Chemotaxis and Migration Tool (Fig. 34). When 
comparing migration perpendicular to the gradient of conditioned medium (xFMI), no 
significant differences in forward migration were found between conditions or compared to 
medium control (two way ANOVA with Tukey‟s post hoc test, P<0.05). Forward migration 
parallel to the conditioned medium gradient (yFMI) is significantly increased (P<0.01) toward 
both live and dead CFS compared to control. Forward migration to JK CFS and aJK CFS 
was also significantly increased compared to aJK whole culture (P<0.01).  
When looking at SD of angle (Fig. 34), significant directional migration was only observed 
toward aJK CFS compared to control (P<0.05), and no significant differences were found 
between conditioned medium groups (one way ANOVA with Tukey‟s post hoc test). Overall, 
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the two approaches to assess directionality, FMI and SD of angle, broadly agree in their 
analysis of data. 
5.2.5.2. Chemotaxis to apoptotic THP-1-derived macrophages 
The Dunn Chamber was then used to assess horizontal migration of monocytes to MØ-
conditioned medium. Monocyte infiltration into the arterial intima and differentiation to MØ is 
one of the initiating events in plaque formation45, and further understanding of how and when 
MØ recruit further inflammatory cells to the plaque would be beneficial in understanding 
disease progression. 
Figure 35 shows representative plots of monocyte migration toward medium conditioned with 
live MØ (MØ whole culture/ MØ WC), live MØ conditioned medium with cell bodies removed, 
leaving MPs and soluble factors (MØ cell-free supernatant/ MØ CFS), UV-induced apoptotic 
MØ conditioned medium (aMØ WC), and UV-induced apoptotic MØ conditioned medium with 
cell bodies removed (aMØ CFS). All four plots show directional movement towards an 
attractive factor. 
Figure 35. Monocytes migrate towards medium conditioned with live or apoptotic THP-
1-derived macrophage cells VD3 stimulated THP-1 in chemically-defined (CD)-MØ medium 
were allowed to migrate to live MØ or aMØ whole cell (WC) or cell-free supernatant (CFS) 
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(2h; 37C). Monocyte migration was monitored using time-lapse video microscopy. Migration 
of 40 cells per assay was measured using Image J and analysed using the Ibidi Chemotaxis 
and Migration Tool (V2.0). Qualitative plots and FMI and SD of angle measurements are also 
shown. Quantitative data shows mean values ± SEM of 3 independent experiments. *P<0.05, 
**P<0.01, ***P<0.001 one way (SD of angle) or two way (FMI) ANOVA with Tukey’s post hoc 
test. 
To look at directional migration quantitatively, forward migration index (FMI) and SD of angle 
measurements are compared using the Chemotaxis and Migration Tool. When comparing 
migration perpendicular to the gradient of conditioned medium (xFMI), no significant 
differences in forward migration were found between conditions or compared to medium 
alone control (P>0.05, two way ANOVA with Tukey‟s post hoc test). All MØ conditioned 
medium groups showed significant increases in forward migration parallel to the conditioned 
medium gradient (yFMI), compared to medium alone control, with aMØ WC at P<0.01, and 
MØ WC, MØ CFS and aMØ CFS at P<0.001 (two way ANOVA with Tukey‟s post hoc test). 
There were no significant differences in forward migration between conditioned medium 
groups.  
When looking at SD of angle (Fig. 35), significantly decreased variation is seen when 
migration is toward MØ WC and aMØ WC compared to control (P<0.05), however variation 
when migration is toward MØ CFS and aMØ CFS show even greater significance when 
compared to control (P<0.01) (one way ANOVA with Tukey‟s post hoc test). Significant 
differences were not seen when comparing directional migration toward each different 
conditioned medium (P<0.05). Overall, the two approaches to assess directionality, FMI and 
SD of angle, broadly agree in their analysis of data.  
Trends in yFMI and SDoA data indicate that soluble factors or MPs within CFS, from both 
live and dead MØ, are chemoattractive, and that the presence of cells dampens monocyte 
attraction by comparison. 
5.2.5.3. Chemotaxis to apoptotic THP-1-derived foam cells 
Next, the Dunn Chamber was used to show horizontal migration of monocytes to FC 
conditioned medium. MØ infiltration to the plaque is followed by lipid uptake and foam cell 
formation, leaving questions on the effects of lipid-loading on MØ function162, many of which 
remain unanswered, including effects on further monocyte recruitment to the plaque and 
phagocyte recruitment to apoptotic foam cells. 
Figure 36 shows representative plots of monocyte migration toward medium conditioned with 
live FC (FC whole culture/ FC WC), live FC conditioned medium with cell bodies removed, 
leaving MPs and soluble factors (FC cell-free supernatant/ FC CFS), UV-induced apoptotic 
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FC conditioned medium (aFC WC), and UV-induced apoptotic FC conditioned medium with 
cell bodies removed (aFC CFS). All four plots show directional movement towards an 
attractive factor. 
Figure 36. Monocytes migrate towards medium conditioned with live or apoptotic THP-
1 foam cells VD3 stimulated THP-1 in chemically-defined (CD)-MØ medium were allowed to 
migrate to live FC or aFC whole cell (WC) or cell-free supernatant (CFS) (2h; 37C). 
Monocyte migration was monitored using time-lapse video microscopy. Migration of 40 cells 
per assay was measured using Image J and analysed using the Ibidi Chemotaxis and 
Migration Tool (V2.0). Qualitative plots and FMI and SD of angle measurements are also 
shown. Quantitative data shows mean values ± SEM of 3 independent experiments. *P<0.05, 
**P<0.01, one way (SD of angle) or two way (FMI) ANOVA with Tukey’s post hoc test. 
To look at directional migration quantitatively, forward migration index (FMI) and SD of angle 
measurements are compared using the Chemotaxis and Migration Tool (Fig. 36). When 
comparing migration perpendicular to the gradient of conditioned medium (xFMI), no 
significant differences in forward migration were found between conditions or compared to 
medium alone control (two way ANOVA with Tukey‟s post hoc test, P<0.05). Surprisingly, 
only migration toward FC WC and FC CFS showed significant increases in forward migration 
parallel to the conditioned medium gradient (yFMI), (P<0.05). There were no significant 
differences in forward migration between live or dead FC conditioned medium groups.  
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When looking at SD of angle (Fig. 36), significant directness was observed toward FC WC 
and FC CFS (P<0.01), and aFC WC (P<0.05), compared to control (one way ANOVA with 
Tukey‟s post hoc test). Significant differences were not seen when comparing directional 
migration toward each different conditioned medium (P>0.05). Overall, the two approaches to 
assess directionality, FMI and SD of angle, broadly agree in their analysis of data. 
Trends in SDoA values, and yFMI results, indicate that soluble factors or MPs within CFS 
from live FC are chemoattractive, however unlike live MØ WC, the presence of FC in the 
supernatant does not appear to inhibit monocyte recruitment. Monocyte chemoattraction to 
aFC WC/CFS (SDoA) is also less uniform, indicating a potential reduction in functional „find-
me‟ mediator release in aFC, or upregulated mechanisms of monocyte chemoattraction in 
live FC, which could both have pathological implications. 
5.2.5.4. Combined data 
Comparison of SDoA values towards live and apoptotic cell-conditioned medium showed 
largely comparable uniformity of monocyte migration between cell types apart from 2 
noticeable differences. Firstly, whole live MØ and FC cultures induced significant uniform 
monocyte migration compared to control (P<0.05), whereas live JK WC did not induce 
significant migration (Fig. 37). Secondly, aFC CFS induced significantly less uniform 
migration of monocytes compared to aMØ CFS, which could have implications in defective 
cell clearance (Fig. 37). 
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Figure 37. Chemoattractive properties of medium conditioned with Jurkat cells and 
THP-1-derived macrophages and foam cells Combined SDoA values from figures 31-33 to 
compare chemoattraction properties across cell types. Data shows mean values ± SEM of 3 
independent experiments. *P<0.05, **P<0.01 one way ANOVA with Tukey’s post hoc test. 
Distance measures were not sensitive enough to establish significant differences in 
monocyte migration in these chemotaxis assays (Fig. 38). 
 
Figure 38. Distance of monocyte migration 
toward apoptotic cell conditioned cell-free 
supernatant Data shows mean values ± SEM of 
at least 3 independent experiments. Control © 
n=3, MCP-1 n=4, aJK CFS n=3, aMØ CFS n=6, 
aFC CFS n=6. 
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5.2.6. Mechanisms of monocyte chemotaxis toward apoptotic cell-derived MPs and 
soluble factors 
In order to establish the molecular mechanisms that could be enlisted in monocyte attraction 
to apoptotic cells, in particular plaque-relevant ACs, roles of attractants ICAM-3 and 
CX3CL1, previously found in AC-derived MPs61,71, were investigated. The role of CD14, an 
LPS receptor also implicated in tethering of apoptotic cells31, was also investigated. 
Whilst it has been shown that CD14 acts minimally as a tethering receptor for AC, it may also 
have the ability to be stimulated by AC and AC-derived material, such as MPs, as is true 
when it is ligated by LPS368. It is unknown whether CD14 recognition of ACAMPs on MPs 
may activate monocytes and trigger migration123,124,370.  
Initially, cell surface expression of CD14 in VD3 stimulated THP-1 cells was confirmed using 
indirect immunofluorescence staining, followed by flow cytometric analysis (Fig. 39). Results 
showed positive CD14 staining in VD3 stimulated THP-1 monocytes, with a mean 7 fold 
increase in mean fluorescence intensity (MFI) following CD14 staining, compared to isotype 
matched control staining, in agreement with Thomas et al.312.  
 
 
Figure 39. Presence of CD14 on monocyte model VD3 differentiated THP-1 cells were 
stained with 61D3, a primary monoclonal antibody targeting CD14 (black plot on frequency 
histogram diagram) or isotype matched control antibody MOPC21 (grey plot on frequency 
histogram), followed by secondary antibody FITC, and fixed with 1% w/v formaldehyde in 
PBS. Expression levels were compared using flow cytometry and plots displayed as log 
fluorescence. Frequency histogram (left) is a representative example of 2 independent 
experiments. Data shown is mean fluorescence intensity (MFI) of the cell population ± SD. 
Following confirmation of CD14 expression on the monocyte cell surface, migration toward 
aMØ- and aFC-conditioned medium was assessed in the absence and presence of the 
CD14-blocking antibody, 61D3 (Fig. 40). Cell-free supernatant (CFS) was used as an 
attractant in antibody-blocking studies as previous results have shown some reduction in 
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variability of monocyte migration toward CFS compared to whole-cell culture (figs. 31-33), 
and MPs, which are of particular interest to these studies, would remain in CFS71. As we are 
investigating the effects of blocking migration, Euclidean distances travelled by monocytes 
will be compared. 
Plots shown in Fig. 40 do not show any significant reduction in migration in the presence of a 
CD14-blocking antibody, either toward aMØ CFS or aFC CFS. When comparing mean 
Euclidean distance of migrated monocytes toward aMØ CFS and aFC CFS, no significant 
differences in distance migrated were found in the presence of CD14-blocking antibody 61D3 
(unpaired t test). A small reduction in distance migrated toward aFC CFS in the presence of 
61D3 is shown, but this is not significant.  
 
Figure 40. CD14 does not mediate monocyte migration toward apoptotic MØ and 
apoptotic FC-derived MPs and soluble factors VD3 stimulated THP-1 in chemically-
defined (CD)-MØ medium were allowed to migrate to aMØ or aFC CFS (2h; 37C) in the 
presence or absence of excess 61D3, a CD14 blocking antibody. Monocyte migration was 
monitored using time-lapse video microscopy. Migration of 40 cells per assay was measured 
using Image J and analysed using the Ibidi Chemotaxis and Migration Tool (V2.0). Graphs 
show mean distance of cell migration ± SEM of multiple independent experiments. CFS n=6, 
CFS + anti-CD14 n=3. Results show no significant differences (unpaired t test). 
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Previous studies using a vertical migration chamber have found a role for ICAM-3 in the 
clearance of apoptotic cells, in both the phagocytic recruitment and tethering stages71. It is 
suggested that surface-bound ICAM-3 is lost during the apoptosis programme via shedding 
of ICAM-3 on microparticles (MPs), during a process known as zeiosis, or blebbing71. In 
these studies, monocyte migration toward aMØ- and aFC-CFS was assessed in the 
presence of the monoclonal ICAM-3-blocking antibody, MA4 (Fig. 41). 
Comparing plots in Figure 41, migration to aMØ CFS in the presence and absence of an 
ICAM-3 blocking antibody are comparable, which is supported by mean Euclidean distance 
values of migrated cells. Distances are comparable when looking at migration toward aMØ 
CFS in both the presence and absence of an ICAM-3 blocking antibody. Comparison of plots 
toward aFC CFS appears to show a visible reduction in monocyte migration in the presence 
of the ICAM-3 blocking antibody MA4. Mean Euclidean distances were compared, but 
although distance of monocyte migration was reduced in the presence of MA4, this was not 
found to be statistically significant. (P=0.12, unpaired t test). 
Figure 41. ICAM-3 mediated monocyte migration toward apoptotic foam cell-derived 
MPs and soluble factors Dunn chemotaxis assays were set up as in Figure 40, with the 
exception of the antibody used, which in this figure was an ICAM-3-blocking antibody.  Plots 
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shown are representative of 3 independent experiments. Graphs show mean distance of cell 
migration ± SEM of multiple independent experiments. CFS n=6, CFS + anti-ICAM-3 n=3. 
Results show no significant differences (unpaired t test). 
To investigate expression levels of ICAM-3, before and after induction of apoptosis, MØ and 
FC were stained with MA4, a primary monoclonal antibody targeting ICAM-3. If expression 
levels reduce following induction of apoptosis, it could be an indication that ICAM-3 is shed 
on MPs via blebbing. 
Histograms show very low levels of ICAM-3 surface expression (Fig. 42), however further 
analysis of mean fluorescence intensity shows a small decrease in ICAM-3 staining in 
apoptotic FC, and to a small extent apoptotic MØ, though differences were not significant. 
 
Figure 42. Macrophage and foam cell surface ICAM-3 expression before and after 
apoptosis induction Live and apoptotic MØ/FC were stained with an anti-ICAM-3 antibody 
(black plot on frequency histogram) or isotype matched control antibody MOPC21 (grey plot 
on frequency histogram), followed by secondary antibody FITC. Expression levels were 
compared using flow cytometry and plots displayed as log fluorescence. Data shown are 
mean fluorescence intensity (MFI) of cell population ± SEM from 3 independent experiments. 
Data analysed by two way ANOVA with Tukey’s post hoc test. 
Through the use of a vertical migration assay system, previous studies have shown CX3CL1 
to act as an attractant to apoptotic cells, including CX3CL1 derived from UV-induced 
apoptotic BL cells61. Using UV-induced apoptotic Mutu, a BL cell line, chemotaxis to AC-
derived supernatant in a horizontal assay system was observed (Fig. 43). Plots showing 
monocyte migration to aMutu CFS appeared to show more migration than control plots, 
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however whether this was direct migration towards aMutu CFS is unclear. When comparing 
SD of angle, results shows less variable, therefore more direct, movement towards aMutu 
CFS compared to control (P<0.01, unpaired t test) (Fig. 43, bottom left). When comparing 
mean Euclidean distance of migrating monocytes (Fig. 43, bottom right), distance migrated 
was not significantly different toward aMutu CFS in the presence or absence of CX3CL1-
blocking antibody (P>0.05, unpaired t test). This is in contrast to previous studies, which 
observed robust blocking to apoptotic B cell supernatant with a CX3CL1-blocking antibody, 
however there were differences in experimental conditions61. 
            
Figure 43. CX3CL1 mediated monocyte migration to apoptotic mutu-derived MPs and 
soluble factors VD3 stimulated THP-1 were allowed to migrate to aMutu CFS in the 
presence or absence of 5ng/ml anti-CX3CL1. Monocyte migration was monitored using time-
lapse video microscopy. Migration of 40 cells per assay was measured using Image J and 
analysed using the Ibidi Chemotaxis and Migration Tool (V2.0). Graphs show SD of angle 
(left) and mean Euclidean distance of cell migration (right) ± SEM of 3 independent 
experiments.  
CX3CL1 has been heavily implicated in the development and progression of 
atherosclerosis289. The role of endothelial cell-derived CX3CL1 in the recruitment of 
monocytes to the arterial intima has previously been studied68,290,298. CX3CL1 has also been 
detected within human plaque MØ using reverse transcription-polymerase chain reaction 
(RT-PCR)371, and was found to be associated with MØ-derived FCs in the plaque366. The role 
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of aMØ- and aFC-derived CX3CL1 in monocyte recruitment to ACs in the plaque, and 
retention within the plaque, has not been characterised.  
Figure 44 shows monocyte migration to aMØ and aFC CFS in the presence or absence of a 
CX3CL1 blocking antibody. Plots showing migration toward aMØ CFS appear to show a 
significant reduction in migration in the presence of an anti-CX3CL1 antibody. This was 
shown to be a significant reduction (P<0.05, unpaired t test) when comparing mean 
Euclidean distance of monocyte migration. Interestingly monocyte migration toward aFC CFS 
does not appear reduced in the presence of anti-CX3CL1, which is confirmed by data 
showing mean Euclidean distances migrated. Distance migrated is not significantly different 
toward aFC CFS in the presence or absence of anti-CX3CL1 (P<0.05 unpaired t test).  
 
Figure 44. CX3CL1 mediated monocyte migration toward apoptotic macrophage-
derived MPs and soluble factors Dunn chemotaxis assays were set up as in Figure 40, 
with the exception of the antibody used, which in this figure was a CX3CL1 blocking 
antibody. Graphs show mean distance of cell migration ± SEM of at least 3 independent 
experiments, P<0.05, unpaired t test. 
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To investigate expression levels of CX3CL1, before and after induction of apoptosis, MØ and 
FC were stained with a primary monoclonal antibody targeting CX3CL1. If expression levels 
reduce following induction of apoptosis, it would support evidence that CX3CL1 is shed in the 
supernatant, as soluble CX3CL1 or bound to the surface of MPs via blebbing, as indicated by 
Truman et al.61. 
Histogram plots in Figure 45 show positive CX3CL1 surface staining of MØ (black plots on 
frequency histograms) compared to isotype control (grey plots). Staining of aMØ is also 
positive but to a lesser extent, supporting a loss of membrane bound CX3CL1 (mCX3CL1) 
following induction of apoptosis (16-20h post UV). This is also shown by the mean 
fluorescence intensity (MFI) of the stained cell population, with a clear reduction in MFI 
values shown in aMØ, when compared to live MØ, however this reduction was not shown to 
be statistically significant (two way ANOVA with Tukey‟s post hoc test). 
Expression of mCX3CL1 on FC can also be seen on histogram plots (black plots on 
frequency histograms), with a reduction of CX3CL1 expression following induction of 
apoptosis (aFC). This was also reflected in the MFI values, however the reduction was not 
shown to be statistically significant (two way ANOVA with Tukey‟s post hoc test). 
 
Figure 45. Macrophage and foam cell surface CX3CL1 expression before and after 
apoptosis induction Live and apoptotic MØ/FC were stained with an anti-CX3CL1 antibody 
(black plot on frequency histogram) or isotype matched control antibody MOPC21 (grey plot 
on frequency histogram), followed by secondary antibody FITC. Expression levels were 
compared using flow cytometry and plots displayed as log fluorescence. Data shown are 
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mean fluorescence intensity (MFI) of cell population ± SEM from 3 independent experiments. 
Data analysed by two way ANOVA with Tukey’s post hoc test. 
Reduction in detected membrane bound CX3CL1 expression could be occurring for a 
number or reasons, including internalisation or epitope-masking. In order to further support 
the hypothesis that CX3CL1 is shed from the surface of dying cells, either by blebbing or 
cleavage, an aMØ CFS sample was analysed for CX3CL1 (preliminary data). Presence of 
CX3CL1 in CFS would support the hypothesis that apoptosis induction results in CX3CL1 
shedding from the cell surface, where it may exert its effects as an attractant. Preliminary 
studies showed CX3CL1 presence in aMØ CFS, but levels were not detectable (nd) in 
medium control (C). This supports the proposed hypothesis, however more work needs to be 
done, with the appropriate controls, to determine CX3CL1 presence in CFS, and to elucidate 
whether it is MP-associated or soluble. 
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Figure 46. Preliminary data. Presence of CX3CL1 in apoptotic macrophage-
conditioned medium CX3CL1 concentrations in harvested aMØ CFS, or CD-MØ medium 
control (C), were assessed with a CX3CL1 antibody DuoSet according to manufacturers’ 
instructions (R&D Systems, Abingdon, UK). n=1. 
5.2.7. Effects of apoptotic macrophage and apoptotic foam cell-derived cell-free 
supernatant on endothelial cells 
To add an additional level of understanding to this model as may be observed in a 
physiological setting, the effects of intra-plaque mediator release by aMØ and aFC on 
endothelial cells (ECs) will be modelled. ECs are the natural barrier between the blood 
stream and the atherosclerotic plaque, mediating monocyte recruitment to the plaque. 
Inflammatory mediators or MPs released by phagocytes or ACs within the plaque may effect 
EC activation and exacerbate monocyte recruitment, a pro-atherogenic effect. The effects of 
live and apoptotic MØ/FC mediators on ECs will be modelled by culturing human umbilical 
vein endothelial cells (HUVECs) in CFS from each AC type (16-20h), and measuring 
changes in cell surface expression of E-selectin (CD62E), which mediates monocyte 
adhesion to the artery wall, promoting diapedesis372. Results in Figure 47 show very low 
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levels of E-selectin expression following culture with medium alone (control), however the 
percent of the cell population staining positive for E-selectin was significantly increased by 
aFC CFS (P<0.05), and even more so by MØ, aMØ and aFC CFS (P<0.01).   
 
Figure 47. Apoptotic MØ and apoptotic FC cell-free supernatant upregulate E-selectin 
expression in HUVECs Live and apoptotic MØ/FC CFS or medium control (C) were placed 
neat onto cultured human umbilical vein endothelial cells (HUVECs) (16-20h; 37C). HUVECs 
were harvested and stained with FITC labelled anti-CD62E (black plot on frequency 
histogram) or control antibody (grey plot on frequency histogram diagram) and expression 
levels were compared using flow cytometry. Data shown are mean ± SEM from 3 
independent experiments. *P<0.05, **P<0.01, two way ANOVA with Tukey’s post hoc test. 
5.3. Discussion 
The aims of these studies were to establish a horizontal assay system to investigate 
phagocyte chemotaxis to apoptotic cells. This could then be used to investigate chemotaxis 
to models of apoptotic cell types found in the atherosclerotic plaque, and elucidate possible 
mechanisms in the „find-me‟ stage of apoptotic cell clearance, in particular, the roles of 
CD14, ICAM-3 and CX3CL1. 
Defective AC clearance and consequent failure to resolve inflammation, have been 
implicated in atherosclerotic plaque progression58,195,197, however research into the CX3CL1 
receptor (CX3CR1) has shown that knocking down key mechanisms of monocyte recruitment 
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to the arterial intima greatly reduces formation of atherosclerotic plaques239. As excessive 
monocyte recruitment is not beneficial to established plaque resolution, reduction in 
monocyte recruitment to the plaque could be a key aim for future therapies. To develop 
these, full understanding of the mechanisms and kinetics of monocyte recruitment to the 
plaque, and to apoptotic cells once within the plaque, is required. 
Results in this chapter show that aMØ and aFC are both strong inducers of chemotaxis in 
monocytes, however chemotaxis mechanisms vary which could alter the monocyte subtype 
attracted to the atherosclerotic plaque. Results also show that both aMØ- and aFC-derived 
MPs/soluble factors have the ability to upregulate monocyte capture molecule E-selectin on 
the surface of endothelial cells. 
  
Phagocyte 
 
Apoptotic cell 
 
 
Monocyte 
Apoptotic MØ 
(aMØ) 
non-lipid laden MØ and aMØ attract monocytes, which was 
not significantly inhibited via blocking antibodies targeting 
CX3CL1, but not targeting CD14 and ICAM-3 
 
Apoptotic FC 
(aFC) 
FC and aFC attract monocytes, in a stronger but more 
disordered manner than aMØ, which was not significantly 
inhibited via blocking antibodies targeting CD14, ICAM-3 and 
CX3CL1 
Table 8. Summary of results from key research questions addressed in Chapter 5 
5.3.1. Use of the horizontal system 
The vertical chamber showed significantly increased (P<0.05) mean number of monocytes 
per HPF migrating towards apoptotic foam cell-derived cell-free supernatant (aFC CFS), 
compared to aMØ CFS or medium control (Fig. 27). The methods of analysis used for the 
Dunn assay does not account for total number of monocytes migrated, as a set number of 
cells are sampled within each assay, so differences in total number of migrated cells would 
not be teased out using the Dunn method.  The different methods of measuring monocyte 
migration can therefore show discrete data, and give different insights into mechanisms of 
chemotaxis. This was highlighted by Wilkinson (1998), who suggested multiple assays be 
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used to understand full locomotive properties of cells373. Dunn chemotaxis assays allow 
visualisation of each stage of chemotaxis, including cell morphology, whereas vertical assays 
use excess monocytes. This allows total counts of monocyte migration to be established, 
giving another dimension to understanding of chemoattractive properties of the mediator 
being tested. However, if you consider overall in vivo relevance, vertical chambers are not 
the strongest assay. Meyvantsson et al. developed an assay that combines good optics and 
high throughput, which was successful in the investigation of neutrophil chemotaxis, however 
the method is lengthier and more complex than more established assays, and requires the 
use of an automated liquid handling system (96-tip CyBiWell, CyBio, Jena, Germany)293. 
The effects of gravity in a vertical assay system, must not be ignored. Migrating cells, e.g. 
monocytes, settle onto the porous polycarbonate membrane. The effect of this on the 
activation state of monocytes and subsequent migration, following contact with the 
membrane or other monocytes, is unknown. Using a horizontal assay, such as the Dunn 
chamber, negates the effects of gravity on monocyte migration. Growth on glass coverslips, 
in the presence of PDL, may affect migration characteristics, however all tracked monocytes 
are in contact with coverslips, providing a homogenous state of activation. Migrating cells are 
also packed into upper chambers in excess in the vertical chamber, which will also have 
untold effects on activation state of monocytes, an issue not present using the Dunn method.  
5.3.2. Optimisation of the Dunn chamber assay and defining ‘directness’ 
5.3.2.1. Selection of migrating cell model 
Initially a phagocyte model proficient in chemotaxis that worked in the Dunn chamber had to 
be identified. Unstimulated THP-1 cells did not have the necessary characteristics to be used 
in the Dunn chamber as adherence to glass coverslips is required. Differentiation with PMA, 
or PMA and VD3 (DS), resulted in a phenotype that appeared overly adherent for migration 
assays. Despite small amounts of visible movement by these cells in the presence of MCP-1 
in the Dunn chamber assay, cells appeared to be anchored too strongly to migrate (Fig. 28). 
This was found using both glass and plastic coverslips. Human peripheral blood monocytes 
were also too adherent for short-term migration assays using plastic or glass coverslips. 
Differentiation of THP-1 cells with VD3 results in a monocyte like phenotype that appeared to 
be further down the differentiation pathway than unstimulated THP-1 cells, but still with 
monocyte-like characteristics, rather than MØ-like characteristics, e.g. as seen with PMA/DS 
stimulated THP-1. This conclusion is based on features including maintenance of small, 
round morphology (fig. 5: Chapter 3) with a lot of homogeneity, a weakly adherent 
phenotype, maintenance of a low cytoplasmic: nuclear ratio, high expression of monocyte 
marker CD14 (Fig. 9: Chapter 3), and continued proliferation. This agreed with observations 
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made by Schwende et al.310, Daigneault et al.311, and Thomas et al.312. Daigneault et al. 
found VD3 stimulated THP-1 were most similar to human primary monocytes in terms of 
CD14 expression, compared to undifferentiated or PMA differentiated THP-1 cells311. 
Schwende et al., and Thomas et al. found high CD14 expression, low nuclear:cytoplasmic 
ratio, low LPS response and continued proliferation in VD3 stimulated THP-1 cells, all 
indications of a monocytic phenotype310,312. VD3 stimulated THP-1 could be a better 
representation of monocytes than unstimulated THP-1, which have been likened to 
monoblast/immature monocyte-like cells374. Studies in murine embryonic stem cell-derived 
macrophages (ESDM) found increased migration of immature macrophages toward apoptotic 
BL cell supernatant, compared to migration of mature ESDMs, whereas mature ESDMs were 
more proficient at phagocytosis of ACs compared to their immature counterparts, seen in 
these studies when comparing monocytic VD3 and macrophage-like PMA/DS cells375. VD3 
stimulated THP-1 were also found to be a successful model of monocyte migration in vertical 
assays by Torr et al.71, as seen in these studies (Fig. 27). 
5.3.2.2. Optimisation of control assays 
Monocyte chemotactic protein -1 (MCP-1), or CCL2, was originally identified as a novel 
monocyte chemotactic and activating factor produced following THP-1 culture at high cell 
density304. It is a CC chemokine family member, and is a recognised inducer of monocyte 
migration376, and was the chemokine of choice to optimise and characterise VD3 stimulated 
THP-1 monocyte migration in the Dunn chamber. MCP-1 has a molecular weight of 
approximately 13kDa376, which will form a linear concentration gradient between the inner 
and outer wells of the Dunn chamber approximately 30 minutes following assay set up, with 
a half-life of around 30 hours292. This is well within the parameters of methods used here, in 
which monocyte migration is assessed over a 2 hour time period. Assaying monocyte 
migration to MCP-1 as a positive control, a known attractive agent to monocytes304,306,377, 
also allowed for the evaluation of a variety of qualitative and quantitative analysis tools to 
assess the various ways in which the data could be interpreted, depending on analysis 
methods employed. 
5.3.2.3. Qualitative analysis methods for the Dunn assay 
Cells are tracked using Image J and qualitative plots are created using the Ibidi Chemotaxis 
and Migration Tool. As chemotaxis chambers are circular, and monocytes are monitored 
from any chosen fixed position of the microscope over the circumference of the circle, the 
positive direction of movement towards MCP-1 could be at any angle over 360 degrees. To 
make comparison of qualitative data easier, all plots are rotated so direct positive migration 
would show at 0/360 degrees. Results show clear directional monocyte migration towards 
MCP-1 (Fig. 29), which is also reflected in P values obtained using the integrated Rayleigh 
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Test for unimodal clustering. This test measures uniformity of a circular distribution of points, 
in this case the cell endpoints on a plot, and takes into account distance from the origin 
based on X and Y axis coordinates, and is often employed in conjunction with qualitative 
plots, as part of Dunn chamber assay analysis369,377-379. The null hypothesis of uniformity is 
rejected when P>0.05. This gives a good indication of direct migration on an individual assay 
basis. Rayleigh test results show much higher levels of significance of migration towards 
MCP-1 than medium control (see P values in Fig. 29), with all MCP-1 assays showing 
significance levels of at least P<0.001. The most significant P value toward medium control 
was P=0.002, with the other assays both at P>0.05, rejecting the null hypothesis of non-
uniform migration. Studies using murine bone marrow-derived macrophages have 
successfully modelled chemotaxis to MCP-1 using the Dunn chamber over 24 hours377. Many 
studies use rose diagrams to display data377-379, however raw data plots were chosen in this 
instance for a clear representation of results.  
5.3.2.4. Quantitative analysis methods for the Dunn assay 
5.3.2.4.1. Distance, velocity and directness 
The chemotaxis and migration tool also provides quantitative outputs including Euclidean 
distance, accumulated distance, velocity and directness. Interestingly, despite clear 
qualitative differences between migration toward MCP-1 compared to CD-MØ medium 
control, differences in directness, velocity, Euclidean distance and accumulated distance 
were not significantly different, even with the recommended number of cells tracked to allow 
for statistical significance. Although cells in control experiments do not migrate in a 
directional manner, they do show varying levels of chemokinesis, non-directional 
movement240. This means that unless quantitative measures take into account the direction 
of migration, differences may not be highlighted. The provided measure of directness in this 
software measures how efficiently cells move from the starting point (A) to the endpoint (B), 
rather than taking into account the location of B according to the gradient of the attractive 
agent, and whether cell migration is along the established gradient of attractant369 . 
5.3.2.4.2. Forward Migration Index (FMI) 
To combat this, another measure is provided, the forward migration index (FMI). FMI values 
take into account positive and negative migration, distance migrated, and provides values for 
endpoints of cells both parallel (yFMI) and perpendicular (xFMI) to the attractive gradient. If 
both yFMI and xFMI values are close to zero, this corresponds to no chemotactic effect. A 
yFMI value nearer to 1, and an xFMI value close to zero, indicates a strong chemoattractive 
effect369. 
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5.3.2.4.2. Standard Deviation of Angle (SDoA) 
Looking at the variability of the cell end points is a useful method to distinguish whether the 
cell population has moved in a uniform manner, and this can be done by taking the angle (A) 
measurement of each cell, and calculating the mean standard deviation (SD) of these end 
points (SDoA). Using the SDoA of cell endpoints also shows statistically significant 
differences between data sets that show qualitative differences in cell migration of the overall 
population. Trends of SDoA reflect trends shown by FMI (figs. 31-33). A drawback of this 
method of analysis is that perfect negative migration would give the same value as perfect 
positive migration, however negative migration of the cell population was not seen in any of 
these studies. With attractants present, e.g. Fig. 29, overall migration of the cell population 
toward the attractant was observed, whereas directional migration of the cell population was 
not seen in control assays, giving higher SD values when looking at angle measurements. 
Also, this method fails to take into account distance migrated, unlike the Rayleigh test, which 
takes into account both distribution of endpoints and distance migrated. 
Each method provides useful information on the migration of monocytes. If complex 
measures of migration are not reflecting the apparent qualitative differences observed in 
monocyte migration to different attractants, comparing more basic methods such as distance 
migrated and SDoA may tease out differences, as less variables come into play. 
5.3.3. Modelling monocyte chemotaxis towards apoptotic cell models 
Whole cell supernatants and cell-free supernatants (supernatants centrifuged at 350xg, 6 
mins) were compared to establish differences in attractive properties of live or apoptotic cell 
bodies and large cell detritus, versus the attractive properties of cell-free supernatant, which 
would contain microparticles and soluble factors71. As crude supernatants were used in these 
studies, a plethora of „find-me‟ signals will be present that have been released by apoptotic 
cells to attract phagocytes for clearance.  
5.3.3.1. Monocyte migration to live cell-conditioned medium 
Live cell supernatants were investigated as a control for apoptotic cell supernatants, and 
were not expected to have strong attractive properties, however monocyte chemotaxis to live 
Jurkat, MØ and FC whole cell culture (WC) and CFS was observed qualitatively on raw data 
plots (figs. 31-33). Plots show directional migration of monocytes towards all Jurkat-
conditioned medium (Fig. 34), however SDoA data shows only migration toward aJK CFS 
was significantly less variable than assays towards medium control. yFMI values show 
comparable forward migration toward live and dead Jurkat CFS, which was significantly more 
directional than medium control (P<0.01). Forward migration to JK CFS and aJK CFS was 
also significantly increased compared to aJK whole culture (P<0.01). Results failed to identify 
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differences in migration toward whole cell cultures compared to CFS, which could explain 
differences in the presence or absence of „keep-out‟ signals. To date, only granulocyte „keep-
out‟ signals have been characterised78,79, but it is likely that more will be discovered in the 
pursuit of therapies for conditions where cell-specific dampening of immune responses would 
be of benefit, e.g. atherosclerosis or asthma70,79.  
Monocyte migration towards MØ-conditioned medium (Fig. 35) was directional under all 
conditions, with significant migration according to SDoA and yFMI values to both live and 
dead, whole cell culture or cell-free supernatant, compared to control. Although there were 
no significant differences in migration between conditioned medium groups, CFS from both 
live and dead MØ showed greater significant differences compared to control than whole cell 
supernatants (Fig. 35). Interestingly, trends in migration to FC-conditioned medium were 
slightly different, with migration to all conditioned medium observed in plots as with JK and 
MØ, but qualitative plots appear to show increased migration to aFC whole cell culture and 
cell-free supernatants compared, to FC counterparts (Fig. 36). Quantitative data however 
indicates the opposite trend, as SDoA showed significantly less variability (i.e. more direct 
migration) in live FC supernatants, compared control (P<0.01), and migration to aFC whole-
cell supernatant was not as significantly different compared to control (P<0.05), and no 
significant differences were observed between monocyte migration to medium control and 
aFC CFS. This is in contrast to results shown with Jurkat supernatants, in which significant 
directness in monocyte migration was observed only between aJK CFS and medium control, 
when comparing SDoA. yFMI data shows significant forward migration in live FC supernatant 
groups only, compared to medium control (P<0.05). Data indicates that apoptotic foam cells 
strongly induce migration (Fig. 27), but in a variable or disordered manner (Fig. 36), which 
could be a result of mixed messages dispatched by the aFC, e.g. similar to lactoferrin, a 
„keep-out‟ signal which keeps granulocytes away from sites of cell death78,79. 
Live cells would not be expected to be attractive to monocytes, indicative of an early stage of 
an immunological response, whether that be silent or inflammatory. Chemotaxis to live cell-
conditioned medium was observed in this study to the same extent as apoptotic cell-
conditioned medium, and, in the case of FC-conditioning, was even more attractive to 
monocytes than aFC-conditioning. This was particularly true in the case of live cell CFS. This 
was attributed to high cell density culture conditions, which could result in cells becoming 
stressed or activated, and in the case of immune cells as studied here (T lymphocytes, MØ 
and MØ-derived FCs), could result in mediator release that would result in activation or 
attraction of monocytes, e.g. MCP-1304. Recent work has also found that oxidative stress, 
even without cell death, mediates selective recruitment of monocytes380. Further investigation 
also showed high basal levels of apoptosis in live cell cultures, which was most likely due to 
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the culture conditions used to sequester high MP concentrations. PMA differentiation also 
results in terminal differentiation, and can alter THP-1 susceptibility to apoptosis309,311. 
Lauber et al.62 investigated THP-1, Mono Mac 6 (human leukaemia cell line), and HMDM 
migration to a variety of cell-free supernatants (CFS) derived from tumour cell lines, either 
from live cells or following induction to apoptosis via UV irradiation, using a vertical transwell 
system. Results saw that whilst almost all apoptotic cell CFS attracted all monocyte models, 
some monocyte models, but not others, migrated to live cell CFS. For example, THP-1 
migration toward live L929 CFS (murine fibroblast cell line) was observed to at least the 
same extent as other apoptotic cell CFS tested, but not to as great an extent as migration 
toward apoptotic L929 CFS. This supports data presented here where live cell cultures 
induce monocyte chemotaxis (figs. 31-33). Mono Mac 6 and HMDM both migrated to live 
MCF7 CFS (human breast carcinoma cell line) to the same extent as apoptotic MCF7 cells, 
but THP-1 migration was induced to a greater extent by apoptotic MCF7 CFS. This could be 
explained by low levels of migration toward both live and dead MCF7 CFS (<5% 
transmigration). Comparatively high levels of migration toward live Cos7 CFS (African green 
monkey kidney cell line) by HMDM was also observed (approx. 12% transmigration), but 
migration to apoptotic Cos7 CFS was greater (approx. 22%). Some HMDM transmigration 
was also seen toward live HT29 CFS (human colorectal carcinoma cell line). This study 
highlights that differences in phagocyte and target call type, live or apoptotic, can vary 
outcome with regards to chemotaxis induction. In contrast to data shown here (Fig. 34), 
Elliott et al.63 found live Jurkat CFS, harvested from Jurkat cells cultured at the same cell 
density as cultures used here, were not chemoattractive to undifferentiated THP-1 cells, in a 
vertical transwell assay. 
Every stage of apoptotic cell clearance requires a balance of „pro-clearance‟ and „anti-
clearance‟ mediators, e.g. “find-me” versus “keep-out” molecules in the chemotaxis phase, or 
“eat-me” versus “don‟t-eat-me” ligands in the recognition phase80. It is likely that the correct 
balance of pro- and anti-clearance signals is key to successful clearance90,94. Given the 
plethora of effector molecules recognised as having a role in AC clearance, and the levels of 
redundancy observed381, it is quite possible that different combinations are required for 
successful clearance of varying cell types, and in different physiological and 
pathophysiological scenarios. Work by Lauber et al. covered a variety of human 
monocyte/MØ cell models often used in studies of monocyte and MØ function62. In 
combination with the variety of cell lines used to generate CFS as attractants, it provides a 
useful insight to the different migration patterns observed when comparing cell models 
derived from the same species, i.e. cell line versus primary cell62. Results become more 
difficult to interpret and compare when considering cell lines to model ACs are derived from 
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human, murine and simian origin, however the presence of caspase-3 in all cell lines apart 
from MCF-7 gave some clues into mechanistic data62. Care was taken in the current 
chemotaxis studies to select a cell model to represent MØ and FCs, and appropriate 
phagocytes to complete the model. THP-1 cells are a useful tool in this respect as they can 
be induced to varying degrees of differentiation, so were used to model the migrating 
monocyte (+VD3), the MØ (+ PMA) and the FC (+ PMA + oxLDL). 
5.3.3.2. Monocyte migration to apoptotic cell-conditioned medium 
Qualitative plots (figs. 31/32) show robust monocyte migration (VD3 stimulated THP-1) to 
apoptotic JK and apoptotic MØ-conditioned medium. Monocyte migration to apoptotic FC-
conditioned medium was less robust (Fig. 37), with quantitative data suggesting more 
directional migration was seen toward live FC culture and CFS (Fig. 35). This could be due to 
increased expression of „find-me‟ signals and decreased „keep-out‟ mediator release in live 
FC in response to lipid-loading, or a failure of FC to upregulate „find-me‟ mediators, or 
downregulate „keep-out‟ mediators, following lipid-loading.  
Previous studies into monocyte chemotaxis towards apoptotic B cells found a role for AC-
derived MPs in monocyte migration to sites of cell death60,61,71. AC-derived MPs were 
identified by Segundo et al. via centrifugation, filtration, fluorescence microscopy, electron 
microscopy, and flow cytometry60. Recent research suggests that chemoattractants, such as 
CX3CL1 and ICAM-3, are associated with apoptotic B cell-derived MPs, and blocking action 
of these attractants reduces monocyte migration to MP61,71 (discussed further in 5.3.4.). In 
direct support of this, monocyte migration to apoptotic B cell CFS is observed in this model 
(Fig. 43).  
In contrast, Lauber et al. found no loss of chemotaxis induction following removal of 
microparticles (ultracentrifugation or 0.2µm filtration) from MCF-7 caspase-3 replete cells62. 
The authors concluded that chemotactic ability is not mediated by membrane-derived MPs in 
this instance as chemotaxis induction was not lost, and was subsequently found to be lipid 
mediated, however the chemotactic nature of removed MPs were not tested. These results 
may demonstrate a level of redundancy in „find-me‟ mediator function, either in this model or 
as a universal feature of „find-me‟ mechanisms, as seen with „eat-me‟ stages of AC 
clearance381. Further clarification of MP versus soluble factor-mediated monocyte recruitment 
in MØ and FC models would be gained by employing similar methods to Lauber et al., such 
as ultracentrifugation of CFS, followed by pellet resuspension in fresh medium, to investigate 
whether chemotactic activity maintained. 
Alongside the MPs in cell-free supernatants, there will be a wide range of soluble factors, 
including cytokines and chemokines, especially as the apoptotic cells in question have high 
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cytokine outputs upon activation. These may include identified „find-me‟ signals such as 
CX3CL161,LPC62, LPC induced  MCP-1, IL-8 and RANTES74, S1P75, S1P induced IL-8 and 
IL-1076, ICAM-371, ATP/UTP62. CX3CL1 was, until very recently, the only chemokine to be 
implicated in phagocyte recruitment to dying cells61, however a new study has shown release 
of an array of cytokines and chemokines, including MCP-1 and IL-8, following induction to 
apoptosis via Fas/CD95 ligation59. It is important to understand mechanisms of recruitment, 
and perhaps over-recruitment, of monocytes to the atherosclerotic plaque, especially as 
research in murine models suggests reducing recruitment, rather than promoting egress, is 
beneficial in limiting plaque progression156. 
5.3.4. Mechanisms of monocyte chemotaxis towards apoptotic macrophages and foam 
cells 
CX3CL1 release from apoptotic human B cells has been demonstrated61, both as a soluble 
mediator and in association with MPs, and was, until recently, the only classical chemokine 
implicated in the recruitment of phagocytes to dying cells. This was supported by results in 
Figure 43, which showed significant (P<0.01) uniform monocyte migration to UV-induced 
apoptotic B cell-derived CFS. CX3CL1 ligates the receptor CX3CR1 on the phagocyte 
surface to promote directional migration61,64. CX3CL1 also enhances clearance via MFG-E8 
upregulation, a bridging molecule between apoptotic cells and phagocytes69. Further 
chemokines have recently been implicated in leukocyte attraction following induction to 
apoptosis through Fas/CD95 ligation. Release of numerous cytokines and chemokines were 
shown, including MCP-1 and IL-8, which were demonstrated to attract THP-1 monocytes and 
primary human neutrophils respectively59.  
Truman et al. demonstrated that apoptotic human B cell-CFS induced HMDM and murine 
bone marrow-derived MØ (BMDM) chemotaxis using a vertical transwell system61. Migration 
was then inhibited by addition of an anti-CX3CL1 blocking antibody (50µg/ml) in lower wells 
containing CFS, or by the addition of recombinant CX3CL1 (100ng/ml) to upper wells, where 
monocytes are loaded. Results here did not show a significant reduction in VD3 monocyte 
migration to apoptotic B cell-derived CFS in the presence of CX3CL1 neutralising antibody, 
also loaded in the CFS chamber (Fig. 43). However, antibody concentration used by Truman 
et al. was ten times the concentration used in this study61, therefore reduced migration could 
be replicated in this system with further optimisation. MP generation is also unspecified with 
regard to cell culture densities61, and a vertical transwell assay is employed, both of which 
will impact optimal neutralising antibody concentrations across studies. The use of CX3CL1-
neutralising antibodies in aMØ-derived CFS and significantly reduced monocyte migration 
(P<0.05), an effect which was not observed using aFC CFS (Fig. 44). This shows interesting 
differences in „find-me‟ mediator release following lipid-loading, however further investigation 
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is required. The basis of these results could be an increased (non-saturating) presence of 
CX3CL1 in CFS or redundancy in CX3CL1 driven monocyte recruitment by aFC following 
upregulation of other recruitment mechanisms. 
In contrast, Elliot et al.63 found purified CX3CL1 did not induce THP-1 chemotaxis, nor did an 
anti-CX3CL1 depleting antibody inhibit migration, however data was not shown so exact 
assays, concentrations of antibodies and purified CX3CL1 concentration are not known. LPC 
was also shown not to mediate THP-1 chemotaxis in transwell assays, in contrast with data 
shown by Lauber et al., potentially showing differences in AC models62. A possible 
explanation is a lack of expressed CX3CR1 on human THP-1 cells, however expression has 
been shown in other studies382, and CX3CL1 mediated-monocyte migration was shown here. 
Following apoptosis induction in studies here, significant reduction in cell surface CX3CL1 
protein expression was not observed (aMØ/aFC; Fig. 45). In contrast, studies by Truman et 
al.61 (apoptotic B cell) observed significantly reduced levels of cell surface expression, 
supporting the notion that CX3CL1 may be lost from the surface via MP shedding, though 
mechanisms such as epitope masking or internalisation could be at play. To explore this 
notion further, preliminary assays were undertaken to assess the presence of CX3CL1 in 
harvested CFS. Initial data suggests CX3CL1 is present in aMØ-derived CFS (Fig. 46). This 
assay could be used further to compare quantities of released CX3CL1 in both live and 
apoptotic MØ and FC CFS. This would shed light on whether reduction in CX3CL1-mediated 
monocyte recruitment by aMØ CFS, and not aFC CFS, was a mechanistic/functional shift, or 
due to differences in quantities of shed CX3CL1 (Fig. 44). Presence of CX3CL1 in live cell-
derived CFS would also explain observed monocyte migration where it wasn‟t necessarily 
expected (figs. 31-33), as CX3CL1 has been shown to be constitutively shed in live B cells61. 
Studies here do not differentiate between soluble CX3CL1 (TACE/ADAM17 cleaved219) and 
MP-associated CX3CL1, which could be elucidated initially using ultracentrifugation to 
separate MPs and soluble factors. Subsequent immunoblotting could then be carried out to 
assess protein levels, or resuspension in fresh medium could text for function in further 
chemotaxis assays. Truman et al. found soluble and MP-associated CX3CL1 was shed by B 
cells61. 
CX3CL1-CX3CR1 interaction also provides a survival signal against apoptosis383. This has 
implications when considering the accumulation of potentially „sick‟ lipid-laden cells within the 
plaque. Inefficient clearance of dead cells in the plaque is the main pathological event in 
atherosclerosis, resulting in a core of cells undergoing secondary necrosis and contributing 
to plaque instability and rupture162. It could be argued that survival signals from CX3CL1 are 
beneficial to the plaque, keeping macrophages and foam cells alive to engulf cells already 
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undergoing apoptosis. On the other hand it may also be considered that macrophages are 
being kept alive for too long, enabling foam cell production and further recruitment of 
monocytes to the plaque. Macrophage apoptosis is considered to be anti-atherogenic in early 
lesions, but as lesions progress apoptosis is suggested to be pro-atherogenic149,236. 
Considering further „find-me‟ mediators, ICAM-3 is of interest as it has only very recently 
been shown to act as an inducer of monocyte migration to apoptotic cells71, and has had little 
study as it is absent in rodents384. Torr et al. showed ICAM-3 was MP-associated via the use 
of GFP-tagged ICAM-3 and fluorescence microscopy, observing locality of ICAM-3 following 
induction to apoptosis71. ICAM-3 shedding via MPs was further evidenced by the reduction in 
ICAM-3 surface staining following apoptosis induction (flow cytometry), and the presence of 
ICAM-3 (western blot) in association with supernatant harvested MPs71. 
Cell surface expression of ICAM-3 was assessed here using flow cytometry (Fig. 42), and 
MFI values were extremely low. Despite this, a very modest reduction in ICAM-3 surface 
expression was observed following induction to apoptosis, as seen by Torr et al.71. When 
adding ICAM-3-blocking antibody MA4 to CFS in chemotaxis assays, monocyte migration 
toward aMØ CFS was not affected (Fig. 41). There appeared to be decreased migration 
toward aFC CFS in the presence of an ICAM-3-blocking antibody, which may be proved 
significant with further repeats, however it was not shown to be significant here. It could 
indicate an interesting switch in aMØ and aFC phagocyte recruitment mechanisms upon 
induction of apoptosis. The mechanism behind ICAM-3 induced monocyte migration remains 
to be elucidated. 
Also investigated was the role of CD14 in monocyte migration to AC-derived mediators. 
CD14 has been shown to have contributing roles in atherogenesis, including pro-atherogenic 
responses to mmLDL201,323,324, and polymorphisms in the promoter of CD14 gene were found 
to be associated with an altered risk of atherosclerosis385. CD14 also interacts with ACs, from 
which MPs may contain some comparable structures, such as PS or ACAMPs31,284. Figure 
39 shows high expression of CD14 in the VD3 stimulated THP-1 monocyte model, however 
addition of a CD14-blocking antibody had no effect on monocyte migration toward aMØ or 
aFC CFS. This supports earlier work by Truman et al. (2004), which showed migration 
toward apoptotic B cells was not impaired in BMDM from CD14-/- mice386.  
5.3.5. Effects of apoptotic cell mediators on endothelial cell adhesion molecule 
expression  
The majority of plaque microparticles are thought to be macrophage-derived269, however the 
role of these AC-derived MPs on endothelial cell (EC) function has not been fully established. 
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A murine LDLR-/- model combined with P- and E-selectin double deficiency (P/E-/-) were 
found to develop 40% smaller and less calcified lesions, confirming the role for E-selectin in 
plaque development, and re-affirming the importance of inflammation in atherosclerosis, 
which mediates E-selectin expression372. Figure 47 shows the ability of MØ and FCs to 
induce E-selectin expression in HUVECs, an accepted endothelial cell model. This could 
indicate an un-modulated mechanism of monocyte recruitment, beyond the point of which 
recruitment is athero-protective. Further aspects of apoptotic MØ and apoptotic FC-derived 
MP-modulation on monocyte recruitment and inflammation in the plaque would be of interest. 
Human atherosclerotic plaque-derived MPs were shown to promote endothelial ICAM-1-
dependent adhesion and transendothelial migration by monocytes, by increased ICAM-1 
expression on ECs in a concentration-dependent manner281. This was attributed to transfer of 
ICAM-1 from plaque MPs to ECs, as an increase in ICAM-1 mRNA expression was not 
observed281. Whether AC-derived MPs can confer CX3CL1 in the same manner, contributing 
to circulating monocyte trapping in the arterial lumen, would be an interesting point of 
investigation. 
Mesri et al. found that primary human polymorphonuclear leukocyte (PMN)-derived MPs 
induced IL-6 production in HUVECs. Human T cell-derived MPs were also shown to induce 
pro-inflammatory cytokine production and apoptosis in bronchial epithelial cells, in which 
phagocytosis of MPs was suggested to be required387. Cytokines such as TNF-α do not 
regulate P-selectin expression in humans, but can induce P-selectin expression in mice, 
which has been attributed to species-specific transcriptional regulation388. This highlights the 
care that needs to be taken in experimental design. 
In summary, MPs could have a variety of roles in atherogenesis and plaque progression, 
many of which are yet to be investigated. 
5.4. Conclusions and Future work 
In conclusion, this is very early, but much needed work on mechanisms of monocyte 
attraction to sites of cell death, including those that may be encountered in the human 
atherosclerotic plaque. 
Dissecting out the roles of MPs versus soluble factors would be a logical next step to see if 
CX3CL1 and ICAM-3 are soluble or MP-associated in this model. Ultracentrifugation of cell-
free supernatants, and reconstitution of pellets in fresh medium, should be able to remove 
and then replace chemoattractive properties to monocytes respectively. Western blotting of 
pellets for CX3CL1 and ICAM-3 would further support MP-association, as seen in work with 
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apoptotic B cells61,71. Further profiling of MPs could also be carried out with immuno-staining 
and flow cytometry analysis.   
Fluorescently labelled MP could be used to assess binding of MP to MØ in the presence of 
the CX3CL1, ICAM-3 and CD14 blocking antibodies. This would allow analysis of binding 
mechanisms and mechanisms of immune modulation to be compared.   
The use of an endothelial cell barrier between monocytes and AC-conditioned medium would 
add an additional level of understanding. This could be carried out using a transwell-based 
assay, and could be used to assess whether microparticles with chemoattractive properties 
could attract cells from the other side of an endothelial cell barrier. A further development 
could then seek to use such a system under conditions of flow, so as to more closely model 
the interaction of blood monocytes with inflamed endothelium at sites of cell death. 
Transwell assays could also be used to assess preferential recruitment of primary human 
monocyte subtypes to apoptotic MØ and apoptotic FC MPs, as migrated cells can be 
collected and stained from lower chambers, for analysis by microscopy or flow cytometry. 
This would be interesting as CX3CR1 monocytes have been hypothesised to be 
preferentially recruited to the atherosclerotic plaque389. 
Utilising the Dunn chamber method to assess potential mechanisms, or failed mechanisms, 
from a plaque-like environment may also advance understanding of failed resolution of 
inflammation.  
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Macrophage function throughout ageing : A Pilot Study  
6.1. Introduction 
Individuals within the aged population show an increased susceptibility to infection, implying 
a decline in immune function, a phenomenon known as immunosenescence8. Paradoxically, 
an increase in autoimmune disease, such as rheumatoid arthritis, is also associated with 
ageing, therefore some aspects of the immune system appear to be inappropriately active in 
the elderly9-11. The above evidence suggests inappropriate control of the immune system as 
we age. 
Macrophages, and their precursors monocytes, play an important role in host defence in the 
form of phagocytosis, and also link the innate and adaptive immune system via antigen 
presentation 18. Inappropriate control of macrophage function has been a continuing theme 
throughout this thesis. The following small-scale pilot study aimed to address whether 
changes in primary monocyte-derived macrophage function could be observed between 
young and mid-life adults. 
Despite immunosenescence now being a widely accepted consequence of ageing, it has 
proven difficult to reproduce at the cellular level, and the approach to research in this area 
varies widely 390. Research into age-related changes in innate immunity is less advanced 
than that of adaptive immunity, and research into function of mononuclear phagocytes as we 
age demonstrates the variability in research methodology towards one aspect of innate 
immunity, and consequently the conflicting results 7. It could be argued that the use of human 
cells ex vivo, from an age-range of donors, would provide the closest insight into functional 
changes in cells in human ageing.   
The following studies used macrophages derived from human peripheral blood mononuclear 
cell isolations from an age-range of healthy donors (BMDM). The ability of BMDM to interact 
with, and respond to, apoptotic cells was investigated. This was to assess the hypothesis 
that reduced capacity for MØ from aged individuals to be turned off effectively by dying cells 
may contribute to inappropriate control of the immune system as we age. To investigate the 
influence of age-related environments on apoptotic cell clearance was also studied, by co-
culture of THP-1-derived MØ with apoptotic cells following pre-treatment with plasma 
samples from individuals of different ages. Investigation into apoptotic cell clearance 
mechanisms as a result of an aged cell, or an aged environment, may provide clues as to at 
what point control is lost in the atherosclerotic plaque. 
Given the inflammatory environment in the atherosclerotic plaque, despite high levels of cell 
death, it is hypothesised that the inflammatory environment may result from apoptotic 
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MØ and apoptotic foam cells exerting an inflammatory effect by aged MØ. Research 
questions covered in this chapter are shown in the following table. 
   
Phagocyte 
 
Function 
 
 
Aged HMDM THP-1 derived MØ 
+ aged plasma 
 
Interaction with AC 
Do MØ from mid-life donors 
interact with AC as efficiently 
as MØ from young donors? 
Is CD14-dependent 
interaction the same in MØ 
from young and mid-life MØ?  
Does an aged environment 
impair MØ ability to interact 
with AC? 
 
Immune modulation 
Do MØ from mid-life donors 
respond to stimuli in the 
same manner as MØ from 
young donors? Can an 
inflammatory response be 
switched off effectively in MØ 
from mid-life donors? 
 
 
Table 9. Summary of key research questions addressed in Chapter 6 
6.2. Results 
6.2.1. Participant statistics; age and gender groups  
Recruitment of local healthy donors was carried out for preliminary experiments under 
existing ethical approvals.  Preliminary data gathered in this pilot study would then be used 
for study design for larger cohorts recruited through the Aston Research Centre for Healthy 
Ageing (ARCHA) following ethical approval for a larger scale study, where individuals could 
be recruited externally from a broader age-range. 
Data in Figure 48 show that 44 participants were recruited, from an age range of 18-58 
years. This data is the total number of participants recruited, and encompasses successful 
blood donations, and also donations or monocyte isolations that were not successful. The 
number of monocytes isolated per participant also varied greatly, so some participants were 
148 
 
used in individual studies only, and some were used across all studies. Interesting to note is 
the skew of gender groups. Males are the more prominent gender in younger age groups 
(18-26yrs), whereas females are the more frequent gender in the older age groups (46-
57yrs), which should be noted when interpreting some of the following data. As participants 
from older age groups were not readily available, young (age <25 years) and mid-life age 
(age >40 years) age groups were compared, excluding results from some participants. This 
is a limiting factor of this cohort, as access to the „healthy aged‟ population was lacking.  
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Figure 48. Summary of participants; age and gender Results show the cohort of 
participants in this pilot study, revealing an age range of 18-57 years, and a skew towards 
males in younger age groups (age<25 years) and women in older age groups (age>40 
years). n=44. 
6.2.2. Comparison of function in young versus mid-life primary human monocyte-
derived macrophages 
Both persistence of ACs, and increased autoimmune disease in the elderly has been 
observed11,33. These processes may also contribute to increased systemic inflammation in 
aged individuals, as they have been shown to have roles in immune modulation14,391. This is 
supported by data on C1q deficiency, where persistence of AC has been shown to drive 
autoimmunity392. CD14 is the prototypic pattern recognition receptor, with roles in 
inflammatory responses and AC clearance31. Whether CD14 contributes to reduced 
clearance by MØ in aged individuals is unknown, however reduction of CD14 in aged murine 
splenic MØ has been reported393,394. 
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The ability of HMDM to interact with UV-induced apoptotic Jurkat cells was assessed in the 
presence or absence of the monoclonal CD14 blocking antibody (mAb) 61D3, and compared 
to the non-blocking mAb 63D331 (Fig. 49). Results show no significant differences between 
AC interaction between age groups, either in the presence or absence of a CD14 blocking 
antibody, however both groups displayed a trend in reduced AC interaction in the presence 
of 61D3. 
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Figure 49. CD14 dependent and independent apoptotic cell interaction by young and 
mid-life primary human monocyte-derived macrophages Human monocyte-derived MØ 
(HMDM) were co-cultured with aJK, in the presence or absence of CD14 blocking antibody 
61D3, or non-blocking CD14 binding antibody control (63D3) (1h; 37C). Unbound AC were 
removed by washing, cells stained with Diff-Quik and the number of MØ interacting with AC 
was counted out of 200 cells per well. Data shown are mean % interaction ± SEM of 3 
(age<25) or 4 (age>40) independent experiments. Data analysed using two way ANOVA with 
Tukey’s post hoc test. 
As the ability of MØ to interact with AC did not appear to be impaired between young and 
mid-life age groups, it was then investigated whether immune-modulation was comparable 
between age groups following stimulation with pro- or non-inflammatory mediators, given the 
link between inflammation and ageing, and the hypothesis that a lack of appropriate MØ 
control is the source14. 
The levels of TNF-α release was assessed without MØ stimulation to investigate whether 
basal levels of inflammatory cytokine release were associated with either age group (Fig. 
50). Results showed no significant differences in TNF-α release between age groups in 
unstimulated MØ. TNF-α response to apoptotic Jurkat is the same by MØ from young and 
mid-life age groups. Trends showed increased TNF-α release in response to LPS, compared 
to basal and AC co-culture, by MØ from both young and mid-life age groups, as seen with 
THP-1-derived MØ (Fig. 19; Chapter 4). These results were not found to be significantly 
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different, however an increased sample size would boost statistical power of these assays. 
Trends suggest an increased TNF-α response by MØ from mid-life donors, compared to 
young donors, in response to LPS. 
To investigate the ability of apoptotic Jurkat to „switch-off‟ an inflammatory response by MØ, 
as seen in THP-1-derived and primary MØ previously (figs. 16/20; Chapter 4), MØ were co-
cultured with apoptotic Jurkat prior to addition of LPS (Fig. 50). Interestingly, whilst trends 
showed AC-induced reduction in LPS-induced TNF-α release in young MØ (as seen in Fig. 
23), ACs did not appear to switch off the TNF-α release in mid-life MØ, potentially implicating 
inappropriate control of immune responses by MØ as we age. 
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Figure 50. Immune modulation of young and mid-life primary human monocyte-
derived macrophages by apoptotic cells HMDM were co-cultured with aJK or CDMØ-
medium control (20h; 37C). 5ng/ml LPS or CDMØ-medium control was added to relevant 
wells with normal human serum (10% v/v final conc.) and incubated (4h; 37C). Samples were 
diluted 1/5 in sfRPMI prior to ELISA analysis. TNF-α ELISA was carried out according to 
manufacturer’s instructions (PeproTech Ltd). Data shown is mean ± SEM of 5 independent 
experiments per age group. Data analysed using two-way ANOVA with Tukey’s post-hoc 
analysis. 
6.2.3. Effect of young versus mid-life plasma on THP-1 macrophage ability to interact 
with apoptotic cells 
As human ageing studies are based largely on observation of end-points, such as cytokine 
profile in the blood, or presence of apoptotic cells in situ, it is unknown whether apparent 
defects in immune modulation are a result of altered functional ability of ageing cells, or the 
effect of an aged environment on what would be otherwise fully functional cells. Results 
above (Fig. 49) suggest no change in cell function, with regards to AC clearance, however 
failed clearance may be impaired in vivo if cells are affected by an age-related environment. 
This could have particular relevance with regards to AC clearance due to the necessity for 
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bridging molecules in efficient clearance. This area is currently understudied in humans, 
though some data suggests an increase in anti-C1q autoantibodies in aged individuals350. An 
inflammatory environment can also reduce AC clearance, an environment associated with 
ageing, as demonstrated by Aprahamian et al. in mice6,14,57. 
To this end, the effect of plasma on the ability of THP-1-derived MØ to interact with apoptotic 
Jurkat cells was investigated. THP-1 MØ provide a consistent model system with a baseline 
ability for AC interaction. Differentiated THP-1 MØ were cultured in sfRPMI with 10% (v/v) 
plasma (72h; 37C) to investigate any long-term effects of young or mid-life plasma on 
function. AC (UV-induced Jurkat) interaction assays were then carried out with pre-treated 
THP-1 MØ, in the presence of plasma from the same donor as pre-treatment (10% v/v), or in 
the absence of plasma. This will differentiate between the effects of young versus mid-life 
plasma conditioning on THP-1 MØ function, and the immediate effects of donor plasma 
presence on assisting phagocyte:AC interaction, e.g. via bridging molecules or complement 
components. 
Results showed that THP-1 MØ conditioning with young versus mid-life plasma did not 
significantly alter THP-1 MØ ability to interact with apoptotic Jurkat cells (Fig. 51), though a 
very small decrease in AC interaction following mid-life plasma conditioning could prove 
interesting given a larger cohort or older participants (grey bars). This effect was abrogated 
in the presence of plasma, which appeared to restore full capacity for AC interaction (black 
bars). These results are not significant, but given a larger cohort, it would be interesting to 
pursue the hypothesis that an age-related environment may decrease macrophage function. 
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Figure 51. Effects of young versus mid-life plasma samples on THP-1-derived MØ 
function DS differentiated THP-1, seeded at 2x104 cells/well in 24 well plates, were treated 
with young or mid-life donor plasma (72h; 37C). 16-20 hours post UV-induction, apoptotic 
Jurkat were resuspended in fresh sfRPMI, medium in all wells also replaced, and phagocytes 
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co-cultured with a 10:1 ratio of AC:MØ , in the presence or absence of the same donor 
plasma (1h; 37C). Unbound AC were removed by washing and samples fixed. To count, cells 
were stained with Diff-Quik and the number of MØ interacting with AC was counted out of 
200 cells per well No significant differences were found (two way ANOVA with Tukey’s post 
hoc test). Data shown are mean % interaction ± S.E of 3 (age<25) or 4 (age>40) 
independent experiments. 
6.3. Discussion 
Increased susceptibility to infection implying loss of immune function and, conversely, an 
increase in immune cell activation, leading to autoimmune disease, have been linked with 
ageing1,7,14,9,10. Autoimmune diseases, e.g. rheumatoid arthritis, and increased autoantibody 
titre have been associated with ageing as a risk factor 11,12, suggesting inappropriate control 
of the immune system as we age. 
Results from this chapter show no significant differences between the ability of MØ from 
young and mid-life donors to interact with or respond to apoptotic cells. The use of plasma 
from mid-life donors does not affect the ability of MØ to interact with AC and vice versa. It is 
likely that much bigger sample sizes would be required to establish significant differences.  
  
Phagocyte 
 
Function 
 
 
Aged HMDM THP-1 derived MØ 
+ aged plasma 
 
Interaction with AC 
MØ from mid-life donors 
interact with AC as efficiently 
as MØ from young donors. 
 
CD14-dependent interaction 
is the same in MØ from 
young and mid-life MØ.  
An aged environment does 
not significantly impair MØ 
ability to interact with AC. 
 
Immune modulation 
MØ from mid-life donors 
respond to stimuli in the 
same manner as MØ from 
young donors.  
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Inflammatory responses can 
be switched off effectively in 
MØ from mid-life donors. 
Table 10. Summary of results from key research questions addressed in Chapter 6 
Adaptive immune responses are more widely studied than innate immunity in ageing 
research, and even within monocyte and macrophage research on ageing, responses to 
pathogenic challenge have held the focus395. Of the MØ roles that have been studied, 
primarily in murine models, defective MØ function is implied. Impaired peritoneal 
macrophage function was found with ageing in BALB/c mice with regard to adherence, 
opsonisation, phagocytosis and antibody-dependent cell cytotoxicity23.  
PBMC-derived monocytes can be differentiated into human monocyte-derived MØ (HMDM), 
as was used in this pilot study. Previous studies from monocytes isolated from aged 
individuals display a decrease in IL-6 and TNF production following LPS activation, as 
observed in murine models, which was attributed to deficient PKC and MAPK activation32. A 
drawback of using PBMC-derived macrophages is the comparability with tissue 
macrophages, another advantage of murine models, where tissue macrophages can be 
used. Because of this, human monocytic cell lines are often used instead of PBMCs due to 
accessibility and ease of use and comparable disadvantages. 
Some evidence suggests reduction in apoptotic cell (AC) clearance with ageing in mice6. 
Aprahamian et al. found more apoptotic keratinocytes in skin samples harvested 24 hours 
post UV-irradiation in skin from aged mice, in comparison to young mice33. This could also be 
explained by increased susceptibility to UV-induced cell death by aged mice, as it is only a 
correlative result. Further study by the same authors found that aged (thioglycollate) elicited 
peritoneal MØ were less efficient at clearing injected apoptotic (human) Jurkat cells than their 
young counterparts33. This study found no significant differences in the ability of aged murine 
MØ to clear AC in vitro, however addition of aged murine serum, on young murine MØ, 
resulted in a reduction in AC clearance33. This was supported by trends in data shown here, 
where no significant differences were observed, between MØ from young and mid-life 
donors, to interact with apoptotic Jurkat cells (Fig. 49). A very modest trend in the ability 
aged plasma to reduce THP-1 derived-MØ interaction with AC was observed, and may show 
significant differences with the use of a larger cohort (Fig. 51).  
Research into this area in human cells is sparse, and the relationship between failed AC 
clearance and inflammation in ageing tends to be correlative rather than causative in 
nature6,36. For example the presence of autoantibodies in ageing is linked to failed AC 
154 
 
clearance6,12. Studies on macrophage phagocytosis have largely focused on that of microbial 
material or beads, whereas studies into AC uptake in aged cells are absent. 
The initial aims of this pilot study were to identify mechanisms behind suggested defective 
clearance of ACs, and subsequent immune modulation, with ageing and age-related 
disease33,195. Given time constraints and challenges in recruiting aged individuals, these 
studies could not be undertaken as originally planned, however future work could focus on 
several areas of AC clearance. The release of „find-me signals by AC to attract phagocytes 
precedes AC-phagocyte contact, e.g. ICAM-3 or CX3CL161,71. Whether these „find-me‟ 
signals are recognised by phagocytes, or released by ACs, in ageing and age-related 
disease is unknown. Work presented here indicates a role CX3CL1 in THP-monocyte 
chemotaxis to apoptotic MØ (Fig. 44; Chapter 5), a mechanism that could contribute to 
progression of atherosclerosis, a prominent condition in older adults321. The ability of 
phagocytes to migrate towards ACs throughout ageing and age-related disease is yet to be 
fully established, and could be investigated using chemotaxis assay methods outlined in 
Chapter 5. Immune cells from young and aged donors could be used as the phagocyte 
and/or the apoptotic cell, to establish at which point defects in phagocyte recruitment may, if 
relevant, come about. 
Expression of receptors responsible for AC recognition may also be downregulated, or 
impaired, in phagocytes as age progresses. For example, CD14 expression was found to be 
reduced in peritoneal and splenic MØ from aged C57BL/6 (B6) mice393,394, and splenic MØ 
from BALB/c mice393, however expression in human monocytes and MØ with ageing has not 
been extensively studied. As CD14 has often been used as a marker for monocytes, it is 
likely that the data already exists, but requires analysis in conjunction with ages of 
participants. Data presented here (Fig. 49) does not show any reduction in MØ interaction 
with AC from young or mid-life adults, nor any increased or decreased dependence on CD14 
mediated recognition of AC. This does not mean the same can be said for older age groups, 
and the sample size is small, but data of this nature is lacking and could be studied with 
larger cohorts. 
ACs must present „eat-me‟ signals, in conjunction with downregulation of „don‟t-eat-me‟ 
signals found on viable cells204. Effective upregulation of „eat-me‟ signals, such as 
phosphatidylserine (PS), or downregulation of „don‟t-eat-me‟ signals, such as CD31 and 
CD47, may not be occurring in the aged or diseased environment, or recognition may be 
impaired by phagocytes under the same conditions. Alteration of existing antigens, such as 
intercellular adhesion molecule-3 (ICAM-3) has also been shown to have a role in AC 
clearance84. It is unclear whether surface expression in aged PBMCs is altered, but any 
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changes in expression could affect ability of phagocytes to clear apoptotic cells391. 
Investigation into surface expression of these antigens could provide further insight into 
defective apoptotic cell clearance in the elderly. Figure 49 did not find any defects in young 
versus mid-life adult MØ ability to recognise AC, however the ability of primary ACs from 
young and older age ranges were not studied, a cell line, apoptotic Jurkat cells, was favoured 
instead. The use of primary neutrophils, which undergo spontaneous apoptosis, are often 
used as models in AC clearance studies, and could also be utilised in the application of 
clearance of old versus young donor-derived ACs. This leads to the discussion however of 
the definition of an „old‟ cell. The short half-life of neutrophils makes them popular AC models 
in clearance studies, however is a cell with a short life-span perpetually „old‟, e.g. close to 
death, or „young‟, e.g. new born? Will this effect apoptotic cell clearance mechanisms, and 
therefore skew in vitro studies? 
If engulfment is inefficient this would also delay AC clearance; this is supported by previous 
research into defective clearance in the plaque197,201. Delayed clearance has also been linked 
with autoimmune disease, e.g. SLE396. As atherosclerosis is prominent in the aged 
population, it can be questioned whether increased lipid uptake in MØ and impairment of AC 
clearance in the plaque is due to impaired function of aged MØ, or a direct result of the high-
lipid local microenvironment195. For example, would a lipid-laden foam cell show impaired 
clearance in a non-lipid environment? And would a MØ function fully in a high lipid 
environment? Do lipid-laden apoptotic cells elicit a different response in MØ than untreated 
apoptotic MØ? It may also be questioned whether, within the aged population, the incidence 
of atherosclerosis is increasing, with increases in disorders where CVD is exacerbated, such 
as obesity and diabetes320,322. These are also relevant questions to other MØ functions 
throughout ageing, including AC clearance. If clearance is defective in ageing, as studies by 
Aprahamian et al. suggest33, is this a primary effect of reduced cell function through ageing, 
or the secondary effect of an aged environment, e.g. an inflammatory or high lipid 
environment.  
Some preliminary work in this chapter has aimed to address this with the use of plasma from 
donors of different age groups (Fig. 51). Mediators found in aged environments could have 
primary effects on cell function, e.g. a loss of necessary bridging molecules in phagocyte:AC 
bridging molecules, or competition for AC receptors in a high lipid environment, as seen with 
oxLDL in the plaque195. Long term exposure to aged environments could also affect cell 
activity, especially if the inflammatory status associated with ageing, and the potential knock-
on effects on MØ activation, are considered29,37. In this study, THP-1 MØ were conditioned 
with plasma isolated from young and mid-life donors, for 3 days (grey bars) (Fig. 51). 
Interaction with apoptotic Jurkat cells was then assessed, and although significant 
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differences were not found, a modest trend in reduced AC interaction was observed in THP-1 
MØ following culture with mid-life plasma. Interaction rates were restored in the presence of 
plasma from the same donors, which may imply that chronic exposure to an aged 
environment, rather than the gain or loss of mediators required for AC interaction, may affect 
clearance in older adults. Gomez et al. carried out a study in rats, which showed pre-
incubation with serum from aged rats impaired the ability of young rat MØ to release TNF-α, 
in response to LPS397. Aprahamian observed similar results trends with young mouse MØ, 
which showed reduced AC uptake following incubation with serum from old mice6. 
Following successful interaction with apoptotic cells, immune modulation occurs. This work, 
and work by others, has shown that apoptotic cells have the capacity to reduce inflammation 
following interaction with MØ54-56 (fig .16; Chapter 4; Fig. 50). Results also shown here using 
HMDM, have shown that under certain conditions, immune-modulation by ACs may favour 
inflammation (Fig. 23; Chapter 4; Fig. 50). Figure 23 shows HMDM released TNF-α in 
response to THP-1-derived apoptotic MØ and apoptotic foam cells, a cell type induced by a 
high-lipid environment. Results in this chapter (Fig. 50) also implied that HMDM from mid-life 
donors released TNF-α in response to apoptotic Jurkat cells, a cell line not usually found to 
induce inflammation, though statistical significance was not reached (Fig. 23). These results 
have interesting implications on the roles of lipid-rich/aged environments (Fig. 23) or aged 
cells, in a failure to modulate immune responses appropriately.   
The differences in recruitment of each gender group and the association with age groups 
should also be considered (Fig. 48), as disparities are present in inflammatory markers in 
man and women through ageing. For example Gale et al. found links between incident frailty 
risk and inflammatory markers in the blood, namely fibrinogen and CRP, were different 
between man and women398.  
It is important to note that reduced innate immune function could also be a result of a 
decrease in the population of innate immune cells. A decrease in CD68-positive 
macrophage-lineage cells has been observed in human bone marrow in aged subjects 21 
which may account for the impact ageing has on innate immunity as macrophages are one of 
the first cells to respond to invading microorganisms. Wang et al. found an increase in Mac-1 
positive cells, a murine macrophage antigen, in aged mice, representing the differences 
between species 22. This is important to note as murine models are popular in ageing 
research due to the short lifespan and viable source of tissue macrophages, allowing direct 
comparison of young and aged organisms from the same genetic background which have 
been kept under the same environmental conditions. 
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Overall, these studies provide some interesting clues as to where macrophage control may 
fail in ageing, however a much larger cohort, or alternative study design is required to 
achieve significant results, especially if additional markers such as cell surface expression 
want to be investigated (requiring more cells). Using whole blood or PBMC preparations 
rather than isolated monocytes may provide the cell numbers required for more powerful 
data, however this is that expense of investigating the effects of ageing on specific cell types.  
6.4. Conclusions and future work 
In conclusion, these studies imply some functions may be impaired as we age, starting as 
early as mid-life (>40 years). Significant differences were not observed due to small sample 
sizes, however trends suggest immune-modulation following AC clearance may not promote 
resolution of inflammation in macrophages from mid-life donors. This would be interesting 
research to take forward to a larger cohort, given the hypothesis that ageing results in loss of 
control in macrophages. Bigger differences in young and aged MØ function may be observed 
with inclusion of younger and older participants, or of those with pathology such as 
atherosclerosis.  
Further research into the effects of an aged environment, as used here with plasma 
conditioning, would provide interesting insights into which aspects of „inflammaging‟ are a 
result of loss of cell function, rather than a direct influence of an aged environment.  
As such little research in this area has been done in human cells, there is much scope for 
expansion of this study.   
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Discussion 
 
As discussed throughout this thesis, the atherosclerotic plaque is a highly inflammatory 
site58, despite the presence of large numbers of MØ and ACs46, which, when interacting, 
should dampen inflammation54-56. To resolve inflammation, recruitment of inflammatory cells 
must cease, apoptotic cells must be cleared and egress of live inflammatory cells must take 
place151. It is apparent that control of one or all of these mechanisms must be functionally 
defective in the atherosclerotic plaque if resolution of inflammation is not achieved, however 
whether that is a result of the local microenvironment or a loss in cell function, or both, is not 
known. 
A similar loss of immunological control has been observed with ageing. A reduced response 
to pathogenic challenge (e.g. cytokine), a systemic increase in inflammatory markers and an 
increase in autoantibodies in the presence or absence of overt pathology, all evidence that 
as we age, control of immune responses is becoming less tightly regulated3,12.  
Monocyte recruitment to the plaque is a very early stage of plaque formation45 Research on 
recruitment of monocytes to the plaque, a process that also drives plaque progression, has 
centred around the role of inflammatory mediators on monocyte recruitment to the artery 
wall, via modulation of endothelial cell (EC) responses, and chemoattractant and adhesion 
molecule expression by ECs. Recruitment to apoptotic cells following diapedesis through the 
EC layer has not been investigated, and is largely overlooked by popular methods of 
assaying AC clearance, where ACs are loaded directly onto adherent phagocytes. An 
emerging role of MPs in the attraction of monocytes to sites of cell death is also of interest, 
as although MPs have been studied in atherosclerosis, it is in the context of biomarkers to 
deduce pathology and risk of acute events399, and as mediators of inflammation, particularly 
in endothelial cells268. The role of MPs in phagocyte recruitment to apoptotic cells in the 
plaque has not been assessed. 
Despite much research into the immunological background of atherosclerosis over the last 
two decades, research around apoptotic cells in the plaque has focused on dissecting out the 
inflammatory potential of individual components of modified LDL, the mechanisms of 
apoptosis induction in MØ, and whether MØ apoptosis is beneficial or detrimental to plaque 
pathology. Clearance of apoptotic cells is likely to have a multifactorial impact on 
atherogenesis and plaque progression, and only a handful of papers have investigated this in 
detail. Across one key paper on defective apoptotic cell clearance in atherosclerosis, 
observations, and investigated subsequent mechanisms behind these, were spread across a 
variety of models. These included human endarterectomy samples, rabbit endarterectomy 
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samples, murine thioglycollate-elicited peritoneal MØ (phagocyte), murine J774 macrophage 
cell line (phagocyte) and human U937 monocyte cell line (AC)195.  Persistence of AC and 
inflammation are contributing factors to unstable plaque formation and subsequent rupture. If 
mechanisms of AC clearance in an environment that mimics features of the atherosclerotic 
plaque can be better understood, means of clearing persistent AC and dampening 
inflammation may be elucidated. 
Data is virtually non-existent on modulation of inflammatory responses following corpse 
clearance in the plaque, and data on human cells is completely absent. The effect on 
apoptotic cell-elicited immune-responses, and the impact on this following lipid-loading is 
unknown in humans, and only partially explored in mice, as is the immuno-modulatory effects 
of apoptotic cells on aged MØ. A more complete understanding of apoptotic cell clearance 
mechanisms, including phagocyte recruitment and immune responses, in both ageing and 
atherosclerosis, would contribute to, and likely link further, both research areas. 
7.1. Modelling clearance mechanisms in human atherosclerosis 
From an immunological perspective, the atherosclerotic plaque is extremely complex. The 
full interplay between live and dead resident cells, live and dead recruited inflammatory cells, 
lipid-loaded cells, modified lipids and inflammatory mediators may be impossible to fully 
characterise in vitro, making assays on excised endarterectomy samples attractive58,195. 
However, taking into account individual variation on genetic background and metabolic age, 
and the fact that data is correlative, full insights into the mechanisms driving inflammation 
and atherosclerosis would remain ill-defined without broader methods of investigation. With 
evidence gained from endarterectomy samples, a comprehensive collective of cell types, cell 
status (i.e. live, stressed or dead), and inflammatory mediators have been reported137,147, 
which can allow more accessible ex vivo and in vitro methods to be utilised whilst still being 
relevant to mechanisms within the plaque. 
In a bid to model potential clearance mechanisms akin to those observed in the 
atherosclerotic plaque, with a consistent model of phagocytes and AC, the monocytic cell line 
THP-1 was chosen, and model systems developed to utilise in the investigation of multiple 
stages of apoptotic cell clearance. Much research into AC clearance uses accessible cell 
types that are easy to manipulate, rather than use the most physiologically relevant model 
which, in this case, is apoptotic MØ46. Often research uses a multitude of cell lines that span 
across cell lineages and species195. Some additional human AC models (e.g. Mutu and 
Jurkat) were brought in as controls and to enable comparison of results across studies, the 
key aim of these studies was to use a representative human cell line to investigate the roles 
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of monocytes and macrophages in mechanisms that may be of key importance to 
atherogenesis and subsequent pathology. 
The THP-1 model approach used here was then broadened to include human monocyte-
derived MØ for comparison between human cell lines and primary human cells. This yielded 
some interesting results, and highlighted strengths and limitations of THP-1 as a 
monocyte/MØ model, which could have been overlooked in other functional monocyte/MØ 
research.  
Overall, models used here show that the ability of FC, compared to MØ, to interact with 
apoptotic cells is decreased in some, but not all cases, and that results were comparable 
across cell line and primary cell studies. 
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20% 20% 20% 
17 Interaction with 
aFC 
20% 20% 20% 
19/23 Basal TNF-α 
release 
Lo Lo Lo 
19/23 TNF-α response to 
LPS 
Hi Hi Med 
19/23 TNF-α response to 
aJK 
Lo Lo Lo 
19/23 TNF-α response to 
LPS + aJK 
Knocked down  
(P<0.05) 
 
Knocked down  
(ns) 
 
Knocked 
down  
(ns) 
21/23 TNF-α response to 
aMØ 
Lo Lo Hi 
21/23 TNF-α response to 
LPS + aMØ 
50% Knock Down 
(P<0.05) 
60% Knock Down 
(P<0.01) 
Hi 
21/23 TNF-α response to 
aFC 
Lo Lo Hi 
21/23 TNF-α response to 
LPS + aFC 
50% Knock Down 
(P<0.01) 
60% Knock Down 
(P<0.0001) 
Hi  
 
26 Inducer of TNF-α 
response 
Cause of TNF-α 
response cell-derived 
and soluble/MP derived 
Cause of TNF-α 
response cell-derived 
and soluble/MP derived 
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27 Apoptotic CFS as 
an inducer of 
vertical chemotaxis 
No significant induction 
of monocyte chemotaxis 
Significant induction of 
monocyte chemotaxis 
P<0.05 
 
35/36 Monocyte 
migration to live 
WC 
Directional + Directional ++  
35/36 Monocyte 
migration to live 
CFS 
Directional ++ Directional ++  
35/36 Monocyte 
migration to 
apoptotic WC 
Directional + Directional +   
35/36 Monocyte 
migration to 
apoptotic CFS 
Directional ++ ns  
37 Summary of 
monocyte 
migration 
Directional 
 
Directional/disordered  
40 Monocyte 
migration to aCFS 
w/ CD14 blocking 
Migration not inhibited Migration not inhibited  
41 Monocyte 
migration to aCFS 
w/ ICAM-3 blocking 
Migration not inhibited Reduced migration 
(ns) 
 
44 Monocyte 
migration to aCFS 
w/ CX3CL1 
blocking 
Reduced migration  
P<0.05 
Reduced migration 
(ns) 
 
47 HUVEC E-selectin 
expression 
following 
live CFS treatment 
Upregulation of E-
selectin expression 
(P<0.01) 
Upregulation of E-
selectin expression 
(P<0.05) 
 
47 HUVEC E-selectin 
expression 
following 
apoptotic CFS 
treatment 
Upregulation of E-
selectin expression 
(P<0.01) 
Upregulation of E-
selectin expression 
(P<0.01) 
 
  Young Old  
49 CD14 dependence 
for interaction 
Comparable Comparable  
50 TNF-α responses 
to AC and LPS 
Comparable Comparable  
51 THP-1 MØ rates of 
interaction 
following serum 
conditioning 
Comparable Comparable  
Table 11. Summary of macrophage versus foam cell function and young vs. mid-life 
function 
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7.2. Role of monocyte recruitment, apoptotic cell clearance, modulation of immune 
response, inflammation and ageing in atherosclerotic plaque progression 
Previous research indicates a reduced phagocytic efficiency of MØ in atherosclerosis195,197. 
Data presented here reveal that THP-1-derived MØ, following lipid-loading, have a 
decreased ability to clear apoptotic Jurkat cells (Figure 14), but interaction with apoptotic 
MØ/FC was unchanged (figs. 14/15), indicating a case for clear definitions of AC models. 
Despite efficient interaction of THP-1-derived MØ with apoptotic MØ/FC, and non-
inflammatory immune responses to these cells by interactions, primary human monocyte-
derived MØ (HMDM) behaved differently. Data presented here show, for the first time in 
human cells, primary HMDM release TNF-α in response to THP-1-derived apoptotic MØ and 
apoptotic FC, but not apoptotic Jurkat (Fig. 23). This supports research by Li et al. in murine 
peritoneal MØ, which demonstrated an inflammatory response to free-cholesterol loaded 
apoptotic MØ210, however these comparisons have not been done before in human cells.  
Apoptotic Jurkat dampened LPS-induced TNF-α release by HMDM (Fig. 23), indicating a 
possible classical to alternative phenotype switch, however inflammation was not dampened, 
but enhanced, by apoptotic MØ and apoptotic FC. Studies by Lucas et al. found that 
apoptotic neutrophils can boost an early LPS-induced TNF-α response (0-2h post LPS 
exposure), and that this is dampened in the presence of ACs after 8 hours co-culture, so 
timings may be crucial358. However, apoptotic neutrophils in the absence of LPS were non-
inflammatory358. Whilst data here indicate apoptotic MØ and apoptotic FC are strongly pro-
inflammatory, future work is now required to assess the inflammatory effect of apoptotic 
primary HMDM and their apoptotic foam cell counterparts.  
Lucas et al. also showed that apoptotic neutrophils do not switch off a TNF-α response in the 
presence of IFN-γ, suggesting that IFN-γ overrides AC-mediated resolution of 
inflammation358. IFN-γ stimulates a pro-inflammatory, or classical, phenotype of MØ 
activation, and has been found in human atherosclerotic plaques49,58,400. Classically activated 
MØ have also been associated with less efficient clearance of apoptotic cells, which is 
perpetuated in an autologous manner by TNF-α357. Studies in specialised MØ (microglia) in 
mice have also found reduced responsiveness to alternative activating inducer IL-4 in aged 
cells401. Aged peritoneal MØ were also found to produce increased oxygen free radicals, 
compared to their young counterparts, following treatment with latex and zymosan402, which 
could have implications when considering oxidative modification of retained lipoprotein in the 
sub-endothelium, and the overall pro-inflammatory milieu.  
Taken together these data suggest that monocyte entry into early plaques is likely to be 
athero-protective, but following entry into an inflammatory environment, with possible 
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contribution from TNF-α-inducing apoptotic MØ and apoptotic FC, a classically-activated MØ 
phenotype may be induced. Classical activation of MØ in the plaque is not a new theory, but 
the contribution of apoptotic MØ and apoptotic FC to inflammation has not been shown 
previously in vitro in HMDM. Adopting an inflammatory phenotype reduces clearance 
efficiency by MØ57. The contribution of failed phenotype switching to an alternative 
phenotype by aged MØ may also contribute to plaque formation in the aged population401, 
however this needs further study (Fig. 50). Reduction in monocyte recruitment, inflammation 
or promotion of reparative MØ phenotypes could be key areas for targeted research into 
atherosclerosis therapies.  
Monocyte recruitment is an established initiating factor of plaque formation, following 
subendothelial lipid retention45. It could be debated whether monocyte recruitment following 
plaque formation is pro- or anti-atherogenic. It has been suggested that apoptosis of plaque 
MØ, and therefore recruitment of phagocytes for clearance, is beneficial to early 
atherosclerotic lesions, due to immuno-modulatory effects of engulfment and the clearance 
of corpses prior to secondary necrosis149. As phagocytic efficiency appears to be lost in more 
developed lesions, apoptotic cells persist and continual recruitment of monocytes is not likely 
to be of benefit149. The role of apoptotic MØ/FC „find-me‟ mediator release has not been 
investigated, either in monocyte recruitment from the blood stream, or in directed monocyte 
recruitment to apoptotic MØ/FC following diapedesis. Results here suggest roles for ICAM-3 
and CX3CL1 in monocyte recruitment to aMØ/aFC (figs. 38/40).  
Results in these studies show that apoptotic MØ and apoptotic FC may use alternative 
mechanisms to recruit phagocytes for clearance. Monocyte migration to apoptotic MØ is 
significantly reduced by blocking CX3CL1, but significant reduction is not seen in apoptotic 
FC-induced monocyte migration (fig.41). This could result from an upregulation of alternative 
mechanisms, e.g. release other „find-me‟ mediators, by apoptotic FC, or non-saturated 
blocking of CX3CL1 in FC, due to excess secretion or shedding via MPs. This could be 
further investigated by assessing concentrations of „find-me‟ mediator release in conditioned 
medium, as shown in preliminary data (Fig. 46). In contrast, ICAM-3 blocking showed a trend 
in reduction of monocyte recruitment to apoptotic FC, but not in recruitment to apoptotic MØ. 
Whether these finding are a result of upregulation use of some „find-me‟ mediators one AC 
type, or downregulation of „find-me‟ mediators in other cell types, remains to be elucidated. 
The interesting part of this research is that phagocyte recruitment mechanisms by AC vary 
following culture in an aged environment. This could imply a loss of control of monocyte 
recruitment by cells in an aged-environment, especially if you consider that data together 
suggest that apoptotic FCs are potent but less direct inducers of monocyte migration. Trends 
suggest that more monocytes migrate (Fig. 27), and they may migrate further in distance 
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(Fig. 38), towards apoptotic FC-derived CFS, but that this is less ordered than recruitment of 
other AC types (Fig. 37). Investigating a wider spectrum of chemokine release by these cells, 
including „keep-out‟ signals,  and expanding the model to primary human cells, would provide 
further insight on disordered monocyte recruitment to the plaque, and whether mediators 
such as ICAM-3 and CX3CL1 could be targets for future intervention. CD14 was not shown 
to play a role in AC-induced chemotaxis in either model, so future work should encompass 
alternative receptors for „find-me‟ mediator interaction, as this is poorly defined if you 
consider the role of microparticles in chemotaxis induction. 
 
Figure 52. The role of monocytes/macrophages in plaque progression - schematic of 
results  
 
Pilot study data did not show any differences in the capacity of HMDM from young and mid-
life donors to interact with AC. However, it would be interesting to investigate the ability of AC 
to „switch-off‟ inflammation in MØ from mid-life donors, versus those from young donors, 
further, and with a bigger sample size (Fig. 50). This could mean that as we age, resolving 
inflammation may become less controlled. Also, if you combine this with foam cell data from 
the THP-1 model, ACs in the plaque may induce inflammation and, in conjunction with this 
effect, aged monocyte-derived MØ may not respond to mediators that resolve inflammation. 
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The modest trend in reduced THP-1 MØ:AC interaction following culture in an „aged‟ 
environment, using plasma samples from mid-life donors, may also contribute to 
understanding of pathology in ageing and atherosclerosis (Fig. 51). The use of serum from 
young and old donors is an accessible method of studying MØ function in an aged 
environment, and whether ageing at the cellular level, or in the local microenvironment, has a 
greater effect on modulation of immune responses, and the potential loss of control as we 
age. 
Overall, work here has established a flexible and robust in vitro model for the derivation of 
apoptotic MØ/FC, and assays of MØ attraction to, and clearance of, AC.  Coupled to this, the 
responses of phagocytes, in terms of migration and inflammatory mediator release, have 
been assessed. This shows data that suggest apoptotic MØ and apoptotic FC are strongly 
pro-inflammatory to HMDM.  A potential role for AC-derived CX3CL1 in recruitment of 
monocytes to apoptotic MØ and apoptotic FC has also been shown for the first time. CD14 
was not found to have a prominent role in recruitment of monocytes to apoptotic MØ or 
apoptotic FC, but there is a trend that implicates AC-derived ICAM-3 in the recruitment of 
monocytes to apoptotic FC, but possibly not to apoptotic MØ (fig 38). This raises the 
possibility that ICAM-3 may be a potential target for therapy in atherosclerosis.  Whilst no 
single therapy may be effective, combined therapies as used in cancer can often provide 
excellent results. 
MØ from mid-life individuals have also be shown to be less responsive to resolution of 
inflammation by apoptotic cells so, if trends are reproduced in larger studies, these factors 
would come together to drive the inflammatory pathology.  Taken together, data also 
suggests that CX3CL1 might be an ideal target to help modulate this complex pathology, by 
modulating monocyte recruitment to the atherosclerotic plaque. 
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